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S u m m a r y
A clearer understanding of HIV-specific immune responses in highly-exposed, persistently 
seronegative (HEPS) subjects is important in developing models of HTV-l protective 
immunity, and ultimately for vaccine development. Various HTV-specific immune responses 
have been described in HEPS cohorts, including cytotoxic T lymphocyte (CTL) responses, T 
helper (Th) responses, and IgA specific for HTV-1 envelope proteins. The presence and 
correlates of these responses were examined in a Kenyan cohort of HEPS sex workers, and 
the frequency, specificity, and clinical significance of HTV-specific CD8+ responses were 
studied. Systemic HTV-1 Env-specific CTL and CD8+ lymphocyte responses against 
predefined CTL epitopes were present in most HEPS sex workers, as were HTV-1 Env- 
specific IgA and Th responses. The proportion of HEPS women with HTV-specific CTL or 
CD8+ responses increased with the duration of uninfected sex work, suggesting that 
responses were acquired over time. CD8+ responses were also found in the genital tract of 
HEPS sex workers, where they were enhanced in comparison to seropositive women.
Overall, while systemic CD8+ responses in HEPS women were approximately tenfold 
weaker than those in infected women, they also targeted different epitopes. This suggests 
that qualitative rather than quantitative differences may explain HTV-1 protection. Several 
HTV-1 ‘resistant’ sex workers became infected by HTV-1 despite pre-existing HTV-specific 
immune responses (CTL, CD8+ responses, and/or IgA), possibly related to the waning of 
HTV-specific immunity after a temporary break from sex work. These findings imply that 
vaccine-induced protective HTV immunity may be possible, but that vaccine strategies of 
boosting or persistent antigen may be necessary for long-lived protection.
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C h a p te r  O ne; INTRODUCTION
Scope of the HIV-1 epidemic
The first recorded case of HTV-1 infection was identified in a blood sample taken in 
1959 from a man living in what is now the People's Democratic Republic of Congo(l). 
Although it is likely that the virus first entered the human population some time before this, 
recent models of HTV-1 viral evolution suggest that HTV-1 originated no earlier than 1931(2). 
Despite -  or, perhaps, because of -  the short period of time that humans have coexisted with 
HTV-1, the scale of the HTV epidemic has spread from isolated case reports to a global 
pandemic within the space of 40 years. The World Health Organization / UNAIDS estimated 
that at least 34.3 million people were infected with HTV-1 as of 2001, with Africa accounting 
for the great majority of these cases(3).
Table 1.1 UNAIDS estimates of the number of adults and children living with 
HIV/AIDS in June 2000, by region(4).
Geographic region Adults and children living with HIV/AIDS
North America 920,000
Caribbean 390,000
Latin America 1,400,000
Western Europe 540,000
Eastern Europe and Central Asia 700,000
North Africa and Middle East 400,000
Sub Saharan Africa 25,300,000
South and South East Asia 5,600,000
East Asia and Pacific 640,000
Australia and New Zealand 15,000
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HTV-1 has had an enormous impact in Africa. In Namibia, life expectancy has 
dropped from 61 years in 1991 to 45.5 years in 1996, while infant and child mortality rates 
have steadily increased(5). The focus of the HTV/ATDS epidemic on adults of reproductive 
age and their children has shifted African population structures from the pyramidal structure 
typical of developing countries, to a novel “chimney” profile(4). This results from deaths in 
children and young adults, together with reduced fertility rates, which combine to erode the 
base of the population pyramid and give an unsustainable top-heavy profile.
Despite calls for the provision of antiretroviral therapy in Africa at reduced cost, the 
required money, infrastructure and political will make this unlikely in the foreseeable 
future(6). When access to basic drugs and childhood immunization is beyond the means of 
much of the population, the routine provision of antiretroviral therapy seems an overly 
optimistic goal. An effective HTV-1 preventative vaccine would be the most easily 
implemented solution to the global HTV-1 crisis, although this is not to belittle the enormous 
problems inherent in the manufacture, distribution and administration of such a vaccine. The 
main obstacle to the development of an HTV-1 vaccine has been the lack of a model of 
naturally occurring immunological protection from HTV-1. Over the past few years, 
however, the finding that certain rare individuals appear to remain uninfected by HTV-1 
despite repeated exposure suggests that host immune responses may exist that can either 
protect against HTV-1 infection, or control infection below the level of detection(7-9).
Transmission dynamics of HIV-1
In contrast to the industrialized West, HTV-1 in Africa is predominantly spread 
through heterosexual sex, or from an infected mother to her child(lO). In is still not 
completely clear why there has been such rapid spread of HTV-1 within the heterosexual
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community in Africa, while in Europe and North America the epidemic has been more 
focused on the gay and IV drug using populations(ll-13). The potential for epidemic spread 
of HIV-1 within a population can be (over)simply expressed as the magnitude of the basic 
reproductive rate (Rq), where interacting variables are the probability that an individual will 
infect their sexual partner over the course of a relationship (P), the average number of new 
sexual partners per unit time (c), and the duration of infectiousness (D), as follows(14):
Ro = p X c  X D
When Ro exceeds one, secondary cases of HTV-l will occur and the epidemic will 
expand. Although it has been suggested that the HTV-1 subtypes common in Africa might be 
more transmissible(6), which would increase P in the equation above, recent work from 
Uganda shows no difference in rates of sexual transmission by HTV-1 clade(15). Rather, 
statistical modelling based on more complex versions of the equation above suggests that so- 
called “core transmitter” populations are vital in the maintenance of the African HTV-1 
epidemic(16). These are groups with very high rates of heterosexual partner exchange 
(increasing c), and which also have high rates of both HTV-1 and conventional sexually- 
transmitted infections (STI). STI in HTV-infected subjects, in particular those which are 
associated with genital ulceration, are associated with increased shedding of HTV-1 in the 
genital tract, and therefore increase infectiousness (P)(17-20). In addition, HTV-1 infection 
itself increases host susceptibility to STI(21), particularly to genital ulceration(22), and 
increases the duration of these infections. The interdependence and resulting amplification of 
STI and HTV-1 within these core transmitter populations may be a critical factor in the 
maintenanee of HTV-1, and subsequently in viral transmission to the broader community(23).
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An obvious group of core transmitters is prostitutes, or female commercial sex 
workers(16). The nature of their work means that these women have multiple sex partners, 
and that rates of STI such as gonorrhoea and chancroid are very high(24). In addition, sex 
workers are frequently marginalized, and may be unable to access even the limited health 
care facilities available(25). This means that they often continue to have sex for a 
considerable period of time despite the presence of a symptomatic STI or symptomatic HTV- 
1/AIDS(26). The baseline prevalence of HTV-l in sex workers from Mombasa and Nairobi is 
between 30-80%, with an annual HTV-1 incidence among seronegative sex workers of 15- 
50%(27-29). The socio-economie climate in many African countries means that sex work is 
the only means of survival for many women, and also means that men often migrate away 
from their families in rural areas, in order to seek work in the cities(30-32). Within this 
unnatural social structure, it is common for migrant workers to visit prostitutes(33, 34). Sex 
workers may therefore play a pivotal role in HTV transmission at a population level, serving 
as a reservoir for both HTV-1 and the STI that enhance its transmission to their clients. This 
indirectly leads to the infection of wives and children in rural areas ‘up country’(35), and may 
explain why East African men are twice as likely as women to bring HTV-1 infection into a 
marriage(36).
The Pumwani sex worker cohort
Collaboration between the Universities of Manitoba and Nairobi has afforded the 
opportunity to study the dynamics of HTV-1 infection in a cohort of female sex workers from 
the Pumwani slum area of Nairobi, Kenya. The cohort was initially established in 1983 to 
study the epidemiology and therapy of ulcerative STI(37). At around this time, the rapid 
spread of HTV-1 was noted among gay men and TV drug users in North America(l 1-13). 
Subsequent serologic screening revealed that there was already a huge burden of HTV-1
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infection among urban Kenyan sex workers(38). This was particularly true for the prostitutes 
of lower socio-economic strata working in Pumwani, where the seroprevalence was over 
60%. Condom promotion and the provision of free condoms, as well as peer counselling 
regarding safer sexual strategies, rapidly became a major focus of the Pumwani clinic(25). 
Despite considerable success, with reported condom use during client contacts increasing 
from 0% in 1983 to 80% in 2000(39), these sex workers still have an estimated 60 
unprotected sexual exposures to HTV-l per annum. This results in an extraordinarily high 
risk of HTV-1 infection, with an annual seroincidence in the early 1990s of approximately 
50% among sex workers who were HTV-1 seronegative at cohort enrolment(29).
HIV-1 resistance in Kenyan sex workers
Despite the high HTV-1 incidence in the Pumwani cohort, 13% of initially 
seronegative women have remained infection-free for periods up to 16 years(29). The 
absence of HTV-1 infection has been confirmed by repeatedly negative ELISA and Western 
blotting (including serologic tests for unusual viral strains), and by a lack of PCR 
amplification using primers for env, nef and vÿ" HTV-1 pro virus genes which have been 
specifically adapted to detect African clades(40). Analysis of HTV-1 free survival time 
indicates that a plateau in HTV-1 incidence becomes evident after three years of follow up, 
and gradually becomes more pronounced, as shown in Figure 1.1. Modelling of the survival 
times shows that these data best fit a model which assumes a declining risk of HTV-1 
seroconversion over time in this subset of the cohort(29). Women who continue in sex work 
for at least 3 years while enrolled in the Pumwani cohort, and who remain HTV-1 
seronegative and PCR negative, are epidemiologically defined as HTV-1 resistant. It should 
be stressed that this is a somewhat arbitrary cut-off, and that since the cohort inception 
women meeting criteria for HTV-1 resistance have occasionally become infected. However,
15
the seroincidence in this group is far lower than that among seronegative women newly- 
enrolled in the clinic, making them an ideal group in which to study epidemiologic and 
immunologic correlates of decreased HTV-l susceptibility.
Lack of HTV-1 infection in these HTV-1 resistant, or HEPS, women does not correlate 
with differences in sexual risk taking (types of sex, numbers of clients or condom use), or 
with ethnicity(29). In addition, statistical modelling clearly shows that this group does not 
simply represent a long tail of a exponentially decaying survival curve. If all cohort members 
had a similar probability of becoming HTV infected, then the survival curve should be an 
exponential decay to zero -  instead, the curve follows most closely that predicted by a model 
in which a subgroup of the cohort are resistant to HTV. This epidemiological observation 
cannot provide any explanation for HTV resistance, however. It is possible that highly 
exposed, persistently seronegative (HEPS) individuals are intrinsically resistant to primary 
infection by HTV-1, or that their immune systems have encountered HTV-1 and cleared virus 
without generating a conventional antibody response. In order to address these hypotheses, it 
is necessary to review the virology of HTV-1, and the components of the host immune 
response to persistent viral infections.
16
Figure 1.1 Survival modelling of time to HIV-1 seroconversion in the Pumwani
cohort
—  Kaplan Meier plot
— Model 1 
Model 2 
Model 3
S >  0 8
o  0-6
>s 0)
Ë 0-4
50 67 83 100 117
Time (months)
The figure shows the proportion of Pumwani sex workers remaining seronegative over time, 
and compares this survival curve to those predicted in different statistical models.
Model 1 = the expected time to seroconversion if seronegative survival time is
exponentially distributed;
Model 2 = the expected time to seroconversion under a Weibull distribution;
Model 3 = the expected time to seroconversion under a mixture model;
Kaplan-Meier plot = actual time to HIV-1 seroconversion among initially uninfected 
sex workers, closely following the curve predicted by Model 3.
From: Fowke K, Nagelkerke N, Kimani J, et al(29).
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O v e r v ie w  o f  HIV-1 t r a n s m is s io n  a n d  p a t h o g e n e s is
HIV-1 is a lend virus, an RNA virus from the class of retroviruses. The predominant 
mode of transmission is through heterosexual sex(41), and sexual transmission accounts for 
virtually all cases of HIV-1 infection in the Pumwani cohort(24). This section will review the 
structure and life cycle of HTV-l, the epidemiology and biology of sexual transmission, and 
the viral and host factors that influence the natural history of HTV-1 infection.
Structure of HTV-1
HTV-1 is an enveloped RNA virus whose structural components can be broadly 
divided into the viral envelope, matrix and core (Gag), viral RNA and enzymes, as shown in 
Figure 1.2, overleaf. The viral envelope is made up of a lipid bilayer, acquired during 
budding from the host cell, together with viral glycoproteins and an assortment of host 
proteins such as MHC class I and II molecules. The viral envelope glycoproteins consist of 
extracellular glycoprotein 120 (gpl20), and transmembrane glycoprotein gp41 (gp41), both 
derived from the common precursor gpl60. As will be discussed later, these glycoproteins 
play a vital role in HTV-1 cell entry through interaction with host cell surface receptors, and 
their inherent variability is also important in evasion of host immune responses. Enclosed 
within the viral core are two RNA molecules, together with stabilizing structural proteins 
such as p i7 and p24. Key enzymes are also found within the viral core, including reverse 
transcriptase (RT), integrase, and protease. The function of these enzymes will be reviewed 
shortly.
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Figure 1.2 The structure of HIV-1.
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A schematic figure of the structure of HIV-1 (see text for description of specific 
components).
From: The Toronto Hospital HIV-1 Clinic, http : //www. tthhivclinic. com/home .html
Life cycle of HIV-1
These structural components each play important roles in the various stages of the life 
cycle of HIV-1, as outlined in Figure 1.3, and several of these stages are discussed in more 
detail in subsequent sections. HIV-1 interacts through gpl20 (SU) and gp41 (TM) with host 
cell CD4 and coreceptors CCR5 or CXCR4, triggering the sequential events of cell 
membrane fusion and viral cell entry. The enzyme reverse transcriptase (RT) then transcribes 
viral RNA into proviral DNA, which is transported into the nucleus as the preintegration 
complex, where the enzyme integrase catalyses integration into the host chromosome. At this
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point the virus may remain quiescent (latent), with no transcription of viral genes, assisting in 
the evasion of detection by the host cellular immune response. Alternatively, viral genes may 
be transcribed into mRNA, either immediately or after the period of latency, with subsequent 
export to the cytoplasm and translation of viral proteins. The envelope glycoproteins are 
transported to the plasma membrane via the secretory pathway, while the Gag and Gag-pol 
polyprotein precursors assemble into dense areas under the plasma membrane that 
incorporate two copies of the viral RNA. Budding of the overlying plasma membrane then 
occurs, with incorporation of gpl20 and gp41 into the membrane of the newly-formed virion. 
After the virion has separated from the host cell, HIV-1 protease cleaves the Gag and Gag-pol 
precursors to form mature Gag and Pol proteins, generating a mature and infectious virion 
that is now capable of repeating the life cycle(42). This process of HIV-1 replication must be 
highly effieient, since it is estimated that the average life of an infected T cell is 
approximately one day(43).
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Figure 1.3 Summary of the HIV-1 life cycle.
^  CCR5 or CKCR4
DNA
RNA
RNA
The figure depicts the life cycle of HIV-1, divided into several critical stages:
(1) HIV-1 attachment; (2) Fusion; (3) Cell entry; (4) Reverse transcription, formation of the 
pre-integration complex (PIC); (5) Nuclear transport; (6) Chromosomal integration of DNA 
pro virus; (7) Transcription of viral RNA; (8) Nuclear export of RNA; (9) Translation and 
processing; (10) Membrane transport; (11) Virion assembly; (12) Budding; (13) Maturation.
from: Weiss R, 2000(42)
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Organization of the HIV-1 genome
Figure 1.4 (below) shows the organization of the HlV-1 genome(42). It is very 
similar to that of HlV-2, and can be divided into the major genes gag, pol, and env, and the 
accessory genes nef, rev, tat, vpu, vif and vpr. The long terminal repeat (LTR) found at each 
end of the virus is responsible for encoding binding sites for the initiation of virus 
transcription, as well as for utilizing cellular transcription factors(44).
Figure 1.4 Organization of the HIV-1 genome.
e 10
HIV-1 0
LTR j LTR
1 pof ............1 B I T L ............... .*1'^ 1
HIV-2 or
( B O 'O nE [
LTR r— w — 1 1 1 a  1.......  '"Y.. LTR
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The figure shows the genomic organization of HlV-1 and HlV-2, with viral genes shown in 
their respective reading frames. The upper scale represents kilobases of proviral DNA.
from: Weiss R, 2000(42)
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LTR (Long Terminal Repeats) are key elements in HIV-1 transcription, which depends on 
the complex interaction of the LTR with host cell transcription factors. The regulatory 
elements within the LTR interact with constitutive and inducible transcription factors to 
direct the assembly of a stable transcription complex that stimulates multiple rounds of 
transcription by RNA polymerase. However, the majority of these transcripts terminate 
prematurely in the absence of the virally encoded trans-activator protein Tat (see below).
Gag is initially translated as the Pr55 polyprotein precursor, which encodes the matrix (MA; 
pl7), core or capsid (CA; p24), p6 and nucleocapsid (NC) proteins(45). MA is responsible 
for the targeting of Gag to the plasma membrane and for assembly of the new virion prior to 
budding(46,47). In addition, MA is responsible for the incorporation of Env into the plasma 
membrane of the budding virion. CA (capsid, p24) forms a structural shell around viral RNA 
and core proteins. The core domain consists of seven alpha helices, two beta-pleated 
hairpins, and an exposed loop. NC is important in the encapsulation of two copies of viral 
RNA in the progeny virion, and p6 plays a crucial role in the release of budding virions(48).
Pol encodes the viral enzymes reverse transcriptase, integrase, and protease (49).
Integrase (IN) catalyses the integration of HIV-1 into the host genome, first by the removal of 
two 3' nucleotides from each strand of the proviral DNA, and then by their linkage to the 5' 
ends of the target DNA. The viral 5' ends are then joined to the target site 3' ends, a step that 
probably requires additional enzymes. Viral DNA is most likely to integrate in areas of 
distorted host DNA, but the mechanisms surrounding site preference are poorly understood. 
Reverse transcriptase (RT) catalyses the most fundamental step in HIV-1 integration into the 
host chromosome, namely the reverse transcription of viral RNA genome into dsDNA. This 
process consists of two broad steps, initiation and elongation, and was the target of the
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earliest antiretroviral drugs. RT inhibitors are divided into (1) the nucleoside analogues, such 
as AZT, ddl and ddC, which bind directly to the polymerase active site; and (2) the non­
nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine, which induce an 
inactivating conformational change by binding to a hydrophobic site near the active site. 
Protease (PR) is responsible for cleavage of the large Gag-Pol and Gag polyproteins into their 
component parts, an essential step in the transition from immature, noninfectious budded 
particles into mature, infectious virions. Inhibition of PR has been a highly successful 
strategy in antiviral drug design, and protease inhibitors (Pis) have been key to the recent 
success of HAART, although viral mutants resistant to Pis are now common.
Env encodes the envelope proteins gp41 and gpl20, which are secreted as gpl60 and cleaved 
by a cellular protease(42,49). These proteins are crucial to HIV-1 binding to host cell 
receptors and subsequent cell entry, with surface gpl20 responsible for binding to host cell 
receptors (CD4), and transmembrane gp41 mediating fusion of virus and host cellular 
membranes (see section “HIV cell entry”).
Tat is responsible for high-level transcription of integrated HIV-1 provirus, and its function 
is dependent on the Tat activation region (TAR) at the 5' end of all transcribed viral 
RNAs(49). Transcription elongation is inefficient in the absence of Tat, but the interaction of 
Tat and TAR -  along with host cofactors Cdk9 and CycT -  on RNA polymerase complexes 
is critical in determining HTV-l transcriptional processing(50). It is thought that the Tat 
cofactors are activation sensitive, so that viral transcription is repressed in the absence of 
activation, allowing latency. Upon activation, however, the high levels of replication 
conferred by Tat allow HTV-1 to replicate efficiently within the short life span of an infected, 
activated T cell (mean ti/% 1-2 days(43)).
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Rev (regulator of expression of viral protein) plays a critical role in the nuclear export of 
unspliced viral transcripts to the cytoplasm, where they are either translated or packaged into 
HTV-l virions(50). This is important because HIV-1 generates a wide array of unspliced or 
partially spliced mRNAs for export through its strategy of alternative splicing, and unspliced 
(intron containing) RNAs in the nucleus would normally be retained until fully spliced or 
degraded(51).
Nef (negative regulator) has multiple functions. It down regulates surface expression of CD4 
(along with Vpu), through routing CD4 from the cell surface to lysosomes, which is thought 
to enhance incorporation of Env into the budding virion membrane(49). Nef also down 
regulates the expression of class IMHC on the cell surface, which may protect virally 
infected cells from killing by HIV-specific cytotoxic T lymphocytes (CTL; see later section). 
Finally, Nef induces the expression of Fas ligand on the surface of infected cells, which 
interacts with Fas on the cell surface of neighbouring cells and induces bystander cell death, 
another important mechanism of host immune evasion (52).
Vpr (virus protein R) is the key regulator in the process of importing the pre-integration 
complex (which consists of RT, IN, pl7, and genomic RNA) into the host nucleus. It is also 
able to induce cell cycle arrest in G2, although how this activity is important in the viral life 
cycle is unclear (49).
Vpu (virus protein U) is a transmembrane protein, and is responsible for the binding of CD4 
in the endoplasmic reticulum, retarding its transit to the cell surface, and for targeting bound 
CD4 for degradation(53, 54). As discussed for the case of Nef (see above), the reason for
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CD4 down regulation is unclear, but this may enhance the traffic of transcribed HTV Env to 
the cell surface.
Vif (virus infectivity factor) encodes a small (192 residue) protein that enhances the 
infectivity of mature virions, and that may also play a role in viral assembly and/or 
maturation(49). Its mechanism of action is not clear.
mV-1 access to susceptible cells in the genital tract
The most fundamental event in the pathogenesis of HIV-1 infection is the entry of 
virus into a host cell. In order for this to occur during sex, HTV-l must come into contact 
with a susceptible cell population in the genital tract. Such cells must express two separate 
receptors: CD4, which acts as the primary HTV-l receptor; and a second receptor 
(coreceptor), generally either CCR5 or CXCR4(55). Viruses using CCR5 as a coreceptor are 
generally referred to as R5 strains, and those that use CXCR4 as X4 strains(56). CCR5 is the 
major HTV coreceptor expressed in the female genital tract, with CCR5 mRNA expression in 
the ectocervix 10-fold greater than CXCR4, and CXCR4 is the predominantly expressed HTV 
coreceptor in peripheral blood(57). R5 viral strains are responsible for the great majority of 
sexual transmission, and X4 strains are generally seen relatively late in disease, when they are 
associated with progressive immunosuppression(58, 59).
There are several cell populations present in the genital tract which express the 
requisite receptors for productive HTV-l infection, including CD4 lymphocytes, Langerhans 
cells and macrophages. There is still some disagreement, but recent work in a human 
cervical tissue-derived organ culture model suggests that the earliest cell type infected is the 
activated CD4+ T cell(60), although the Langerhans cell, a type of immature dendritic cell 
which is found in the epidermis and genital mucosa, was previously felt to be the most likely
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candidate(61-64). Whether or not they represent the earliest cell population infected, 
dendritic cells (DCs) still play an important role in the establishment of HTV-l infection. A 
protein commonly expressed on the surface of DCs, known as DC-specific intercellular 
adhesion molecule (ICAM)3-grabbing nonintegrin (DC-SIGN)(65), may take advantage of 
the fact that dendritic cells preferentially migrate toward R5 strains of HTV-1(66). DC-SIGN 
then binds to HTV-l gpl20, but this does not result in productive infection of DCs: instead, 
DC-SIGN induces infection in trans of cells expressing both CD4 and CCR5(65). Since the 
immature DC will normally migrate from mucosal sites to regional lymph nodes, where it 
presents processed antigen to T cells, it may act as a ‘Trojan horse’, enhancing the interaction 
between R5 virus and both activated and resting CD4+ T lymphocytes(67).
The female genital tract is lined with a mucosal epithelium -  a columnar monolayer 
in the cervix, and a pluristratified squamous epithelium in the vagina. Although free HTV 
particles are able to infect epithelial cells directly in an in vitro model of intact vagina 
epithelium(68, 69), it is thought that most transmission involves viral infection of 
CD4+/CCR5+ susceptible cells found deep to this layer, in the submucosa(70, 71). In order 
for HTV-l to interact with these submucosal cells, it must first cross the epithelial barrier. 
Breaks in the epithelium, caused by trauma or sexually-transmitted infections, are an obvious 
portal of entry(41). Although HTV-l can penetrate the intestinal mucosa via specialized M 
cells, which transport antigen directly to submucosal susceptible cells, there is no known M 
cell equivalent in the genital tract(72, 73). However, the cervical monolayer has adapted to 
allow selective and rapid transcellular transport of pathogens from the apical to the 
basolateral pole of the cell, generally resulting in the induction of pathogen-specific immune 
responses through interaction with DCs and T cells(74, 75). This process of transcytosis also 
results in the internalisation and transepithelial transport of HTV-l, with subsequent infection 
of susceptible cells on the serosal side of the intact mucosal epithelium(76).
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HIV may also access the submucosa through Langerhans cells, which are specialized 
DCs in the vaginal mucosa and endocervix that sample antigen from the lumen of the 
reproductive tract(77), and may transport DC-SIGN associated virus to susceptible T cells in 
the submucosa or regional lymph nodes. In the gut, subepithelial DCs are able to sample 
luminal contents by sending processes between epithelial cells while maintaining the integrity 
of inter-cell tight junctions(78), although this has not yet been shown to occur in the genital 
tract. Cervical epithelial cells can also sequester HIV-1 without becoming productively 
infected, and later transmit virus to activated immune cells(79). Finally, HIV-1 may 
occasionally access susceptible cells in the lumen directly, when activated CD4+ 
lymphocytes or macrophages are recruited to the site of a mucosal infection such as 
gonorrhoea, an effect that is likely to be amplified by the upregulation of the expression of 
CCR5 on genital tract cells due to STI(57).
Depending on the type of mucosal epithelium at the site of HIV-1 contact, there are 
therefore several mechanisms by which R5 strains of HTV-l are able to access CD4+/CCR5+ 
target cells, generally macrophages, CD4 lymphocytes or DCs. HTV-l can then spread to 
regional lymph nodes and be propagated systemically, perhaps assisted by binding to DC- 
SIGN on immature DCs (see Figure 1.5, overleaf). Recently, primary HTV-l isolates have 
been described that are able to use CD8 as a primary receptor, and therefore to target CD8+ 
lymphocytes(80). Infection of CD8+ T cells was independent of CXCR4 and CCR5 
coreceptors, although this virus was still able to infect CD4+ T cells, using CXCR4 as a 
coreceptor. To date, this phenomenon has only been described in a single patient, and may 
be a rare phenomenon -  alternatively, it may be a relatively frequent occurrence in late HTV-l 
infection, associated with the fall in CXCR4+ / CD4+ T cell numbers(81). Other HTV-l 
coreceptors have recently been identified, including CCR3, CCR2b, Bonzo and BOB, but the 
relative contribution of these coreceptors to HTV pathogenesis is not clear(82-84).
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Figure 1.5 Early events in HIV-1 sexual transmission
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Recent work suggests that the chain of events outlined can also occur without productive 
infection of DCs, via transport of HIV-1 bound to DC-SIGN (see text above).
From: Kahn J and Walker B(71)
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HTV-l cell entry
After coming into contact with susceptible target cells, it is still necessary for HTV-l 
to engage the appropriate receptors and enter the host cell. It is only quite recently that these 
events have begun to be elucidated, and much work still remains to be done. For an R5 virus 
to gain access to a host cell, it must generally interact with a host cell expressing both CD4 
and CCR5. This initiates a complex process involving three key phases, shown overleaf in 
Figure 1.6(85, 86). Viral envelope gpl60 is made up of a gp41 transmembrane trimer, which 
anchors the envelope gpl60 ‘spike’ to the virion surface, together with an external trimer of 
gpl20 containing the binding domains for host cellular receptors (CD4 and CCR5 or 
CXCR4). HTV entry is initiated when gpl20 interacts with CD4, the primary host receptor, 
with high affinity. This induces a conformational change, which brings together the 
chemokine receptor binding areas of gpl20 with the chemokine receptors on the host cell, so 
that both primary and secondary host receptors are bound. In the native state, the fusion 
peptide is buried within trimeric gpl20. After gpl20 interaction with both host receptors, 
however, the gpl60 envelope complex undergoes a dramatic conformational change, with 
insertion of the fusion peptide into the target cell membrane. This complex, known as a pre­
hairpin intermediate, is quite long-lived, but resolves into the fusion-active hairpin structure 
when the C and N peptides interact to form a helical arrangement with the N helices at the 
centre. This process brings the membranes of the host cell and virion into direct apposition, 
resulting in fusion and viral entry(86).
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Figure 1.6 Steps in HIV-1 cell entry.
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To summarize, it is thought that there are several steps involved in the sexual 
transmission of HTV-l. Virus present in the ejaculate, cervical secretions or blood of an HIV- 
infected sex partner gains access to susceptible host cells, generally after crossing the genital 
tract epithelium. Although the HTV-l population present in the ejaculate/secretions will be a 
mixture of R5 and X4 virus, it is R5 virus that usually infects CD4+/CCR5+ host cells. This 
involves the binding of gpl20 to both CD4 and CCR5, insertion of the fusion peptide into the 
host cell membrane, and subsequent rearrangement of the fusion complex to appose the host 
and viral membranes.
Establishment of HTV-l latencv
After productive infection by HTV-l, there are still several possible fates for an 
infected host cell. Despite some controversy over the cell populations that are responsible for 
the initial establishment of host HTV-l infection, the main cell target during established HTV- 
1 infection is the activated CD4+ lymphocyte(87). Infection of resting T cells can occur, but 
in this situation the rate of HTV-l nuclear integration is very slow, and the process is 
essentially ‘stalled’ at the stage of the pre-integration complex(88). After infection, most 
HTV-infected, activated cells will die quickly (ti/2 one day), either through direct cytopathic 
effects of the virus or through the host antiviral immune response(43, 89). However, a 
fraction of these infected, activated T cells revert back to the resting state. In essence, these 
CD4+ lymphocytes now constitute a population of long-lived memory T cells that harbour an 
integrated copy of HTV-l, but which are not transcribing viral genes and so are not 
susceptible to killing by host HTV-specific cellular effectors. However, the integrated HTV-l 
genome will actively replicate upon cell activation(87). Based on an estimated half life of 44 
months for these latently-infected T cells(90), and an estimate of 10  ^total cells within the
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latent pool(91), is has been estimated that eradication with HAART would require 73 years of 
total viral suppression(87).
Epidemiology of HTV-l sexual transmission
HTV-l sexual transmission is surprisingly inefficient. Sex with an infected person 
carries a transmission risk of approximately 0.4%(41), considerably lower than that of other 
sexually-transmitted infections, such as H. simplex or N. gonorrhoeae. However, the risk of 
transmission is higher under certain circumstances. The clearest risk factor for sexual HTV-l 
acquisition is sex with multiple partners, since this will increase the likelihood of exposure to 
an infected partner.
In addition to behavioural issues, there are a number of biological risk factors 
associated with HTV-l acquisition, and their identification has helped to direct research into 
HTV pathogenesis. These risk factors are summarized overleaf, in Table 1.2. Female gender 
initially appeared to be associated with a higher risk of HTV-l acquisition(92-94), perhaps 
due to the greater mucosal surface area exposed to infectious virus. However, recent work 
suggests that gender may play a smaller role in susceptibility than originally thought(15). 
Breaks in the genital epithelium, either through trauma or due to ulcerative STI, are 
associated with increased shedding of virus(20), as well as with increased susceptibility(lO), 
presumably by allowing improved viral access to submucosal target cells. Menstruation is 
associated with sloughing of the endometrial lining and a transient loss of mucosal integrity, 
which also increases HTV-l shedding(95, 96) and susceptibility(97). Hormonal contraception 
increases viral shedding(20) and may enhance HTV-l susceptibility(98, 99), perhaps related 
to hormonal thinning of the vaginal epithelium(98) or to an increased likelihood of genital 
ulceration(22). Nonulcerative genital tract infections, such as candidal vulvovaginitis or 
cervicitis due to N. gonorrhoeae or C. trachomatis, also increase genital tract shedding of
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virus(19, 20, 100) and enhance HIV acquisition(lO). The latter is due to the migration of 
susceptible, activated CD4+ lymphocytes to the region, as well as to CCR5 upregulation in 
the genital tract(57). Interestingly, genital tract colonization by lactobacilli, which is 
associated with reduction in the vaginal pH, may reduce HTV-l susceptibility, while bacteria 
that cause vaginosis and are associated with higher pH enhance susceptibility( 101).
As discussed earlier, HTV-l requires the cell surface expression of both CD4 and an 
appropriate coreceptor in order to productively infect a host cell. The R5 tropic virus strains 
responsible for sexual HTV-l transmission require CCR5 as a coreceptor. The CCR5 A32 
mutation is associated with reduced cell expression of CCR5, so that homozygotes are 
strongly protected against sexual acquisition of HTV-1(102), although occasional infections 
are seen(103, 104). In addition, CCR5 A32 heterozygosity may be associated with reduced 
plasma viral load(105). Plasma viral load correlates strongly with shedding in the genital 
tract(106,107), so that subjects during primary or advanced HTV-l infection, when plasma 
viral load is highest, are also likely to be most infectious(41). One might therefore expect 
infected heterozygotes to shed less virus, although this has not been described to date.
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Table 1.2 Factors influencing HIV-1 transmission.
Biologic factor HIV genital shedding HIV transmission HIV susceptibility
HIV coreceptor ? T ? TTT
mutations
Primary HIV infection TT TT N/A
Advanced HIV infection TT TT N/A
Genital tract T T TT
inflammation (STI)
Genital tract trauma T TT TT
Foreskin ? T TT
Hormonal contraception TT ? ?
Condom use No effect TTT U T
Menstruation ? TT T
Low pH (lactobacilli) T ' i ? T ?
Immune activation T T T
Pregnancy TT T? T?
The associations shown have been significantly associated with HTV-l acquisition in at least 
one study (see text for references). The number of upward or downward arrows represents 
the strength of the positive or negative association, respectively, and a question mark 
represents a hypothesized association.
Adapted from: Royce R et al{A\)
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Clinical course of untreated HTV-l infection
The clinical course of HTV-l infection can be divided into three distinct clinical 
stages: acute HTV-l syndrome, clinical latency and AIDS. During the latter stage the 
opportunistic illnesses develop that are characteristic of HIV-related immune suppression, 
and if untreated this stage will progress to death. This simple clinical summary, outlined in 
Figure 1.7, belies the complexity of the underlying host-virus immunological struggle.
A) Acute HTV-l infection
Acute HIV-1 infection is characterized by widespread viral dissemination, prior to the 
induction of host immune responses that are able to temporarily control viral replication. 
Viremia is high in the absence of an effective host immune response, leading to a transient 
CD4+ lymphocytopenia. This stage is associated with nonspecific “flu-like” clinical 
symptoms in 40-90% of cases(71), which appear within days to weeks of infection. In a 
cohort of Kenyan female sex workers, fever was the most common complaint (53%), 
followed by headache (44%), fatigue (26%) and arthralgia (24%)(108). High levels of virus 
are also present in the genital tract during primary infection(109), likely increasing 
infectivity. This has important public health implications, particularly since the routine HIV- 
1 FLIS A is unable to detect new infection for several weeks, the so-called “window period”. 
Although it takes up to three months for conventional FLISA tests to become positive, the 
symptoms and high viremia associated with primary infection generally decline after 1-4 
weeks, as the host cellular immune response reduces plasma viremia and immune activation.
B) Clinical latencv
With the resolution of the clinical symptoms associated with primary infection, CD4+ counts 
generally return to normal levels, and the HTV-infected subject enters a period of clinical
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latency(71). As the name suggests, this phase of HIV-1 infection is associated with no (or 
minimal) clinical symptoms, although in the absence of antiretroviral therapy it is associated 
with a gradual fall in CD4+ lymphocyte numbers, eventually resulting in immunological 
collapse and AIDS(llO) (see Figure 1.7; below). The time taken to progress from clinical 
latency to AIDS, a median of ten years in the absence of antiretroviral therapy, is dependent 
on several host and viral factors which will be discussed in detail in the following sections. 
From a clinical perspective, the infected subject feels and looks healthy. Although plasma 
viremia is dramatically reduced from the peak levels associated with primary infection, 
genital tract shedding of HTV-l does not correlate well with plasma virem ia(lll, 112), and so 
the cumulative chance of heterosexual transmission to a regular sexual partner is high(36).
An intriguing observation, and one that will constitute a focus of later work in this 
thesis, is that sex workers from the Pumwani sex worker cohort with a known date of 
seroconversion progress much more rapidly than has been seen elsewhere. Instead of a 
median of ten years, they progress to AIDS more than twice as fast, in a median of just 4.4 
years(l 13). While this was initially hypothesized to be a general feature of the “African” 
HTV-l epidemic, it is now clear that this is not the case, and that subjects elsewhere in Africa 
progress at a rate similar to that seen in the West(114). The reason for accelerated 
progression in this sex worker cohort is not clear, but it is tempting to ascribe it to unique 
features of this cohort, such as recurrent sexually-transmitted infections.
C) Svmptomatic HTV-l infection / AIDS
When the CD4+ count has fallen sufficiently low, generally to between 200-400/mm^, plasma 
viremia begins to increase again, and the subject develops symptoms related to HIV 
infection. Although detailed clinical algorithms will not be presented in the context of this 
immunology thesis, these symptoms can be divided loosely into nonspecific and
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constitutional symptoms, and those symptoms related to specific AIDS-defining illnesses. 
Examples of nonspecific or constitutional symptoms include fever, lymphadenopathy, weight 
loss, nonspecific diarrhoea, mucocutaneous candidiasis (thrush), herpes zoster infection 
(shingles) and oral hairy leukoplakia. AIDS defining illnesses, which often occur at a CD4+ 
count below 200/mm^, generally comprise infections or neoplasms which are rare or unheard 
of in people with a normal immune system, and are related to cellular immune dysfunction. 
These include invasive fungal infections, cytomegalovirus (CMV) infection of the retina, 
Kaposi’s sarcoma, pulmonary or extrapulmonary tuberculosis, and progressive multifocal 
leukoencephalopathy (PML). Treatment is available for most of these conditions, but is 
expensive and often toxic. In addition, multiple conditions are likely to occur concurrently at 
the stage of severe immune compromise. Unless the underlying immunodeficiency can be 
addressed by the use of antiretroviral drugs(115), subjects who have reached the stage of 
AIDS will generally die within one to two years(llO).
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Figure 1.7 Expected clinical, virologie and immunologic course of untreated HIV-1
infection
1200 Primary
infection DeathPossibie acute HIV syndrome 
Wide dissemination of virus 
Seeding of lymphoid organs
1100
1000
Opportunistic
diseases 1:512900
Clinical latency
256800E
E ^
1  •  700
5 I
H  #  600
Û O
128
Constitutional
symptoms
500
400
300
200
100
YearsW eeks
BF
■| n
2 
> 
m o
Io_
Within weeks of primary infection there is widespread dissemination of virus, which is often 
associated with a transient decrease in the peripheral CD4 T cell count. With the advent of an 
effective HIV-specific immune response there is a decrease in detectable viremia, and this is 
followed by a prolonged period of clinical latency. However, the immune response is only 
partially effective (see later text sections), so that the CD4 T cell count continues to decrease 
during this latent period. In most infected people, it continues to fall until it reaches a critical 
level, below which there is a substantial risk of opportunistic diseases.
From: Pantaleo, Graziozi and Fauci, 1993(110)
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Establishment of the viral set point
The complex and poorly understood interplay between virus and host immunity 
results in establishment of a viral set point, an equilibrium between virus and host(116), and 
this set point is maintained through the period of clinical latency. Indeed, virus levels will 
generally rebound to this same set point after the discontinuation of prolonged, effective 
antiviral therapy(117). This viral set point is a strong predictor of the subsequent clinical 
course: the higher the set point, the more rapid is immunologic progression, and hence the 
shorter is the period of clinical latency(118,119). Although the factors that determine the 
viral set point are unclear, it may be lowered by efficient host HTV-specific CTL and T helper 
responses(120). In addition, the viral set point may also be lower in the face of viral 
mutations that alter replicative competence, such as the Ae/deletions seen in an Australian 
index case and several individuals that he infected, a group known as the Sydney Blood Bank 
Cohort( 121-123). Unfortunately, spontaneous viral reversion to wild type may eventually 
occur, in association with HTV disease progression(124).
Events associated with CD4+ Ivmphocvte depletion
A major feature of HTV disease progression is the steady fall in the total CD4+ 
lymphocyte count through the latent stage, into the stages of symptomatic HTV-l infection 
and ATDS(110). CD4+ depletion does not only occur from the peripheral blood, but also 
from the total body stores: while a normal adult harbours 2x10^^ CD4+ lymphocytes, this 
number has fallen by half by the time that the peripheral blood CD4+ count has fallen below 
200/mm^(125). The exact mechanisms of CD4+ loss are still a subject of heated debate, but 
are probably a combination of (1) accelerated destruction of mature T cells, (2) decreased 
production of new T cells, and (3) redistribution of existing T cells(125):
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(1) Accelerated destruction of mature CD4+ T cells is the most intuitively obvious cause of T 
cell depletion. HIV-1 preferentially infects host cells expressing CD4 and other coreceptors, 
and also integrates and replicates preferentially within activated T lymphocytes(90, 126). In 
this way the very HTV-specific CD4+ cells that are activated after primary infection, in order 
to marshal an effective cellular immune response, are preferentially infected and killed by the 
virus that they are trying to combat. The rapid rise in CD4+ lymphocyte counts when 
HAART is used to block all viral replication has been used to argue that as many as 2x10^ 
infected CD4+ T cells are destroyed each day within an infected subject(89). However, it is 
likely that this is an overestimate, since many cells lost during HTV infection are not 
productively infected by HTV-l, but are dying through alternative mechanisms such as 
apoptosis due to activation-induced cell death (AICD)(127,128). Chronic immune activation 
is a poor prognostic factor in HTV infection, and is associated with elevated levels of T cell 
proliferation, independent of that occurring to replace T cells lost through direct infection by 
HTV-1(129). Although the exact contribution of these other mechanisms to accelerated 
CD4+ destruction is yet to be elucidated, the end result is a substantial fall in the mean CD4+ 
lymphocyte half-life, to approximately 1/3 of that seen in HTV-l seronegative subjects(130).
(2) Increased destruction of CD4+ T cells, whether direct or indirect, will not cause overall T 
cell depletion if the host is able to replace these cells as rapidly as they are lost. The rise in 
peripheral CD4+ lymphocyte counts seen after initiation of effective HAART therapy is a 
consequence of increased T cell production, rather than of prolonged T cell half-life(130). In 
general, mature T cells are replaced through a pool of CD4+ early progenitor cells. These 
long-lived cells are found in both the bone marrow and thymus, and are able to proliferate 
rapidly into differentiated progeny. HTV may therefore affect hematopoiesis through poorly 
understood effects on both the bone marrow(131, 132) and the thymus(133, 134). Of note.
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X4 viruses cause rapid destruction of early thymic progenitor cells, while R5 viruses appear 
to result in slower depletion of more mature thymocytes(133). Decreased thymopoiesis may 
manifest in the peripheral blood as a decrease in the number of CD4+ T cells bearing TCR 
excision circles (TRECs), which are markers of recent thymic emigrants, and this decrease is 
reversible after the initiation of effective antiretroviral therapy(135).
(3) Finally, peripheral CD4+ depletion may occur through the redistribution of existing T 
cells. In the setting of any infection, antigen-presenting cells (APCs) will migrate from the 
site of antigen encounter into lymphoid organs, such as the spleen and lymph nodes. Naive T 
cells, which generally recirculate through blood and lymph nodes in search of antigen 
encounters, will then undergo stimulation and be retained within the lymph node, while 
activated CD8+ effectors will move from the lymph node into the peripheral circulation. 
Therefore, any APC-antigen encounter will tend to result in reduced peripheral CD4+ T cell 
counts, increased CD8+ counts, and an inversion in the CD4/CD8 ratio(136, 137). In the 
same way, a net movement of CD4+ lymphocytes from the peripheral circulation into lymph 
nodes is seen in HIV-1 infection(138, 139). While this will result in decreased peripheral 
blood CD4 counts, it will not alter the total CD4+ cell number harboured within the host.
Regardless of the mechanism, the progressive loss of mature CD4+ lymphocytes 
during HTV-l infection has major implications for the host. APCs of whatever antigen 
specificity will migrate to the regional lymph nodes after antigen encounter, and may carry 
sequestered HTV-l with them. Subsequent antigen presentation to specific CD4+ T cells may 
therefore result in HTV infection, and subsequent destruction, of mature CD4+ T cells 
specific for commonly encountered pathogens. IL-7 is important in T cell homeostasis, and 
increased secretion of IL-7 would normally be expected to inhibit programmed T cell death
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and to stimulate the proliferation of intrathymic T cell progenitors(140). However, these T 
cell progenitors are susceptible to destruction in the setting of HTV-l infection, particularly 
due to X4 virus(133). In addition, IL-7 enhances HTV replication through transactivation of 
the long terminal repeat (LTR)(141), perhaps resulting in accelerated disease progression and 
the more rapid generation of X4 virus. This vicious cycle, unless arrested by effective 
antiretroviral therapy, results in progressive CD4+ depletion, with eventual immune collapse 
and death. However, the early initiation of HAART may delay this process, with partial or 
complete restoration of normal T cell homeostasis(131,142). Indeed, even in the setting of 
HAART failure due to antiviral resistance, drug pressure favours the maintenance of plasma 
R5 virus(143), which may retard the destruction of thymic T cell progenitors.
THE HOST IMMUNE RESPONSE TO HIV INFECTION
As has already been discussed, sexual transmission of HTV-l is relatively inefficient, 
and well under 1% of sexual contacts with an infected person will result in productive 
infection(15). Nonspecific physical and environmental factors, such as the integrity of the 
genital tract epithelium(lO) and the vaginal pH(lOl), are likely to play important roles in 
protection against HTV-l and other pathogens. However, control of viremia after infection 
(albeit relatively inefficient), as well as protection against infection in persons who are 
multiply exposed but persistently seronegative, is likely to be mediated by additional host 
immune factors(7). The host immune response can be divided into innate and adaptive 
immunity, and the latter into humoral (antibody mediated) and cellular components. In turn, 
the cellular arm of the adaptive immune response can be divided into T helper (CD4+ 
mediated) and cytotoxic T lymphocyte (CD8+ mediated) responses, and plays the major role 
in the host immune control of HTV-1(144). Because it is the focus of most original work 
presented in this thesis, this introduction will provide a detailed background to HTV-specific
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cellular immunity, as well as a more cursory overview of innate and adaptive humoral 
immunity.
In n a t e  im m u n it y
Innate immune responses are not antigen specific and do not have the capacity for 
memory. They recognize pathogens by the pattern of their microbial surface components, 
and can be activated within hours of encounter with the pathogen, without the need for initial 
proliferation. Innate immune responses are relatively nonspecific, with a lower level of 
diversity among innate effectors that distinguish potential pathogens by pattern recognition: 
the total number of receptors involved in innate immune responses is estimated to be in the 
hundreds(145). Unlike the adaptive immune system, innate receptors are encoded in the 
genome, rather than being generated by genetic recombination, so that they are inherited 
directly. The adaptive immune system generates a large number of receptors, many of which 
are specific for self components, and one mechanism for the control of autoimmunity is to 
require that the innate immune system also recognize an antigen before the adaptive immune 
system is activated.
The innate response consists of cellular components, chiefly monocytes 
/macrophages, dendritic cells (DCs), neutrophils, NK cells, and some unusual T cells; and 
soluble factors, principally complement, mannose binding lectins, and other secreted pattem- 
recognition receptors(146, 147). These components will be discussed, with a focus on their 
role in HTV infection.
Monocytes/macrophages
Macrophages, derived from circulating monocytes that have entered extravascular 
tissues and undergone activation, play a key role in linking innate and acquired
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immunity(147). Activation of extravasated monocytes is mediated by a number of possible 
factors, including cytokines (especially IFNy) and CC chemokines (such as RANTES and 
MIP-la/P). Bacterial products, including lipopolysaccharide and mannose, are particularly 
important in activating macrophages via endocytic pattem-recognition receptors. This leads 
to the phagocytosis and destruction of the pathogen, with processing and presentation of 
pathogen proteins to the adaptive immune system (described later). In addition, the 
triggering of signalling pattem-recognition receptors, in particular the toll-like receptors 
(TLR), induces the expression of co-stimulatory molecules (such as CD80 and CD86) that are 
needed for full activation of the adaptive immune system(146). Macrophages are also 
responsible for the phagocytosis of necrotic or apoptotic host cells, the latter mediated 
through surface expression of molecules such as phosphatidyl serine.
In addition to phagocytosis, macrophages may have a direct antiviral effect through 
the release of various cytokines by activated monocytes/macrophages, including IFNoc/p and 
TNFa. Other cytokines (ILl, IL-12 and IL-18) are important in activating vims-specific 
cellular responses, and chemokines (MIP-la/p, RANTES) have a direct antiviral effect and 
also recmit other inflammatory cells. Finally, activated macrophages produce other factors 
with antiviral activity, including ILl and nitric oxide(148).
Dendritic cells (DC)
Dendritic cells are similar in function to activated macrophages, insomuch as they 
also phagocytose exogenous antigen, and trigger adaptive immunity (humoral and cellular) 
through antigen presentation to T helper lymphocytes. However, these cells constitutively 
express much higher levels of class II MHC than do macrophages, and activation through the 
TLR again leads to the expression of much higher levels of B7 costimulatory molecules 
(CD80 and CD86), making them a key link to the adaptive immune response(147). The
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critical role that DC play in priming both the helper and effector arms of the adaptive cellular 
immune response will be covered in detail in the next section.
Immature plasmacytoid DCs, which develop into mature DC-2 cells and promote Th2 
responses (discussed in later section)(149), are the major producer of type I interferons(150). 
These cells are induced by HSV or other pathogens to produce up to 1000 times more IFN 
than any other cell types, and they make up -0.5% of PBMC(150). Loss of these cells is 
associated with clinical and virological progression in HIV disease, and long-term 
nonprogression is associated with preserved function and IFNa production(145).
Granulocytes
Granulocytes can be divided into neutrophils, basophils/mast cells, and 
eosinophils(147). Neutrophils (polymorphonuclear leukocytes; PMNs) are the most abundant 
leukocyte in the blood, and migrate to extravascular sites of inflammation through a process 
of rolling, adhesion and diapedesis. PMNs are primarily responsible for the phagocytosis of 
opsonized particles through cell surface receptors for IgG Fc receptors and complement C3b, 
essentially functioning as the effector cells of the humoral immune system. These cells do 
not play a major role in HTV infection, although neutrophil function may be compromised in 
advanced disease(l 51).
Natural killer (NK) cells and NKT cells
NK cells are bone marrow-derived lymphocytes that share a common progenitor with 
T cells, and are important in the immune control of infections and tumours (152). NK killing 
of antibody-coated cells, by antibody-dependent cellular cytotoxicity, is mediated through 
surface receptors for IgG Fc. In addition, NK cells carry out surveillance and lysis of cells 
that lack sufficient quantities of class I MHC on the cell surface. This function is mediated
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through a complex system of killer-activating and killer-inhibitory receptors, recently 
reviewed in detail by Lanier(153). Binding to their respective ligands on target cells activates 
a variety of activating receptors, including CD2, CD 16, NKR-Pl, NKp44, NKp46, DNAM-1 
and others. Additive or synergistic activation of these receptors initiates NK effector activity, 
generally cell lysis or cytokine production, unless the NK cells are turned off by inhibitory 
receptors, such as Ly49, the KIRs and CD94/NKG2, that recognize class IHLA molecules on 
the target cell surface (154, 155). Some of these receptors are specific for HLA A, B and C 
alleles (eg: the human killer cell immunoglobulin-like receptors; KIRs), and others for 
nonclassical HLA molecules such as HLA-E (eg: the heterodimeric receptor complex 
CD94/NKG2A).
NK cells are particularly important in the control of viral infections in cells that 
express little class I HLA, such as hepatocytes and neural cells. For instance, the release of 
IFNy and IFN(x/p by NK cells in the liver of transgenic mice infected by hepatitis B occurs 
before maximal infiltration of the liver by virus-specific CTL, and is crucial in preventing 
liver disease(148). The effector cells involved in this phenomenon are a subset of T cells, 
which express NK cell markers, known as NKT cells. These cells have a limited TCR 
repertoire, and recognize glycolipid antigens in association with the nonclassical HLA-like 
molecule CD Id. This means that while NKT cells probably play a role in the response to 
pathogens with cell wall glycolipids, such as mycobacteria and some parasites, the role of this 
NK subset in most viral infections remains unclear(148).
However, NK cells do play an important role in innate antiviral defence. CMV acts to 
reduce the surface expression of class I MHC after cell infection, presumably in order to 
evade host CTL responses. However, in order to inhibit the NK-mediated cytolysis that will 
occur without the binding of MHC class I to inhibitory NK receptors, the virus must also 
encode an MHC-like molecule (UL18), demonstrating that NK killing is a powerful enough
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host defence to select for complex viral escape mechanisms(156). In addition, recent work 
has shown that the NK cell activation receptor Ly-49H is critical to innate resistance against 
murine CMV(157). NK cells also play a role in HTV-l infection, and are able to eliminate 
HTV-infected cells, either directly or through ADCC(158).
Soluble factors: complement and mannose-binding lectins
Activation of the complement cascade can occur through the classic pathway (by 
antigen-antibody complexes), the alternative pathway (directly, by microbial cell walls), or 
the lectin pathway (via the binding of microbial carbohydrates to plasma mannose-binding 
proteins)(159). Different components of the complement cascade then perform different 
effector functions. For instance, C3 is cleaved to form C3b, which coats microbial cells and 
promotes phagocytosis by PMNs bearing complement receptors; C5a is a neutrophil 
chemoattractant; and the late components of the complement cascade organize to form the 
membrane attack complex, which punches holes in target cell membranes. Mannose binding 
lectins (MBLs) bind to pathogens directly, and may lyse them directly or target them for 
phagocytosis. HTV-l is a target of both complement( 160) and MBLs, with low levels of the 
latter associated with rapid HTV disease progression(161).
A d a p t iv e  Im m u n it y
The major difference between adaptive and innate immune responses is the capacity 
of the former to generate immunologic memory, such that subsequent encounters with the 
same pathogen will be stronger and faster. In addition, adaptive immune responses are more 
specific, and as a result there is an enormous degree of receptor diversity built into 
lymphocytes, which are the cell type responsible for most adaptive effector functions(147). 
Adaptive immunity can be broadly divided into the humoral arm (antibody-mediated; B
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lymphocyte effectors) and cellular arm (cell-mediated; T lymphocyte effectors), although 
these two arms interact, and components of one will frequently enhance or inhibit the other.
Due to the extraordinary degree of effector diversity that must be generated in order to 
recognize pathogens with such fine specificity, certain underlying principles are shared 
between the humoral and cellular arms. In each case, the component responsible for the fine 
immune specificity, namely the T cell receptor (TCR) of the T lymphocyte and the antigen- 
binding region (Fab) of the B lymphocyte-derived antibody, is generated through a process of 
extensive gene rearrangement. After deletion of B lymphocytes producing self-reactive 
antibodies and T lymphocytes with self-reactive TCR, a pool of cells is left which has 
enormous immune diversity. It is estimated that the lymphocyte pool is able to produce about 
10^  ^different antibody specificities (162), and the same number of TCR. While cells of any 
given specificity are only present in very small numbers in this lymphocyte pool, host 
interaction with a pathogen will result in the processing and presentation of relevant epitopes, 
and in the selective clonal expansion of those lymphocytes specific for the pathogen.
It is beyond the scope of this thesis to delve too deeply into the genetic recombination 
mechanisms leading to the generation of such immune diversity, or into the deletion of self­
reactive lymphocytes. Furthermore, in outlining the fundamental issues of cellular and 
humoral immunity which are most relevant to the thesis research, I will focus on mechanisms 
of antiviral immunity, rather than on aspects of immunity with more relevance to bacterial or 
parasitic pathogens.
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C e l l  m e d ia t e d  im m u n it y
Cell-mediated immunity describes any adaptive immune response in which antigen- 
specific T cells play the main role. In contrast to humoral immunity (see next section), this 
type of immunity cannot be transferred to a naïve recipient with immune serum, but requires 
the presence of specific immune cells(163).
The T cell receptor
The antigen specificity of the cellular immune response lies in the T cell receptor 
(TCR). Unlike antibodies, which are released from the cell, the TCR is strictly a 
transmembrane molecule. The TCR is a heterodimer of either oc/p or y/8  chains, with each 
chain containing a constant and a variable domain. The antigen specificity of the TCR 
depends on three hypervariable complementarity determining regions (CDR) that are found 
in each chain, known as CDR1-3(159).
T lymphocytes are divided into cc/p and y/8  lymphocytes, depending on the chains 
making up the TCR heterodimer. In the case of (X/p T cells, the CDR come together to 
recognize an antigen-derived epitope presented in the binding groove of a class IHLA 
molecule (see below). The mechanism of antigen recognition for y/8  T cells is less clear: 
while some appear to recognize antigen in isolation, like antibodies, others recognize antigen 
presented by ‘nonclassical’ HLA molecules such as CDl. As opposed to o/p T cells, which 
are specific for epitopes derived from peptide antigens, these y/ô T cells may recognize lipid 
or glycolipid antigens, such as those derived from the lipid-rich cell wall of mycobacteria.
The HLA system
HLA genes associated with the human immune response fall into two classes, HLA 
class I and n. As shown in Figure 1.8, the structure of these molecules differs, with class I
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molecules consisting of an a  chain and the P2 microglobulin molecule, while the class II 
molecule consists of a  and p chains(164). The a  chain of the class I molecule is divided into 
five domains, the two peptide binding domains, an immunoglobulin-like domain, a 
transmembrane domain and the cytoplasmic tail, as shown in Figure 1.8 (below). Class II a  
and P chains have four domains, with a single peptide-binding domain, and a similar 
immunoglobulin-like domain, transmembrane domain and cytoplasmic tail. Most somatic 
cells express class I molecules on their surface, while class II molecules are expressed by a 
specialized group of immune cells, including dendritic cells, macrophages, B cells and 
activated T cells.
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Figure 1.8 Schematic diagram of HLA Class I and Class II on the cell surface.
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Beta2-microglobulin (82m) is the light chain of the class I molecule. The a  chain of the class 
I molecule has two peptide-binding domains (a l and oc2), an immunoglobulin-like domain 
(a3), the transmembrane region (TM), and the cytoplasmic tail. Each of the class II a  and p 
chains has four domains: the peptide-binding domain (a l or pi), the immunoglobulin-like 
domain (a2 or p2), the transmembrane region, and the cytoplasmic tail.
From: Klein J and Sato A, 2000(164)
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Although there are 20 class I genes in the HLA complex on chromosome 6, there are 
only three genes, HLA-A, B and C, which play a major role in the cellular immune response. 
Nomenclature for class II HLA is more complex, partly due to the fact that each class II 
molecule has two separately coded antigen binding regions, the a- and p-chains. A three- 
letter code is used, with the first letter (D) representing class II HLA, the second (M, O, P, Q 
or R) the class II family, and the third (A or B) the chain (a  and P respectively). A crucial 
feature for the immune function of HLA class I and II molecules is the peptide-binding 
groove. This structure has a floor, formed by a P-pleated sheet from components of the class 
l a  chain, or a  and P chains in the case of the class II molecule. In addition, the a  chain coils 
into an a  helix to form the two ‘walls’ of the groove. A major difference between the 
binding groove of class I and II HLA molecules is the size of the processed peptide that they 
bind. Class I molecules fit a short peptide, generally 8-12 amino acids in length, since the a  
helix domains forming the groove walls pinch inwards, essentially ‘closing’ the groove, as 
shown in Figure 1.9, below(165). The class II molecule, however, has an ‘open’ groove, and 
so has no restrictions on the size of the peptide that can be bound(166).
Antigen processing and presentation
In order to generate a cellular immune response against a specific pathogen, it is 
essential that the host process antigens from that pathogen in such a way that they can interact 
with the TCR of pathogen-specific T cells, i.e.: as small peptide epitopes complexed with 
HLA molecules. Antigen processing and presentation generally follows one of two 
pathways, as shown in Figure 1.10. These pathways result in the presentation of peptide 
epitopes by class I or class II HLA, respectively, although there is almost certainly some 
crossover between these pathways(164).
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Figure 1.9 Schematic view of the HLA Class I ‘closed’ binding groove, from above.
1 Helix 
p-Pleated sheet
«2 Helix
The figure is a ribbon model showing the tertiary structure of an HLA class I peptide-binding 
groove. The model is shown from the top, and the p pleated sheets are actually composed of 
the a  chain.
From Klein J and Sato A, 2000(164)
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Figure 1.10 Pathways of generating peptides for loading onto class I HLA 
molecules (Panel A) and class II HLA molecules (Panel B).
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Panel A shows the principal pathways of generating peptides for loading onto HLA class I 
molecules, while Panel B shows the processing of extracellular proteins. It should be pointed 
out that endogneous processing of peptide epitopes for class I presentation (Panel A) does not 
necessarily require replication of viral DNA/RNA within the nucleus, since the life cycles of 
most viruses (HIV-1 being an exception) do not involve intranuclear replication. These 
peptide generation pathways are described in detail in the following text.
From'. Klein J and Sato A, 2000(164)
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a) Class I processing and presentation (Panel A in Figure 1.10). All worn-out cellular 
proteins and over 30% of newly synthesized proteins are unfolded by chaperone molecules, 
and the polypeptides are processed into short peptide fragments within the proteasome(167). 
Peptides may be recycled back into amino acids, or may be transferred into the endoplasmic 
reticulum (ER) through membrane channels formed by the transporters associated with 
antigen processing (TAPs)(168). The luminal side of the ER also contains the two subunits 
of a class I HLA molecule, the a  subunit and the P2 microglobulin molecule, which have 
been channelled into the ER from cytosolic ribosomes. These molecules are brought together 
by a series of chaperone molecules, namely calnexin, calmodulin and tapasin. After joining 
to form a class I HLA molecule, a compatible processed peptide entering the ER is added to 
the class I binding groove, and the entire class I-peptide complex migrates to the cell surface. 
Here, processed peptides are displayed on the cell surface in conjunction with class I HLA, 
while the complex remains anchored by the transmembrane component(164).
The end result of class I processing is presentation on the cell surface of 
peptides derived from endogenous cellular proteins, and so this pathway is known as the 
endogenous pathway of antigen processing. Every somatic cell displays hundreds of 
thousands of self-generated peptides on its surface, with a few to thousands of copies of each 
peptide per cell(169). As might be expected, this processing pathway is particularly useful in 
providing defence against intracellular pathogens -  particularly viruses, which use host 
cellular machinery to translate viral proteins. An interesting corollary is that the generation 
of any virus-specific cellular response through the endogenous pathway, which is thought to 
prime most CTL responses, would require productive cellular infection by that virus(170).
The class I peptide binding groove is ‘closed’, restricting the size of the peptide that 
can be accommodated to 7-15 amino acids, oriented with the N and C termini at specific ends 
of the binding groove(164). While side chains of the middle amino acids are oriented to
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point outwards, the other side chains point into the HLA molecule, and must be 
accommodated within six specialized binding pockets in the groove’s floor, numbered A-F. 
The binding pockets B and F, which accommodate side chains from amino acids P2 and P9, 
are particularly selective, and are called anchoring pockets. The HLA-peptide affinity is 
then dependent on the ability of certain critical amino acid residues (the amino acid ‘motif’) 
to bind these anchoring pockets, and these amino acids are known as anchor residues.
These concepts are displayed visually in Figure 1.12 (overleaf).
b) Class n  processing and presentation (Panel B in Figure 1.10). Foreign proteins which are 
taken up by the cell through endocytosis or phagocytosis are processed through the 
exogenous pathway, which results in the expression of peptides on the cell surface in 
conjunction with HLA class n  molecules(168). Again, the two HLA chains are 
manufactured separately and brought together on the luminal side of the ER. Here they 
become associated with the invariant chain, part of which blocks the peptide binding groove 
and prevents premature peptide loading. The class E-invariant chain complex is then 
transported within vesicles to the endosomes, forming the MHC class E compartment.
Within this compartment the exogenous proteins are degraded by protease enzymes, the 
invariant chain is dissociated from the class E molecule, and a suitable peptide becomes 
bound to the class E binding groove. The entire complex is now transported to the cell 
surface, resulting in an HLA class E bearing cell (usually a B cell, DC or macrophage) 
displaying an exogenous peptide in the binding groove.
c) Antigen cross-presentation. The pathways above result in the association of 
exogenous peptides with class E HLA, and of endogenous peptides with class I HLA. This 
prevents the CTL-mediated killing of cells that have processed exogenous antigen from
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infected or tumour cells(171). However, it is well documented that in some circumstances 
class I HLA on professional APCs can display peptides derived from exogenous proteins, and 
class n  peptides from endogenous proteins. This alternative exogenous pathway is also 
known as cross-presentation. Exogenous protein may represent an important source of 
antigen for priming CD8+ responses, as demonstrated by the observation that an EB V epitope 
protected from proteasomal degradation (and thus from endogenous processing) may account 
for up to 5% of CD8+ T cells in the peripheral blood of subjects with infectious 
mononucleosis(172). MHC class I cross-presentation occurs when necrotic or apoptotic 
virally-infected cells are phagocytosed by immune cells(173), and can also be used to present 
HIV-1 epitopes derived from incoming cell-free virions(171).
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Figure 1.11 Interactions between processed peptides and the HLA binding groove.
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Panel A shows examples of nonamer peptide motifs that have been found in complexes with 
the indicated HLA class I molecules. The anchor residues are highlighted in yellow. In Panel 
B, a longitudinal section through the peptide-binding groove of an HLA class I molecule, the 
side chains of amino acid residues composing the bound peptide (PI through P9) are oriented 
either down into the pockets of the HLA molecule or up. See page 6 for amino acid letter 
codes.
From: Klein J and Sato A, 2000(164)
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Antigen specific activation of the T cell: the CD3 complex
Although it is the TCR on the surface of T lymphocytes that recognizes peptides 
bound to class I or II HLA molecules, the expression of the TCR and the process of T cell 
activation that follows its binding to antigen is dependent on the noncovalently associated 
CD3 complex. In fact, the binding of aCD3 antibodies can stimulate T cell responses 
identical to antigen-specific responses(147). These antibodies will induce responses in a 
population of T cells with varying antigen specificities, and are therefore known as 
polyclonal T cell activators. The CD3 complex consists of a cluster of five transmembrane 
proteins, CD3y, CD38, two molecules of CD3e and a disulphide-linked homodimer of the Ç 
chain. The three CD3 molecules belong to the Ig superfamily, although they do not display 
any variability or polymorphism that contributes to antigen specificity, while the Ç chain does 
not. The CD3 molecules contain in their cytoplasmic tail a single copy of the 
immunoreceptor tyrosine-based activation motif (ITAM), within which tyrosine residues 
become phosphorylated upon TCR cross-linking by antigen, initiating a cascade of 
intracellular signalling events. The Ç chain contains three ITAMs within its cytoplasmic tail, 
and is responsible for intracellular signal transduction for the TCR, as well as for other 
receptors (including the NK cell Fc receptor). Several protein kinases are responsible for the 
tyrosine phosphorylation of the IT AM cytoplasmic tails, among them p56^ ^^ , p59^^ and ZAP- 
70(159). Crucially, activation by the CD3 complex also involves the binding of p56^ ^^  to the 
cytoplasmic tail of CD4 (in T helper cells) or CDS (in CTL), as well as ligand interaction 
with other T cell costimulatory molecules. The complex pathway of T cell activation is 
outlined in Figure 1.12 (overleaf).
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Figure 1.12 Steps in T cell activation.
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T cell activation involves a complex series of events that follow cross-linking of the TCR on 
the cell surface, as described in the preceding text. The antigen receptors are associated with 
CD3 and Ç chain signal-transduction molecules bearing cytoplasmic immunoreceptor 
tyrosine-based activation motifs (ITAMs), which are subject to phosphorylation (P) by 
protein kinases such as p56^^\ p59^, and ZAP-70. The initial stages of activation also 
involve the binding of p56'*^  ^to the cytoplasmic tail of CD4 or CDS, leading to downstream 
signaling and the transcriptional activation of genes involved in cell proliferation and 
differentiation. Signals from costimulatory receptors such as CD28 and CD 154 are also 
needed for complete activation, or anergy or apoptosis will occur.
From: Delves PJ and Roitt IM, 2000(174).
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T cell accessory molecules
Although the CD3 complex alone can induce full T cell activation, this requires that a 
threshold of approximately 8000 surface TCRs (from a total of -10,000(164)) be triggered by 
ligand(175). However, T cells become more sensitive to antigenic stimulation if 
costimulatory receptors are simultaneously triggered, lowering the activation threshold to 
-1500 TCR(175,176). Sub-optimal CD3 activation, in the absence of costimulation, results 
in T cell anergy or apoptosis. Accessory molecules are invariant cell surface molecules that 
interact with ligands on the cell surface of antigen-presenting cells or target cells, a process 
which increases the duration of cell-cell adhesion, and may enhance signal transduction. For 
instance, professional APCs such as dendritic cells express particularly high levels of the 
costimulatory molecules B7 (ligand for CD28) and CD40 (ligand for CD 154), and this makes 
them uniquely able to stimulate naïve T cells. It is thought that accessory molecules may be 
necessary to overcome the generally low affinity of TCRs for their peptide-MHC ligands. In 
addition, the requirement for costimulation means that adaptive immune responses are 
dependent in part on pathogen corecognition by innate receptors (such as the TLRs), thereby 
providing another safeguard against autoimmune responses.
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Table 1.3 T cell surface accessory molecules and their ligands.
Accessory
molecule
Cellular distribution Ligand Action
CD4 coreceptor Class II restricted T cells Class II HLA Enhances adhesion and signalling.
(-65% ap  T cells) T Ag sensitivity
CDS coreceptor Class I restricted T cells Class I HLA Enhances adhesion and signalling.
(-35% ap  T cells) T Ag sensitivity
0X40 Activated T cells OX40L (DCs, Costimulates CD4
endothelium. proliferation/cytokine release
T/B cells)
LFA-1 P2 integrin on >90% of bone ICAM-I/2 Adhesion and signal transduction -
marrow-derived cells needed for CTL killing, etc
CD28 -80% CD4+, -50% CD8+ T B7-I (CD80), Î  IL-2 expression, T Bel
cells B7-2 (CD86) expression
CD45 T cells, B cells 7CD22 Enhances T cell activation via Ick
dephosphorylation
CD 154 (CD40L) Activated CD4+ T cells, all CD40 T signal transduction, promotes B
B cells cell class switching
CD2 (LFA-2) Most mature T cells CD58 (LFA-3) T cell activation and cell-cell
adhesion
Fas ligand Activated T cells Fas (CD95) Activation-induced dell death
(apoptosis)
L selectin (CD62L) B cells, T cells, monocytes. Endothelial Endothelial adhesion.
NK cells sialylated extravasation
glycoproteins
Adapted from: Abbas AK, Lichtman AH and Pober JS, 1997(147).
64
CD4 and CD8 coreceptors
CDS and CD4 are particularly important accessory molecules, acting as coreceptors 
for MHC on the surface of antigen-presenting cells. In addition, mature T cells are frequently 
classified into broad functional groups based on the CD4+/CD8+ phenotype, with CD4+ T 
lymphocytes considered cytokine-producing T helper cells, and CD8+ lymphocytes 
considered cytotoxic T lymphocytes (CTL) or their precursors. Although an 
oversimplification, this classification is useful in visualizing the effector arms of the cellular 
immune system, and in understanding the unique immunologic defects that are a consequence 
of CD4 cell destruction in HIV-1 infection. It is also the reason why, although both HLA 
class I and II expressing cells present antigen on their surface, the latter are often referred to 
as target cells and the former as effector cells.
As noted in the table above, approximately 65% of mature T lymphocytes express 
CD4, and 35% express CD8. Both molecules are closely associated with the TCR complex, 
and bind to HLA at the same time as the TCR complex. For this reason, they are known as 
coreceptors. Both molecules are transmembrane glycoproteins, but CD8 molecules exist as 
heterodimers made up of CD8a and CD8|3, while CD4 molecules are found as monomers on 
the surface of T lymphocytes, macrophages and monocytes.
T cell development and selection
T cells develop from bone marrow stem cells that migrate to the thymus, where they 
do not initially express either CD4 or CD8, and are known as double negative thymocytes. A 
programmed series of rearrangements within the a- and P-receptor genes of early thymocytes 
results in a very diverse population of CD4/CD8 double positive cells. However, the TCR of 
most of these thymocytes are unable to recognize self-MHC, and so fail the process of 
positive selection and are deleted. Double positive cells recognizing self MHC are positively
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selected, maturing to express high levels of TCR and losing expression of either CD4 or 
CDS, becoming single positive thymocytes, which are exported from the thymus to the 
periphery. Less than 1% of all T cell progenitors will enter the periphery as naïve T cells. In 
this setting, high affinity interactions between their TCR and an HLA molecule complexed 
with foreign peptide will lead to clonal proliferation. If the HLA molecule engaging the TCR 
belongs to class n, the T cell will differentiate into a CD4+ T helper cell, and into a CD8+ 
cytotoxic T lymphocyte (CTL) if it belongs to class I.
Function of CD8+ cytotoxic T lymphocytes
Engagement of the TCR of an antigen-specific CD8+ lymphocyte by an appropriate 
class I HLA-antigen complex triggers activation of the CD3 complex, setting into action a 
complex signalling cascade and eventually resulting in CTL effector functions(147). These 
functions can be divided into three categories: direct lysis, Fas-mediated cytotoxicity, and 
noncytotoxic functions:
Direct target Ivsis: The classic effector function of CD8+ CTL is perforin-mediated lysis of 
target cells, a process that is calcium dependent(177). Lytic granules within CTL contain 
perforin and proteases such as granzyme B. Engagement of the TCR leads to granule fusion 
with the CTL plasma membrane at the area of target cell apposition, and to release of granule 
contents. Perforin, a molecule that is functionally very homologous to the complement 
membrane attack complex, then integrates into the target cell membrane, forming pores and 
resulting in cell death through osmotic lysis(147). In addition, granzyme B causes DNA 
fragmentation within the target cell.
66
Fas-mediated target lysis: In addition to direct lysis, target cells can also be killed by CTL 
through a calcium-independent process, which results in target cell apoptosis(177). This 
process involves the interaction of Fas-ligand, present on the surface of CD8+ CTL, with Fas 
(CD95) on the surface of target cells, which in turn induces a Cysteine Aspartic Acid 
Proteases (caspase) cascade, resulting in genomic DNA fragmentation, membrane blebbing, 
and the exposure of phagocytosis-stimulating molecules on the cell surface(178).
Other effector functions: While the ability to kill infected cells is a key function of CD8+ 
CTL, it is unlikely that viruses which infect large numbers of host cells can be cleared 
through killing alone (148). Upon antigen recognition the CTL also releases antiviral 
cytokines, chemokines and other soluble factors. The major cytokines released are TNFa 
and IFNy, and the antiviral effect of these cytokines, rather than direct cell killing, is chiefly 
responsible for viral clearance in transfer experiments with hepatitis B virus (HB V) infected 
mice(179-181). Indeed, the release of IFNy by NK and NKT cells in animal models of HBV 
infection can precede the peak of CTL infiltration in the liver, and is crucial in preventing 
liver disease(148). In addition, chemokines, such as RANTES, M IP-la and MIP-1P(182, 
183), and the undefined soluble factor known as T cell antiviral factor (CAE) may play a role 
in the antiviral effect of CD8+ CTL. The antiviral effects of chemokines and CAF appear to 
be particularly important in the immune control of HIV-1(184, 185).
Tel and TcQ / Tc2 CTL: As noted, CD8+ responses are generally associated with the release 
of IFNy, TNFa and IL-2, cytokines that are also associated with a Thl (type 1) T helper 
response (discussed in detail below). Although division of CTL into other subsets is less 
defined than for Th responses, type 0 and type 2 CTL (TcO and Tc2, respectively) have also 
been described(186). The latter CD8+ subsets are characterized by the production of both IL-
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4 and IFNy (TcO), or the production of IL-4 alone (Tc2), may have a reduced cytolytic 
potential(187), and promote Th2 rather than Thl type CD4+ responses(188). CTL clones of 
this phenotype may be more common in HTV infection, perhaps contributing to poor viral 
control(187). While the factors associated with subset differentiation are less clear than for 
CD4+ cells, IL-4 promotes Tc2 differentiation, while IL-12, IFNy and sometimes IL-5 
promote Tel differentiation(188,189).
Epitope hierarchy: the concept of immunodominance
The proteasomal processing of all the proteins expressed by an intracellular pathogen, 
even a simple organism such as a virus, should result in the presentation of a vast number of 
foreign peptide-HLA complexes, and in the generation of a huge array of CTL specific for 
various viral epitopes. In practice, however, CTL are only detected against a small fraction 
of possible viral epitopes, and there is often a clear hierarchy among those responses, with 
certain immunodominant peptide epitopes tending to elicit stronger responses than other, 
subdominant, epitopes(190). In addition, certain epitopes are only recognized in unusual 
circumstances, such as in the form of synthetic peptides, and are known as cryptic 
epitopes(191). There are several possible explanations for these observations(192):
a) Processing of peptide epitopes: In order for a predicted peptide epitope to 
be immunogenic, it must be efficiently processed and presented on the cell surface. The 
DNA sequences that flank a given epitope may have an important effect on proteasomal 
processing orER targeting of that epitope(193, 194), as may subtle sequence changes within 
the epitope itself(195). The abundance of the viral protein from which these epitopes are 
processed will have an effect, and proteins expressed at high levels, or during early stages of 
the viral life cycle might be expected to become immunodominant. For instance, this might
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explain the immunodominance in HTLV-1 infection of CTL directed against the early protein 
Tax(196).
b) HLA class I affinity: Compatible peptides from the proteasome become
associated with nascent class I HLA molecules within the endoplasmic reticulum. Although 
the process of peptide selection is unclear, it seems that the rate of association of a peptide 
with a given HLA molecule depends in part on the peptide-HLA binding affinity, and that 
this also influences immunodominance(192). Indeed, when panels of predicted peptide 
epitopes are used to generate HLA-restricted CTL lines, there is a stepwise association 
between the strength of the peptide-HLA binding and the probability of a given peptide being 
immunogenic(197, 198).
c) Level of cell surface expression: Immunodominance may mirror the levels of cell 
surface expression of a given peptide(192), such as the dominant HTV A2-restricted epitope 
SLYNTVATL, expressed at 30-fold higher levels than subdominant epitope
ILKEPVHGV(169). High surface expression is likely to result from a combination of 
enhanced epitope processing, higher peptide-HLA affinity, and/or the stability of the peptide- 
HLA complex on the cell surface(199). However, it is also the case that epitopes expressed 
at relatively low levels on the cell surface may be immunodominant, as is the case for the 
intracellular bacterium Listeria monocytogenes(200), and for EBV(201).
d) Presence of specific naïve CD8+ T cell precursors: The observations made in the 
L. monocytogenes model suggest that inununodominance does not depend only on the 
efficiency of peptide processing or cell surface expression(202). Rather, measurements of in 
vivo T cell expansion following infection indicate that differences in the sizes of peptide-
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specific T cell responses may be due to differences in the repertoire of naive T cells. 
Dominant T cell populations express a more diverse TCR repertoire than do subdominant T 
cell populations, supporting this hypothesis and suggesting that immunodominance is due to 
higher numbers of pre-existing, naïve T cells with a TCR that will recognize and bind a given 
epitope(200). In some cases this may represent the deletion of epitope-specific CTL that can 
cross-react with certain self antigens. This is seen in EBV infection, where early deletion of 
B8-restricted CTL that cross-react with B*4402 means that subjects who are both B8(+) and 
B *4402(4-) have a smaller population of CTL specific for that EBV epitope, and that within 
this population there is a much less diverse TCR repertoire(203, 204). In addition, the 
affinity of TCR-peptide binding may also be important, another way in which the pre-existing 
TCR repertoire can influence immunodominance(205).
e) Suppression bv immunodominant epitopes: The expression of immunodominant 
epitopes may competitively inhibit the levels of cell surface expression of subdominant 
epitopes(192, 206), and this may alter the protective efficacy of subdominant responses(207). 
However, if processing of these dominant epitopes is blocked, this may not result in the 
enhancement of previously subdominant responses, suggesting that T cell populations 
specific for different antigens but the same pathogen expand independently(208). Part of the 
suppressive effect of an immunodominant epitope may lie in the efficiency of CTL 
generation to this epitope: if CTL to one epitope are generated more quickly, then the 
subsequent rapid reduction in viral load may indirectly suppress the development of more 
slowly-generated (subdominant) responses(192, 205, 209).
Overall, it is thought that only 1/200 possible peptides has sufficient class I HLA 
affinity (Kd>500nM) to be immunogenic, that only half of those peptides can be recognized
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by a naïve TCR, and that only 1/5 of those peptides is efficiently processed. Therefore, only 
1/2000 possible peptides expressed by a foreign antigen will achieve immunodominant status 
with a given class I allele, and roughly the same proportion will become a subdominant 
epitope(199). However, not only are the mechanisms of epitope immunodominance 
incompletely understood, but so is the significance of the phenomenon. This is particularly 
important for HIV, where vaccines are currently being developed based on generating 
specific CTL epitope responses(210). It seems clear is that while immunodominant epitopes 
are important in the control of viral infections(211, 212), subdominant epitopes may also 
be(207). In addition, while different HLA haplotypes are associated with different patterns 
of epitope immunodominance hierarchy, a CTL epitope that is dominant in one haplotype 
may still maintain strong CTL responses in the context of a different ‘supporting cast’ of 
HLA molecules, even if it is no longer actually immunodominant(213). The latter 
observations would suggest that immunodominance hierarchies in the context of differing 
HLA haplotypes are likely to have less of an impact on the efficacy of epitope-based vaccines 
than was once thought(213).
Differentiation of CD4+ T helper (Th) lymphocytes
A high-affinity interaction between the TCR of a naïve CD4+ T cell and foreign 
peptide complexed with class II MHC on the surface of an ARC leads to IL-2 production and 
the clonal expansion of the T cell(214). This activation process will generally occur within 
the secondary lymphoid organs, namely the spleen, lymph nodes and Peyer’s patches. Within 
these sites naïve CD4+ T cells are concentrated within the paracortex (lymph nodes) and 
periarteriolar lymphoid sheath (spleen), in close contact with antigen-presenting dendritic 
cells(215). Activated Th cells then play a key role in antiviral immunity, both by producing 
antiviral cytokines, and by providing help to CTL and antibody-producing B cells(148).
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Although all naïve CD4+ T cells produce IL-2 after initial antigen stimulation, their cytokine 
profile changes after several cell divisions, as the T cell differentiates into the Thl or Th2 
subset(216, 217). The cytokine regulation of these Th subsets is summarized overleaf, in 
Figure 1.13.
Thl Ivmphocvte subset: Thl cells play a major role in the eradication of intracellular 
pathogens, including viruses and some bacteria, and Thl responses are characterized by the 
production of cytokines IL-2, TNFa and IFNy. A Thl response may be associated with an 
antibody switch to the IgG2a isotype, as well as activation of NK cells and CD8+ CTL 
expressing IFNy and perforin. Overactive responses are associated with autoimmune 
diseases and immunopathology(214).
Th2 Ivmphocvte subset: Th2 cells are more important in the control of extracellular 
infections, chiefly helminths, parasites and most bacteria. These responses are characterized 
by the production of cytokines IL-4, IL-5 and IL-13, the activation of mast cells and 
basophils, and the production of antibody IgE. Overactive responses are associated with 
allergy and atopy(214).
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Figure 1.13 Cross-regulation of T helper cell responses.
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Cytokines are major inducers of Thl and Th2 subset development, as shown in the figure 
above. Antigen-presenting cells (APCs), partly as a result of the cytokines that they produce, 
can induce the development of Thl or Th2 cells. Naive CD4^ T cells develop into Thl cells 
in response to interleukin 12 (IL-12). Thl response development depends on IFNy, and 
maintenance on IL-12 and IL-18. Development of Thl responses can be antagonized directly 
by IL-4 and indirectly by IL-10, which inhibits the production of IL-12 and IL-18. Th2 cells 
differentiate in response to lL-4.
From: O’Garra, 2000(214)
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As Figure 1.13 shows, Thl and Th2 subsets produce cytokines which not only 
promote differentiation of their own subset, but which can actively inhibit the differentiation 
of the opposite subset. Because the two subsets are important in clearing different types of 
pathogen, it is important to try to understand what drives the immune response down each 
path. Although factors such as antigen dose(218, 219), peptide-TCR affinity(220) and the 
nature of costimulatory interactions(221, 222) are important, what ultimately determines the 
differentiation pathway of a naïve T cell seems to be regulation by the antigen-presenting 
dendritic cell (DC)(223). IL-12 is the dominant Thl-directing cytokine, and IL-12 
production in humans is limited to monocyte-derived DCs (“D C l” class), as opposed to 
plasmacytoid DCs (“DC2” class)(223). IL-12 production is highest in immature (peripheral) 
DCs, where release is regulated by IFNy and CD40-ligand(224), and in mature DCs 
expressing high levels of CD40(223). CD40L activation of human monocyte-derived (Thl 
prone) DCs, but not plasmacytoid (Th2 prone) DCs, results in rapid IL-12 production(149). 
Although the mechanism of IL-12 action has not been fully elucidated, it may involve the 
activation of transcription factor STAT4 through the IL-12 receptor(225), which is important 
in direct and indirect control of IFNy transcription(223).
DC-derived factors appear to be less important in directing T cells down the Th2 path. 
It is possible that Th2 is a ‘default’ pathway, so that Th2 cells will develop spontaneously in 
the absence of IL-12 production by DCs(223), although the cytokine IL-4 may have 
important Thl inhibitory effects through IL-12 receptor down regulation(226). In addition, 
strong costimulation through CD28 may promote a Th2 phenotype(222). Although much 
work has been done into further understanding the signalling pathways and transcriptional 
factors involved in Thl and Th2 development (reviewed in Murphy KM et al(227)), this 
exceeds the scope of this thesis.
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Function of T helper lymphocytes
Th cells play a key role in the antiviral response, both through the direct production of 
antiviral cytokines, and through the provision of help to B cells and CD8+ CTLs. Viral 
infection by vaccinia, influenza and vesicular stomatitis virus (VSV) can be cleared by Thl 
cells in the absence of CTL, both through cytokines fFNy and TNFa, and through the 
induction of antiviral antibodies(148). CD4+ lymphocytes can be directly cytotoxic, chiefly 
through the calcium independent Fas-FasL pathway (see above), but it seems unlikely that 
this plays a major role in clearing viral infections in v/vo(228).
Cellular immune memory
Pathogen specific memory is the key feature that differentiates adaptive from innate 
immunity, as it permits a more rapid and effective immune response upon rechallenge by the 
same pathogen(229). Memory T lymphocytes (both CD4+ and CD8+) have been stimulated 
by antigen, but they are thought to revert to a quiescent state instead of carrying out effector 
functions, and are activated upon antigen re-exposure, proliferating rapidly and secreting 
cytokines such as IFNy within as little as 4-6 hours(230, 231). While effector CTL are 
actively engaged in cytokine release and lytic function, both naïve and memory CD8+ T cells 
generally require antigen stimulation (or restimulation) to express effector function(232). 
However, a subgroup of ‘memory effectors’ is able to rapidly release high levels of 
cytokines, and may also contain perforin and kill target cells without restimulation(233). The 
study of CD8+ naïve, effector and memory responses is clouded, both by the semantics of 
defining these populations, and by the lack of clear phenotypic markers which can 
differentiate these overlapping groups. That said, these CD8+ lymphocyte populations are 
broadly associated with the following phenotypic markers(144, 234, 235):
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1) Naive: C m T ,  CD28'", CD45RA+, CD44' and CD69‘°
2) Effector: CD27', CD28', CD45RA'", CD44^'‘ and CD69“*''
3) Memory: CD27*, CD28*, CD45RA', CD44“«" and CD69'°
CD8+ memory is most easily thought of in the setting of a transient (nonpersistent) 
viral infection, such as influenza. Acute infection results in the activation of a large number 
of virus-specific effector CTL, and a proportion of activated CD8+ lymphocytes will lose 
activation markers and remain quiescent as memory lymphocytes. How certain activated 
CD8+ T cells are selected to become memory T cells is not clear, but the fact that the TCR 
repertoires of pathogen-specific CTL in the primary and memory pools are usually similar 
suggests a stochastic selection of memory cells from the pool of CD8+ lymphocytes activated 
by the infection(236-238). Likewise, the TCR repertoire induced by primary and secondary 
infection is generally similar(236, 237), although secondary infection may induce expansion 
of a more selective repertoire(238). However, there are exceptions to this rule. The epitope- 
specific CD8+ response in acute and chronic EB V infection may be dominated by quite 
different clonotypes, with a marked switch in dominant TCR usage in chronic infection(239, 
240).
The maintenance of effector CTL is dependent on antigen, so that once a self-limiting 
acute infection has been cleared, circulating effector CTL will decline over months or years, 
largely through a process of activation-induced cell death (AICD)(147). Whether the 
maintenance of a pool of memory CTL is dependent on the persistence of antigen is the crux 
of a long-standing debate. Memory CD8+ T cells have been shown to persist for up to six 
months in the spleens of MHC class I deficient mice, where further class I-restricted antigen 
stimulation is not possible, and to exhibit rapid cytokine responses upon antigen re- 
exposure(231, 241). Likewise, CD4+ memory cells can be generated and maintained from
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activated effectors transferred into class II deficient mice(242). While antigen may not be 
necessary for maintaining the memory pool, there is evidence that IL15 is needed for memory 
CD8+ cell cycling in these central sites(243), and there are conflicting reports on the role of 
IL-2 in this setting(232, 243). In addition, other work suggests that while the maintenance of 
specific CTL precursor frequencies and central T cell memory (in spleen and lymph nodes) is 
long-lived and antigen independent, T cell memory in the peripheral tissues is relatively 
short-lived in the absence of antigen(244). In these models, despite the persistence of 
memory T cells in central sites, the ability of these memory CTL to become activated and 
migrate to peripheral sites of antigen rechallenge is dependent on the time since antigen 
stimulation, as well as on the size of the original antigen inoculum(245). Indeed, long-term 
‘immunity’ to transient viral infections may in fact be dependent on the persistence of virus at 
very low, usually undetectable, levels(246), and a similar phenomenon has been suggested to 
explain some cases of CTL-based resistance to HIV-1(247).
In the setting of a persistent viral infection, the importance of virus-specific memory 
is less obvious: since there is ongoing antigenic stimulation, there would seem to be little 
need for a memory response. However, the ability to establish a true antigen-independent 
pool of memory CTL may be crucial in determining the eradication or persistence of a viral 
infection(248). If CTL are short-lived in the absence of antigen, then, as they reduce the 
level of virus (antigen), the size of the CTL population itself will diminish. This would result 
in the establishment of equilibrium between virus and host immunity, and in persistent 
infection. However, if the CTL response is long-lived and/or antigen-independent, then a 
CTL population of sufficient size will persist as the viral burden diminishes, ensuring 
clearance of virus, or at least an equilibrium at extremely low levels of virus(248).
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Effect of antigenic variation and HIV-1 clade on cellular responses
For a transient infection, the CTL response is strongly influenced by the nature of the 
pathogen used in the original challenge. Rechallenge with a virus that has sequence variation 
within a previously recognized CTL epitope can have several possible effects. Variation at 
residues which are not important in TCR binding may have no effect on class I presentation, 
or in the efficiency of cell killing by epitope-specific CTL. However, mice infected by a 
given virus may respond to rechallenge with a virus bearing a variant epitope by activating 
memory CTL directed against the original epitope, even if these T cells have a reduced or 
abrogated ability to recognize the variant(249). This phenomenon, known as original 
antigenic sin, impairs the hosts’ ability to clear rechallenge by variant viruses, or to suppress 
a persistent infection if variant viruses arise. In influenza infection, for instance, rechallenge 
with a virus variant results in the selective expansion from the memory pool of cross-reactive 
CTL that are able to recognize both the original and the variant epitope(250). In addition, 
challenge with a virus that has a mutation within a normally immunodominant epitope 
generates CTL specific for subdominant epitopes: markedly reduced responses to the 
immunodominant epitope are seen, both during the primary infection, and after rechallenge 
with a wild-type virus containing the immunogenic epitope(208).
These same principles apply to persistent viral infection, since the cellular immune 
response will be primed by epitope sequences present in the virus at the time of initial 
infection. HTV-l reverse transcriptase lacks proof-reading capabilities, and so replication 
errors (nucleotide deletion, insertion or duplication) occur at a frequency of lO'"^  to 10'  ^(251). 
Together with a virus replication rate of 10  ^/day, this means that HIV-1 has an enormous 
capability for sequence variation within an infected host. Indeed, the total worldwide 
diversity of the influenza virus is equivalent to the HIV-1 sequence diversity present within a
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single infected person(252). This inherent variability has significant implications for viral 
control by the cellular immune response, as is discussed in the next section.
Cellular immune responses in HIV-1 infection
HIV-specific CTL play a major role in the immune control of acute and chronic HIV 
infection. After acute infection there is a short period of high plasma viremia, and the 
reduction in this peak to the steady state level coincides with the rise of HIV-specific 
CTL(253). The peak CTL frequency at this time is inversely correlated with the viremia set 
point, so that higher CTL levels are associated with lower levels of steady state viremia, and 
with slower disease progression(254). The relationship between CTL and viral load in 
chronic infection is more complex, with an inverse relationship seen while the immune 
system is relatively intact(211, 212), but with no relationship seen in more advanced HIV 
disease(211). Further evidence that virus-specific CTL are crucial in controlling HTV-l 
infection comes from the observation that escape mutation within immunodominant epitopes 
is associated with increased plasma viral load and disease progression, both in acute(255) and 
chronic(256) infection, as well as in an SIV macaque model(257). CTL immune pressure has 
also been shown in a vaccine model, where SIV infection after the induction of CTL by 
vaccination results in the emergence of virus escape mutants(258). In addition, the depletion 
of CD8+ lymphocytes from SIV-infected macaques using specific antibodies results in a 
rapid rise in plasma viremia, which returns to baseline as the antibody is cleared(259).
Although up to 10% of all CD8+ lymphocytes in an infected person are HIV- 
specific(144), these CTL are generally unable to prevent disease progression and death. 
Mutational escape plays a role in this immune failure, and this may explain the observations 
that rapid progression is associated with the degree of class I homozygosity(260), and with 
oligoclonality of the HIV-specific CTL response(261). However, rapid disease progression
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in the absence of CTL escape is well documented(262). This may relate in part to the 
apparent low efficacy of HIV-specific CTL, which produce less perforin(263, 264), kill less 
effectively(264), produce less IFNy(211, 263), and demonstrate an immature phenotype(211, 
264) when compared to CTL specific for CMV. In a mouse model perforin-deficient CD8+
T cells were unable to clear LCMV infection, but were capable of causing severe 
immunopathology(265), and this has clear relevance to the HTV-l model, where CD8+ 
immunopathology has been suggested as a cause of some disease manifestations(266).
Another compelling reason for the failure of HTV-specific CTL to control disease 
progression is the specific impairment of CD4+ T helper responses by HTV(267). As has 
been discussed, CD4+ is the primary receptor for HTV-l cell entry, and chronic HTV-l 
infection is associated with a progressive decline in CD4+ lymphocyte numbers due to 
destruction of mature CD4-t- T cells and immature thymic progenitors. CD4+ T help is 
essential for normal CD8+ CTL function in a mouse model, where experimental depletion of 
CD4-H T cells leads to progressive decline in virus-specific CTL(268, 269). Qualitative 
impairment of CD4+ help generally happens early in HTV-l infection, even before the decline 
in CD4+ numbers(270). Although HTV-specific CTL can be maintained in the face of low 
CD4+ T cell counts(271), the lack of CD4+ help may relate to the functional impairment seen 
in HTV-specific CTL, as has been described in a mouse model(272). The fact that strong 
CD4+ help is associated with strong CTL responses also suggests that CTL may require 
CD4+ help for their maintenance(273, 274).
Finally, a number of individuals have been identified who show no evidence of 
immunologic impairment despite HTV-l infection for 20 years or more. In general, long-term 
nonprogression is associated with persistently normal CD4+ counts and undetectable viral 
loads, and the phenomenon has been associated with both viral and host immune factors. In a 
group of infected subjects known as the Sydney Blood Bank cohort, long-term
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nonprogression has been associated with infection by a virus with a deletion in the NefFL^^ 
region, as well as with strong HTV-specific CTL and T helper responses(275-277). However, 
disease progression has recently been seen in several members of the cohort, in association 
with reversion to wild-type NeJ{l22, 124). In other LTNP cohorts, not associated with 
infection by a defective virus, long-term nonprogression has been linked to strong and/or 
broadly-directed CTL responses(278-280), as well as with strong Gag-specific CD4+ 
responses, and an inverse correlation has been seen between levels of T help and viral 
load(281). These observations have led researchers to initiate antiretroviral therapy very 
early and/or intermittently in HTV infection, in order to present HTV-l to the immune system 
in limited quantities, minimizing the early impairment of CD4+ responses. Although these 
strategies have been associated with preserved Gag-specific CD4+ responses, and in some 
cases with strong CD8+ responses, the long-term impact on HTV-l infection is not yet 
clear(281, 282).
Significance of sequence variation within HIV-1
The phenomenon of CTL escape demonstrates that epitope variation can be crucial in 
HTV-l progression. What is less clear is the importance of variation between HTV-l clades. 
HTV-l is divided into three distinct groups, M (main), O (outlier) and N (non-M, non-0), 
each of which may have arisen from a separate cross-species transmission event(251). Most 
circulating HTV-l strains fall within group M, which is in turn subdivided into clades A-K. 
Interclade sequence variability is approximately 25-30%, while variants within a given clade 
differ by an average of 11%(251, 283). There is a distinct geographical distribution of these 
clades, with clade B predominating in North America and Europe, clade E in Thailand, and 
clade C in India. The highest degree of clade diversity is seen in Africa, where examples of 
virtually all clades and HTV-l groups have been described(283). The fact that several
81
different clades are circulating within a given region increases the chances of viral 
recombination, whereby a cell infected by two different HTV-l strains gives rise to progeny 
with genomic RNA from each virus, with subsequent strand switching. A recombinant virus 
that becomes established within a population is known as a circulating recombinant form 
(CRF)(251).
It would seem likely that this degree sequence diversity between clades would impair 
the ability of CTL from a subject infected by one clade to recognize the corresponding 
epitope from a different clade -  in fact, the very existence of CRFs implies that infection by 
one clade does not provide complete protection against infection by another. Despite this, 
cross-clade CTL are found in most HTV-infected subjects(284-290), although some strong 
CTL responses may display no cross-reactivity at all(284, 290). The ability of CTL directed 
against one clade to recognize other clades is a major consideration in the development of 
protective HTV-l vaccines(291), and in some cases CTL-based vaccines have been designed 
based on specific CTL epitopes from regional HTV-l clades(210).
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H u m o r a l  im m u n it y
Humoral immunity: background and functions
This thesis is generally concerned with the cellular immune response to HTV-l, and to 
a lesser degree with the role of HTV-specific IgA in protection from HTV infection (see 
section on mucosal immunity, below). I will therefore not provide a detailed review of 
humoral immunity, but rather an overview that focuses on areas of relevance for HTV.
As with the adaptive cellular response, the diversity of the antibody repertoire is 
generated through a process of extensive gene rearrangement(147). After the deletion of B 
lymphocytes producing self-reactive antibodies, it is estimated that the lymphocyte pool is 
able to produce about 10^  ^different antibody specificities (162). The antigen binding region 
(Fab) is made of a variable domain of a heavy and a variable domain of a light chain. It is the 
variable domains that create the diversity in antibodies. Analogous to activation of the T cell, 
ligation of the B cell receptor to class II HLA-associated antigen leads to the BCR association 
with two molecules, Iga (CD79a) and IgP (CD79b), which undergo phosphorylation and 
transduce the signal to the B cell nucleus(174).
In general, antibodies bind to specific epitopes through the Fab portion, but do not 
have a direct effector function, instead targeting pathogens for destruction by other 
components of the immune system. For instance, antigen-antibody complexes activate the 
complement cascade through the classical pathway, as discussed in the section on Innate 
Immunity, and the binding of macrophage FcyR receptors by the Fc portion of IgG 
opsonizing antibodies promotes pathogen phagocytosis(292). These antibody roles are 
illustrated overleaf, in Figure 1.14.
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Figure 1.14 The role of antibodies in adaptive immunity
Antibody
Ciq Macrophage
Classic
complement
pathway
Antigen
Activation of macrophage
Antibodies generally focus components of the innate immune system on a pathogen, and the 
activation of these destructive forces normally requires coordinating events that occur after 
Fab heavy- and light-chain variable regions (Vh and V J  of the antibody are bound to antigen, 
leading to the display of multiple exposed Fc regions. The figure shows two examples of this 
process: the activation of the classic complement pathway after binding of C lq to Fc, and the 
activation of phagocytosis after the cross-linking of Fc receptors and binding of the FcTR on 
the macrophage.
From: Delves P.J and Roitt LI. 2000(174)
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In general, antibodies play a lesser role in antiviral immunity than cellular immune 
responses. However, neutralizing antibodies are able to activate complement-mediated lysis 
and virion phagocytosis, through the mechanisms outlined above. In addition, both 
neutralizing and non-neutralizing antibodies can prevent extracellular viral spread by coating 
viruses and preventing their physical interaction with host receptors(148).
Humoral immunity in HIV infection
HTV is a persistent viral infection, and is characterized by an ineffective humoral 
inunune response -  indeed, the test most commonly used to diagnose chronic HTV infection 
is the IgG ELISA. At the risk of oversimplification, there are three major reasons for the 
ineffectual humoral response in HTV-l infection:
1) Antibodies directed against viral debris:
During the course of natural HTV-l infection, the antibody response is principally directed 
against viral debris rather than virions. However, since the antigenic configuration viral 
debris is quite different to intact virions, these antibodies bind and neutralize viruses sub- 
optimally(293).
2) Low antigenicitv and immunogenicitv of HTV-I envelope:
Even in the presence of intact virions, the HTV-l envelope is both of low antigenicity and low 
immunogenicity. Low antigenicity is largely due to the oligomeric nature of the envelope 
proteins, together with very high levels of gpl20 glycosylation, factors that combine to shield 
most potentially immunogenic epitopes of the mature virion from the immune system(294).
In addition, because large amounts of gpl60 produced by infected cells are recycled 
intracellularly, rather than being processed into gpl20 , a strong humoral response to the
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plentiful gpl60 may prevent effective humoral responses against cross-reactive gpl20 
epitopes(294), through the phenomenon of original antigenic sin(295).
3) Mutational escape within neutralizing epitopes:
Despite the problems of antibodies directed against viral debris, neutralizing antibodies have 
been generated which target several epitopes, including a conformationally-sensitive epitope 
in the C3-V4 region of HIV gpl20; the CD4 binding domain; and the C terminal domain of 
gp4I(294). However, these epitopes fall within variable regions of HTV Env, so that in a 
human-SCID mouse model epitope mutants are able to escape neutralization within a matter 
of days, even when a therapeutic cocktail of all three antibodies is used(296).
Taken together, these factors explain why HTV-specific humoral immune responses 
(with the exception of IgA; see below) have not been found to correlate with protection from 
HTV infection in uninfected subjects, or with rates of disease progression in infected subjects. 
However, the intravenous infusion of a neutralizing antibody cocktail to uninfected macaques 
has been shown to protect against vaginal challenge with SHTV or a pathogenic STV strain in 
a macaque model(297), and this cocktail could also protect neonatal macaques against oral 
SHTV challenge(298). Exactly how these antibodies provide protection against mucosal 
challenge is not clear: it is probably not due to direct virus neutralization in vaginal fluids or 
serum, although they are able to block the infection of DCs by HTV(64). Current vaccine 
strategies result in far lower serum neutralizing antibody levels than this intravenous cocktail, 
but these findings do suggest that classical IgG antibodies may be useful in the setting of a 
protective HTV-l vaccine.
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T h e  m u c o s a l  im m u n e  s y s t e m
Overview of mucosal immunity
The genital tract mucosa is the route of virus entry in 70-90% of HTV-l 
infections(299), and for virtually all incident HTV-l cases within the Pumwani sex worker 
cohort(lO). The target cell populations, receptors, coreceptors and mechanisms of HTV-l cell 
entry have already been discussed. Since the host has an extensive array of protective 
mucosal immune defences, it is likely that some or all of these will be important in HTV-l 
susceptibility.
The mucosal epithelium has a surface area of 400m^ in an adult human(300), forming 
a fragile interface between the host and the external environment. Most mucosal surfaces, in 
particular the oropharynx, gut, and genital tract, are colonized by a rich commensal flora, and 
are in almost continuous contact with a wide variety of foreign but nonpathogenic 
antigens(301). In order to prevent chronic mucosal inflammation, a careful balance is 
required between tolerance to nonpathogens and specific immune responses to pathogens. 
While the maintenance of this balance is poorly understood, what is clear is that there is a 
large degree of functional independence between the cellular and humoral immune responses 
in the systemic (bone marrow, spleen, and lymph nodes) and mucosal compartments(302). 
This functional independence is particularly important in the design and administration of 
vaccines aimed to protect against mucosal pathogens(303).
Key to the mucosal immune system are mucosal inductive sites, aggregates of 
organized lymphoid tissue found in Peyer’s patches and the nasopharynx. Specialized M 
cells overlying these sites phagocytose and present antigen to naïve T cells clustered in the 
submucosal aggregates. However, recent work shows that dendritic cells throughout the gut 
epithelium are able to sample luminal antigens via dendritic processes extending through
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mucosal epithelial tight junctions(78), suggesting that to a limited degree the entire epithelial 
surface can act as an inductive site. Epithelial cells themselves are induced by inflammation 
to upregulate class II MHC, although in the absence of costimulation this may be a 
mechanism of inducing immune tolerance, rather than protective immunity(302). After 
expansion within these mucosal inductive sites, or after migration and expansion within 
regional lymph nodes, activated B and T cells then migrate to mucosal effector sites. These 
consist of the lamina propria, containing predominantly CD4+ T cells and IgA producing B 
cells, and the epithelium itself, which contains large numbers of intraepithélial lymphocytes 
(lELs), mostly CD8+ with some CD4+ T cells(302).
Innate mucosal immunity
The genital tract mucosa itself forms an important immune barrier: integrity of the 
epithelium, trapping of pathogens in mucus, and the presence of endogenous mucosal 
antiviral factors (such as secretory leukocyte protease inhibitor and mucins) may all play a 
protective role against infection(299, 304). NK cells are found at mucosal sites, as are 
phagocytic cells such as Langerhans cells, DCs and macrophages, whose function has been 
discussed. In addition, T cell populations falling on the boundary between innate and 
adaptive immunity, such as y8 T cells and NKT cells, are more common at mucosal than 
systemic sites. These T cells may recognize glycolipid antigens in association with class I- 
like MHC molecules such as CDl, which is commonly expressed on the surface of epithelial 
cells(305-307). However, while innate immune factors and cells constitute the first line of 
defence against invading microorganisms, antigen-specific humoral and cell-mediated 
responses are generally required for partial or full protection from infection(299).
Mucosal humoral immunity
Humoral responses are the best-understood component of the mucosal immune 
system, with IgA as the predominant mucosal antibody isotype. Isotype switching to IgA is 
dependent on the cytokine IL-5(308-310), typically thought of as a Th2 cytokine, but also 
with the ability to promote CTL differentiation(189, 311). Although the mechanism is not 
clear, the latter effect may relate to cross-talk between the IL-5 and IL-2 receptors(312), 
since IL-2 is more classically associated with Thl (CTL) responses. Due to the high 
mucosal surface area, up to 2-5g of secretory IgA (sIgA) is produced daily: the great 
majority of mucosal antibodies are produced locally, with only a small proportion derived 
from transudation from the circulation(301). The mucosal lamina propria contains -80% of 
all Ig-producing plasma cells, with 75-90% of these producing IgA(300). These cells are 
derived by migration from the mucosa-associated lymphoid tissues (MALT) at mucosal 
inductive sites, such as the Peyer’s patches in the intestine. Antibodies for mucosal 
secretion are generally polymeric, either dimeric or polymeric IgA (pIgA) or pentameric 
IgM, and are synthesized with a polypeptide called the joining chain (J chain; see Figure 
1.14, below). There are two subclasses of IgA, known as IgAl and IgA2: IgAl 
predominates in the blood, and there is an equal distribution of the two subclasses in 
mucosal secretions. IgA2 is more resistant than IgAl to the bacterial IgA proteases that 
attack the hinge region of the molecule. However, virus-specific antibodies are generally 
found in the IgAl class, while IgA2 is directed against lipopolysacchaiide or polysaccharide 
antigens(299).
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Figure 1.14 The structure of dimeric IgA
J chain
c/ I K q
IgA antibodies for mucosal secretion are generally dimeric, synthesized with a polypeptide 
called the joining chain (J chain). This chain binds to a transmembrane epithelial 
glycoprotein, polymeric Ig receptor (pIgR), whose major extracellular component is called 
secretory component (SC). The entire complex is then secreted into the mucosal lumen by 
active transport.
From: http://bio221 .mni.uwo.ca/W2000/lectures/Lecture05_99.html
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The J chain binds to a transmembrane epithelial glycoprotein called polymeric Ig 
receptor (pIgR), whose major extracellular component is called secretory component (SC). 
The entire complex is then secreted into the mucosal lumen by active transport, and SC 
remains attached to the polymeric antibody. This pathway is shown in Figure 1.15, overleaf. 
IgA then exerts protective functions through:
(1) the formation of intraluminal immune complexes;
(2) neutralization of biologically active antigens in the lumen;
(3) neutralization of transcytosed viruses within the apical recycling endosome; and
(4) interference with microbial adherence to epithelial cells(313).
Secretory IgA has several advantages over monomeric IgA, including multivalency 
(4-8 antigen binding sites), resistance to proteolysis, which is afforded by SC, and an anti­
inflammatory action that prevents excessive mucosal damage(301).
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Figure 1.15 Steps in mucosal pIgA production, secretion and action
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The figure outlines the steps in secretory IgA production, secretion and action. After the 
synthesis of dimeric IgA, the joining (J) chain binds to pIgR on the surface of epithelial cells. 
This results in active transport to the lumen, where Secretory Component (SC) remains 
attached to the IgA complex. SIgA then exerts its pathogen specific functions, as described 
in the text (above).
From: http://gsbs.utmb.edu/microbook/chOO 1 c.htm
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Mucosal cellular responses
T cell migration to mucosal effector sites appears to depend on the expression of 
mucosal homing markers, in particular the P? integrins QeP? (CD 103) and OC4P7 (314), which 
are expressed on >90% of intraepithélial T lymphocytes (lEL) and 45-50% of lamina propria 
(LP) T cells(315-317). T cell populations may vary widely within the mucosal 
microenvironment, with the great majority of small intestine lEL being CD8+, while T cells 
in the lamina propria are more evenly divided between CD4+ and CD8+(318). Although the 
role of integrins in mucosal homing is still under study, 04p7 appears to be specific for 
homing to the gut mucosa, and binds to the mucosal adressin cell adhesion molecule- 1 
(MadCAMl)(318). However, «Ep? (CD 103) is expressed on T cells from a variety of 
mucosal surfaces, including the gut, oropharynx, genital tract and respiratory tree(318-320). 
Expression of «eP? is regulated in part by transforming growth factor pi (TGpPi), which is 
produced at or near epithelial tissues(314). The only known ligand for «eP7 is E-cadherin, a 
homophilic cell adhesion molecule that is expressed on epithelial cells and mucosal 
DCs(319), and interaction between these molecules is important for T cell retention in the 
mucosa(321). Only mature, effector T cells are able to home to inflamed epithelium, and Thl 
lymphocytes appear to be more efficiently recruited than Th2(322). In keeping with this, 
virtually all lEL and LP T cells express CCR5 and CXCR3, receptors associated with 
Thl/Tcl lymphocytes, while expression of Th2/Tc2 receptors CCR7, CXCRl and CXCR2 is 
uncommon(323). Although IgA and cellular immunity are both important in mucosal 
protection, it is the cellular arm that appears to be most important in protection against 
several intracellular pathogens(324-326). Systemic infections may also give rise to mucosal 
CTL responses, although are generally less efficient than mucosal infections(327, 328). 
Furthermore, the presence and/or specificity of CTL in the blood may not always correlate 
with that of mucosal CTL(329-331).
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Induction of mucosal immunity
Lymphocytes that are primed by antigen in mucosal inductive sites acquire signals 
that allow homing to mucosal effector sites. This implies that priming immune responses 
through the systemic administration of antigen may not result in mucosal effector responses, 
a hypothesis that has been confirmed by recent studies. Disseminated viral infection will 
generally result in viral replication and immune priming at diverse sites, including MALT, 
and so infection by vesicular stomatitis virus, vaccinia virus and attenuated SIV all induce 
virus-specific, T cells at mucosal sites(332, 333). In addition, SIV and HTV-specific 
CTL are found in the genital tract of infected monkeys(334, 335) and people(327, 328), 
respectively, and these CTL may be 0CEp7 (^336). Likewise, infections that are specific for the 
genital tract, such as Herpes simplex, tend to induce strong Th and CTL within that mucosal 
site(337). However, the systemic administration of vaccines is less able than mucosal 
immunization to induce mucosal antibody and cellular responses, while mucosal 
immunization is quite efficient at inducing systemic responses(303, 338, 339). Furthermore, 
the evidence suggests that vaccine-induced immune responses must be present in the mucosa 
to provide protection against mucosal pathogens, and that inducing systemic without mucosal 
immunity does not provide protection(338-342). Clearly, this has significant implications for 
the development of a protective HTV-l vaccine.
Idiosyncrasies of genital tract immunity
Although all mucosal sites are often considered to be part of the common mucosal 
immunologic system(343), some features of the genital tract set it apart from other mucosal 
sites. First, IgG isotypes predominate over IgA, although high levels of IgA are still 
present(299). In addition, there are no mucosal inductive sites within the genital tract, and so
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exposure to antigen at the level of the cervix or vagina is thought to be a poor method of 
inducing pathogen-specific mucosal responses. The induction of specific genital tract IgA or 
IgG requires the intensive local administration of repeated large doses of antigen(299), while 
good genital tract responses can be obtained through intraperitoneal(344) or intranasal(345) 
immunization, or through systemic immunization followed by intravaginal boosting(299). It 
could be extrapolated from findings in the intestinal mucosa that dendritic cells in the genital 
tract epithelium are able to induce mucosal immune responses, although perhaps not as 
efficiently as specialized mucosal inductive sites in the gut or nasopharynx(302).
Mucosal homing pathways, most closely studied for the gut, may also differ between 
sites. While the asP? integrin is important in intestinal mucosal targeting, as discussed, there 
is evidence that genital tract homing markers are more similar to those directing lymphocytes 
to systemic sites of inflammation, namely the interaction of WlPz and OC4P1 with endothelial 
ICAM-1 and VCAM-1, respectively(346). Finally, while levels of cytolytic activity in the 
cervix and vagina are fairly constant, hormonal changes associated with the menstrual cycle 
can affect cytolytic activity in the upper genital tract(347). This may explain the cyclical 
changes in HTV-l viral load that some investigators(95), but not others(348), have seen in the 
genital tract.
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A s s o c ia t io n s  o f  HIV-1 r e s is t a n c e  in  HEPS c o h o r t s
Exposure to HIV-1 without subsequent exposure has been described in several high-risk 
cohorts(9), and the epidemiology of this phenomenon has already been described in this 
thesis. Now that the various effector arms of the immune system have been discussed, the 
immune responses associated with relative resistance to HTV-l will be reviewed.
1) Genetic associations of HTV-l resistance:
The strongest association of protection from HTV-l infection in Caucasian cohorts has been 
homozygosity for the CCR5 A32 allele, a genetic polymorphism encoding a variant CCR5 
molecule that does not function as a coreceptor for HTV-1(102, 349-351), although occasional 
infections are seen in homozygotes, usually in association with infection by an X4 virus(103, 
104). In addition, heterozygosity at this allele may be associated with reduced HTV-l 
progression(102, 349). However, while this gene is found at a frequency of -10% in peoples 
of European descent, and 2-5% in the Middle East and India, it is extremely rare in 
Africa(352), and has not been detected at all in the Pumwani sex worker cohort(353).
2) Bias towards Thl immune responses:
As has been discussed, the Thl arm of the cellular immune system is particularly important in 
antiviral immunity, resulting in enhanced production of the antiviral cytokines TFNy and 
TNFa, as well as in the stimulation of antiviral CTL responses. There is also evidence that 
Th2 responses may down regulate the Thl arm, through a direct suppressive effect of IL-4 on 
TL-12 production. The fact that HEPS Kenyan sex workers have blunted or abrogated TL-4 
responses to both HTV-l and recall antigens(354) therefore suggests that immune protection 
from HTV-l infection may be mediated in part through Thl cellular responses, which have 
been shown in an animal model to be enhanced in the absence of TL-4(355).
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3) HLA associations of HTV-l resistance:
Restrictions imposed by the class I and II HLA binding grooves are crucial in determining the 
specificity and hierarchy of virus-specific cellular responses by CTL and Th lymphocytes 
respectively. Certain HLA types, both class I (HLA A2, A*6802 > A24, B14, B18) and 
class n  (HLA DRB1*01) are associated with a reduced risk of seroconversion in the 
Pumwani sex worker cohort(356), as well as with reduced perinatal transmission(357), again 
suggesting that HTV-specific cellular responses may be involved in resistance to infection.
4) HTV-specific T helper responses:
T helper responses to Env antigens have been detected in a number of HEPS cohorts, with 
responses defined as an TL-2 stimulation index of >3. These cohorts include high-risk gay 
men(358), health care workers exposed to HTV-infected blood(359), children exposed to 
HTV-l during delivery(360), and HEPS sex workers(361). The finding of Th responses 
implies the prior uptake of HTV-l antigens by host APCs, possibly in the form of nonviable 
cells or defective virus from sexual partners, and subsequent presentation to CD4+ 
lymphocytes in association with class II HLA.
5) HTV-specific cvtotoxic T Ivmphocvte responses:
In addition to T helper responses, class I restricted CD8+ CTL have also been found in 
seronegative subjects exposed to HTV-l in the health care setting(362), through 
homosexual(363) or heterosexual(364, 365) sex, TV drug use(366), infected maternal 
secretions(367), or high-risk sex work(368-370). Unlike T helper responses, the standard 
dogma holds that the generation of CD8+ CTL requires productive infection of at least one 
host cell, with the subsequent presentation of transcribed HTV-l peptides in association with
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class I HLA(147). This would imply that there has been infection of host cells in order to 
generate HTV-specific CTL, with subsequent viral eradication or control below detectable 
levels. However, it has recently been shown that HTV-l epitopes derived from the DC 
phagocytosis of infected, apoptotic/necrotic cells or cell-free virions can result in the HLA 
class I cross-presentation of HTV-l epitopes to naïve T cells(171, 173).
6) CD8+ cell noncvtotoxic anti-HTV activitv:
In addition to direct cytotoxicity, CD8+ T cells from HEPS subjects in four North American 
cohorts also demonstrate noncytotoxic inhibition of HTV replication in acutely infected CD4+ 
cells, and are able to inhibit the in vitro infection of PBMC(371).
7) HTV-specific mucosal and svstemic IgA:
Although HEPS subjects lack systemic HTV-specific IgG by definition, IgA antibodies 
specific for HTV-l Env have been detected in the blood and genital tract of various HEPS 
cohorts(365, 370, 372). The specificity of these IgA responses has recently been mapped to 
the coiled-coil region of gp41(373), a region that is important in HTV-l cell entry (see above). 
However, this is not a universal finding, since HTV-specific IgA was not detected in another 
cohort of seronegative prostitutes(374).
8) Nonclassical humoral responses:
In addition to IgA, a number of nonclassical humoral responses have recently been described 
in HEPS subjects. These include IgG antibodies against the host CCR5 receptor(375), 
against CD4(376, 377), and against class I HLA(378). However, HLA allo-antibodies have 
not been detected in other HEPS cohorts(379, 380), and the association of these humoral 
responses with HTV resistance warrants confirmation.
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Ch a pt e r  2
MATERIALS AND METHODS
S t u d y  p o p u l a t io n s  a n d  e t h ic a l  a p p r o v a l
The sex workers participating in all studies described in this thesis were enrolled 
through the prostitute clinic in the Pumwani area of Nairobi, Kenya. Despite behavioural 
counselling and condom provision, it is estimated that these women have a minimum of 60 
unprotected sexual exposures to HTV-l per year. Women were classified as HTV-resistant if 
they were seronegative on enrolment, and remained both seronegative and polymerase chain 
reaction (PCR) negative during at least three years of follow-up, while continuing in sex 
work(361). All women enrolled in the cohort had access to the clinic whenever they felt 
unwell. In addition, women returned to the clinic for resurvey every six months. At this time 
a standard questionnaire was completed, a physical examination was performed, screening 
tests were carried out for common sexually-transmitted diseases, and blood was drawn for 
HTV-l and syphilis serology (RPR). Any sexually-transmitted diseases were treated 
according to the Kenyan National ATDS/STD Control Programme guidelines.
Lower-risk HTV-uninfected control women were enrolled from a family-planning 
clinic in Nairobi, which was participating in ongoing HTV-l surveillance(381). Additional 
lower-risk controls were enrolled from a mother-child health care clinic in the Pumwani 
district of Nairobi, and from an infertility clinic in Nairobi’s Kenyatta National Hospital. 
Informed consent was obtained, and a standardized questionnaire administered. This 
questionnaire included data concerning lifetime number of sexual partners, history of 
commercial sex work, perceived risk of sexually-transmitted disease (STD) or HTV-l 
exposure from current sexual partner(s), history of past or present STDs, and other perceived 
HTV-l risk factors.
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Informed consent was obtained from all study participants at enrolment, and ethical 
committees at both the University of Manitoba and the University of Nairobi approved 
studies.
G e n e r a l  l a b o r a t o r y  m e t h o d s  a n d  s p e c im e n  a c q u is it io n
Molecular HLA typing was performed by a laboratory technician in Oxford, using 
ARMS-PCR with sequence specific primers, as previously described(382). HIV-1 
serological testing employed a synthetic peptide enzyme immunoassay (Detect HIV,
Biochem ImmunoSystems Inc., Montreal, Canada), and positive tests were confirmed using a 
recombinant antigen enzyme immunoassay (Recombigen HIV-1/2 EIA, Cambridge Biotech 
Corporation, Galway, Ireland). HIV-1 seronegative sex workers were confirmed to be HIV- 
uninfected employing a PCR system which uses primers for env, nefm d vif HIV-1 pro virus 
genes, which were specifically adapted to detect African clades(40). HIV serology and 
proviral PCR were performed by laboratory technicians in the Universities of Nairobi and 
Manitoba, respectively.
Blood was drawn into 12 ml tubes containing the anticoagulant ACD. Cervical 
samples were obtained using a cytobrush (Histobrush, Spectrum Labs Inc, Dallas, TX, USA), 
which was inserted into the cervical os, gently rotated through 360°, and transferred 
immediately into 5ml of RPMI. In order to avoid contamination with blood, the cytobrush 
specimen was obtained before other sampling (STI cultures, etc), was not collected from 
women who were actively menstruating, and was rejected if it contained visible blood. All 
samples were transported to the laboratory within two hours. The cytobrush was vigorously 
agitated and discarded, and the remaining cell suspension was agitated to loosen any mucus 
clumps. Both cervical mononuclear cells (CMC) and peripheral blood mononuclear cells
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(PBMC) were then isolated by Ficoll-Hypaque gradient centrifugation, washed and 
resuspended in RPMI with 10% foetal calf serum (RIO).
P h e n o t y p ic  s t u d ie s  u s in g  f l o w  c y t o m e t r y
Peripheral blood T lymphocyte subset analysis was performed using anti-CD4 
FITC/CD8 PE (Becton-Dickinson Immunocytometry Systems, CA). Cervical mononuclear 
cell subpopulations were characterized from cryopreserved specimens, using anti-CD3 FTTC, 
anti-CD4 PE and anti-CD8 TRI. After incubation with monoclonal antibodies for 30 minutes 
at 4°C, 10  ^cells were washed in PBS with 1% foetal calf serum, fixed, and analysed using a 
FACS flow cytometer (Becton-Dickinson Immunocytometry Systems, CA) with CellQuest 
software. Gating was used to select the lymphocyte fraction, based on a typical pattern of 
forward scatter (cell size) and side scatter (cell density).
G e n e r a t io n  o f  im m o r t a l iz e d  B l y m p h o b l a s t o id  c e l l  l in e s
Between 2-5 x 10  ^freshly separated PBMC were incubated for one hour in 1ml of 
supernatant from an Epstein Barr virus (EBV)-producing marmoset cell line B958. Cells 
were diluted with 9ml of RPMI/15% ECS containing Ijitg/ml Cyclosporin (CsA), and 
incubated at 37°C, 5% CO2 in a small tissue culture flask. Colonies of transformed B 
lymphocytes (BCL) were identified as clumps of cells within two weeks. BCL were 
maintained in RIO, and split once or twice weekly depending on the rate of growth.
CTL BULK CULTURE USING VACCINIA-ENF INFECTED AUTOLOGOUS STIMULATOR AND 
TARGET CELLS
CTL bulk culture with lysis of vaccinia-infected autologous B lymphoblastoid targets 
was performed using modification of methods previously described(361, 383). Stimulator
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cells were two-day PHA blasts infected with HTV-lniB and inactivated with mitomycin C. 
These inactivated cells were used as autologous stimulators for bulk autologous PBMC 
(effectors), which were cultured for seven days with recombinant human IL-2 (5 units/ml, 
Boehringer). On day ten of the assay, autologous EBV transformed B cells (targets) were 
infected with one of four recombinant vaccinia/HIV-1 viral vectors. The recombinant 
vaccinia/HTV-l viruses included vSC8 (wild-type vaccinia with the B-galactosidase 
gene)(384), vDKl (HIV-1 gag inserted into vSC8)(385), vCF21 (HIV-1 pol inserted into 
vSC8)(385), and vPE16 (HIV-1 env inserted into vSC8)(386). Viral vectors were obtained 
through the AIDS Research and Reference Reagent Program, AIDS Program, NIAID, NIH. 
The following day, ^^Cr labelled target cells were washed and plated, in triplicate, with the 
effectors, at effector to target ratios of 50:1, 25:1, 12.5:1. Wells containing only target cells 
or target cells with 1% SDS (sodium dodecyl sulphate) were used to determine the 
spontaneous (Min) and maximal release (Max), respectively, of ^ ^Cr from the labelled cells. 
After four hours of incubation, 100 \il of supernatant were removed and added to one ml of 
scintillation cocktail (Ecolume, ICN) and the released ^^Cr detected using a liquid 
scintillation counter. Percent spontaneous release was calculated as Min/Max x 100. Percent 
specific lysis was calculated by (Exp-Min)/(Max-Min) x 100. Lysis of the targets infected 
with the recombinant vaccinia/HIV-1 (vDKl, vCF21 and vPE16) viruses were considered 
mV-specific if lysis was 10% or greater than the lysis of the vaccinia control (vSC8) and the 
results were titratable or were repeatable.
CTL BULK CULTURE USING PEPTIDE-PULSED AUTOLOGOUS STIMULATOR AND TARGET 
CELLS
Peptide-Stimulated CTL bulk assays were performed as previously described(368). 
PBMC were pelleted and pulsed for one hour with lOOjxM of synthetic peptides selected on
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the basis of HLA haplotype, then suspended in RPMI with 10% fetal calf serum (RIO) and 
cultured at 2 x 10  ^cells per well in a 24-well Costar plate. Recombinant IL-7 was added to a 
final concentration of 25ng/ml on day 1(387), and IL-2 (Lymphocult-T; Biotest) was added to 
a dilution of 10% on day 3. After 10-14 days in culture, assays for HTV-specific CTL activity 
were carried out using class I matched B-lymphoblastoid target cells pulsed with the 
appropriate peptides in a ^^Cr release assay. Lysis of peptide-pulsed targets was considered 
to be mV-specific if lysis was at least 10% more than that of the unpulsed control.
INTERLEUKIN-2 (IL -2 ) BIOASSAY
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque
gradient centrifugation, washed and resuspended at 3 x 10^ /ml in RPMI with 5% human AB
serum (RPMIrABS). PBMC were added to a 96-well plate at 3 x 10^ cells/well. They were 
incubated in triplicate with each of five different synthetic antigenic HIV-1 envelope peptides 
at 2.5 mM/ml, and one synthetic nonantigenic HIV-1 envelope peptide (P23), which have 
been described previously(388). The anti-IL-2 receptor monoclonal antibody, anti-TAC, was 
added at 2jLtg/ml to inhibit consumption of IH2. Culture supernatants were collected after 
seven days, frozen at -20°C, and shipped for analysis to the University of Milan. IL-2 levels 
were determined by the ability of culture supernatant to support the proliferation of a mouse 
IL-2-dependent continuous T lymphocyte line (CTLL), as previously desciibed(365). CTLL 
cultures were pulsed with [H^] thymidine after 24 hours, and results expressed as stimulation 
indices (SI), where the mean counts per minute (cpm) of peptide-stimulated PBMC was 
divided by the mean cpm of unstimulated cells from the same subject. Subjects were 
considered to be HIV-1 envelope peptide responsive if a SI greater than 4 was recorded for 
two or more antigenic peptides.
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H IV -1  PEPTIDE EPITOPE SELECTION AND SYNTHESIS
HTV-1 peptides were selected from a panel of 54 previously-defined A, B- and D- 
clade CTL epitopes(389), described in Chapter Four. Epitope selection was based on (1) the 
class I HLA haplotype of the donor; and (2) where possible, on the results of earlier systemic 
HTV-specific CTL assays in this study population. Peptides were synthesized by F-moc 
chemistry using a Zinnser Analytical synthesizer (Advanced Chemtech, Louisville, KY), and 
purity was established by high-pressure liquid chromatography (HPLC).
P e p t id e -b a s e d  in t e r f e r o n  g a m m a  (IFNy) E L IS p o t  a ss a y s
An ELISpot assay was used to detect peptide-specific IFN-y release by mononuclear 
cells, modified from previously-described methods(230, 368, 390). 96-well nitrocellulose 
plates were precoated with IFN-y monoclonal antibody 1-DIK (MABTECH AB, Nacka, 
Sweden). PBMC or cervical mononuclear cells (CMC) were incubated overnight at 37°C in 
5% CO2, in duplicate wells, either with predefined HTV-1 class I-restricted peptide epitopes 
at a concentration of 20jiM; or with RIO alone (negative control); or in 1:100 
phytohaemagglutinin (PHA) (Murex Biotech Limited, Dartford, UK; positive control).
Where possible ELISpot assays were run at 2 x 10  ^cells/well for HEPS women, and at 1x10^ 
cells/well for infected subjects. Cells were discarded and the plate incubated at RT for 3 
hours with a biotinylated anti-IFN-y monoclonal (7-B6-1 biotin; MABTECH), followed by 
streptavidin-conjugated alkaline phosphatase (MABTECH) for 1-2 hours. Individual IFN-y 
producing cells were detected as dark blue spots using an alkaline phosphatase-conjugate 
substrate kit (Bio-Rad Laboratories, Hercules, CA, USA). Spots were counted by eye using a 
dissecting microscope (x40) prior to 1998, and from 1998 onward by an automated ELISpot 
reader (Autoimmun Diagnostika GmbH).
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R e c o m b in a n t  v a c c in ia  v ir u s  IFNy ELISpot a ss a y s
HIV-specific responses were also examined using a modified recombinant vaccinia virus 
ELISpot assay(391). This assay was identical to the peptide-based ELISpot assay, except 
that recombinant vaccinia virus at a multiplicity of infection (MOI) of two was used to 
stimulate HTV-specific responses. For both HEPS and infected subjects 1x10^ PBMC were 
stimulated with either media alone, PHA 1:100, a vaccinia-Zac construct (WR), an HTV-1 
clade A g^v-vaccinia construct (6059 env A), or an HTV-1 clade A gag-vaccinia construct 
(6026 gagA).
C r it e r ia  f o r  a  p o s it iv e  H IV -s p e c if ic  E L IS p o t  a s s a y
HTV-specific IFNy responses were reported as number of spot-forming units (SFU) 
mononuclear cells, after subtracting background rates of spontaneous IFNy secretion.
The background rate of IFN-y secretion was defined as the number of SFU/10  ^mononuclear 
cells incubated in RIO medium alone, without peptide stimulation. An HTV-specific ELISpot 
response was arbitrarily defined as follows:
(1) IFNy release seen in response to 1:100 PHA (positive control); and
(2) >20 HTV-specific SFU/10  ^mononuclear cells; and
(3) IFNy release in HTV-1 peptide wells exceeded background (spontaneous) rates of IFNy 
release by a factor of at least 2 .
This definition was based on a reported limit of detection of 1/50,000 cells for the ELISpot 
assay(230), and was validated by testing low-risk controls (see Chapter Four).
HIV-1 SPECIFIC IgA ELISA
Cervical and vaginal samples for antibody determinations were obtained as follows: a 
single cotton-tipped swab was inserted into the cervix, gently rotated through 360°, and
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placed in 4ml of sterile phosphate-buffered saline (PBS). A second cotton-tipped swab was 
rotated in the posterior vaginal fornix, and also placed into 4ml of sterile PBS. Swabs were 
transported to the laboratory at room temperature, and processed within two hours of 
sampling. On arrival at the laboratory, the swabs were agitated in the PBS, discarded, and the 
remaining PBS frozen at -20°C for shipment to the University of Milan.
Levels of HIV-specific IgG and IgA were measured in genital tract samples using 
methods previously described(365). A recombinant envelope antigen enzyme immunoassay 
(Calypte Biomedical HIV-1 EIA, Calypte Biomedical Corporation, USA) was used to 
determine IgG levels. For IgA measurement, this assay was modified so that horseradish 
peroxidase conjugated to anti-human IgA (The Binding Site Ltd, London, UK) was used as 
the detector antibody at a final dilution of 1:400. IgA-specific binding was measured using 
tetra-methyl benzidine as chromogen and urea hydrogen peroxide as a peroxidase substrate. 
HTV-specific IgA and IgG were reported as absorbance at 450nm, and values exceeding 
[ftseronegative controls + 2 Standard deviations] were considered positive. Vaginal and cervical 
levels of HTV-specific antibodies were measured separately: however, a subject was 
considered genital tract positive if significant levels were found at either site.
S e q u e n c in g  o f  HIV-1 e p it o p e s  f r o m  p r o v ir a l  DNA
In a subset of HTV-1 sex workers who met criteria for HTV-1 resistance, but who 
subsequently became infected by HTV-1 (late seroconverters), regions of the virus 
corresponding to CTL epitopes recognized prior to seroconversion were cloned and 
sequenced, using a modification of methods previously described(392). This addressed the 
hypothesis that late seroconverters might have been infected by a virus with amino acid 
substitutions within this CTL epitope, a phenomenon which has been shown to lead to viral
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‘escape’ from a dominant CTL response in infected donors. The late seroconverters had 
recognized a total of four predefined HTV epitopes prior to seroconversion, namely:
ILKDPVHGV (A2 Pol, ML 1760)
DTVLEDINL (A*6802 Pol, ML 857, ML 1203, ML 1707)
FPVTPQVPLR (B7 Nef, ML 1203)
HPDIVIYQY (B35 Pol, ML 857)
Two to four million PBMC were incubated in RIO with 1:100 PHA (Murex Biotech 
Limited, Dartford, UK) for 36-48 hours. DNA was extracted using the Puregene system 
(Centra Systems, Minneapolis, MN, USA). Briefly, 3-5 x 10  ^cells were spun at 13000- 
16000g for 5 seconds in a 2 ml vial, the supernatant was discarded and the residuum 
vortexed, prior to the addition of 600/H of cell lysis solution. The sample was now stored at 
room temperature (RT) for up to 6 months. At the time of processing, 3jul Rnase was added, 
the sample was incubated at 37°C for >15 minutes, and then mixed at RT with 200jul protein 
precipitation solution. The protein precipitate was vortexed vigorously for 20secs, and after 
centrifugation at 13000-16000g for 3 minutes the supernatant was collected in a clean 2ml 
vial containing 600jLtl of 100% isopropanol. The tube was inverted to form threads of DNA, 
which was then centrifuged at 13000-16000g for 1 minute to pellet DNA. The isopropanol 
was discarded, and 600/rl of 70% ethanol added to wash the DNA pellet. Ethanol was 
removed following centrifugation at 13000-16000g for 1 minute, and the DNA pellet air 
dried for 30 minutes, prior to rehydration overnight in 100/xl DNA hydration solution.
CTL epitopes were amplified from proviral DNA using a nested polymerase chain 
reaction (PCR) with Expand High Fidelity Taq (Boehringer Mannheim). Primers were
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designed based on amplification of predicted clade A HTV-1 sequences(393), since this clade
is responsible for 70% of HTV-1 infection in Kenya(394).
A2 Pol: 5' outer AGA AAA AGA GAG CTG GAG TGT CAA TG
5' inner CTG AGG GGA GCC AAA GCA CTA AGA G 
3' inner GTC CAT TGG TCT TGC CCT TGT TTC TG 
3' outer TGC TAA TTG TTT TAG ATC ATT ACT GTG 
amplified fragment size = 167 bp.
A*6802 Pol\ 5' outer CGC TCA AAT CAC TCT TTG GCA ACG ACC
5' inner AAG CTG TAT TAG ATA GAG GAG GAG AT 
3' inner CCA ATT ATG TTG ACA GGT GTA GGT CCT 
3' outer CCA TTC CTG GGT TTA ATT TTA CTG GTA GAG 
amplified fragment size =196 bp.
B7 Nef. 5' outer GAG GAG GAG AAG GAG TAG GAG GAG
5' inner AAA CAT GGA GCA GTC ACA ACT AGG AAT 
3' inner TAA CGC ATC GAG TGC CGC CTT TTC TTT 
3' outer TGG TGT GTA ATT CTG CCA ATC AGG GAA 
amplified fragment size = 191 bp.
B35 Pol\ 5' outer ACA ATG TGC TTC CAC AGG GAT GGA
5' inner GCA TGA CAA AAA TCT TAG AGG CCT TTA 
3' inner TAT GGT GCC CTA TTT CTA AGT GAG ATC 
3' outer TGC AAA GAA ATG GAG GTT CTT TCT GAT
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amplified fragment size = 108 bp.
The first PCR reaction was run at a low reannealing temperature of 48°C, in a relatively 
nonspecific reaction to amplify a large DNA fragment containing the epitope sequence of 
interest. The second PCR reaction was run with a higher reannealing temperature of 65°C, in 
order to specifically amplify a smaller DNA fragment containing the epitope. This 
reannealing temperature was based on a series of optimizing PCR assays, performed over a 
range of different annealing temperatures. DNA fragment size was confirmed using a PhiX 
174 Hae ladder (New England Biolab), and DNA purified by passage over Sephadex G-50 
beads (Sigma). DNA insertion into the plasmid PCR4-T0P0 and transformation of E. coli 
were performed using the TOPO-TA system (InVitroGen), according to manufacturers 
instructions. Bacteria were grown overnight at 37°C on an LB ampicillin plate coated with 
40pl of 40mg/ml X-gal in DMF. Twenty transformed colonies were selected, cultured 
overnight in LB/ampicillin medium, and plasmid DNA isolated using the QIAprep Spin 
Miniprep Kit (Qiagen). DNA sequencing was then performed by a laboratory technician in 
Oxford, using the Beckman Coulter CEQ-200 (Beckman Coulter).
HLA CLASS I TETRAMER AND INTRACELLULAR CYTOKINE STAINING ASSAYS 
These assays were not the focus of this thesis work, and were only used to validate the 
ELISpot assay (see Chapter 4), using slight modifications of previously-described 
protocols(212, 264). The B*5703 KAFSPEVIPMF tetramer was a kind gift of Dr. Gerry 
Gillespie. 1.5|4l of tetramer was added to one million thawed PBMC, and incubated for 15 
minutes at 37 °C. Cells were washed once, and were then incubated at 37°C, 5% CO2 either 
in media alone, or with the KAFSPEVIPMF peptide at 10|iM, or with a control peptide.
After 45 minutes, brefeldin A was added to a final concentration of lOpg/ml, and cells
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incubated to a total of six hours. 300}xl of Becton Dickinson permeabilizing solution was 
added, according to manufacturers instructions, and cells left for ten minutes at room 
temperature. Cells were then washed and incubated with monoclonal antibodies IFNy FTTC 
and CDS PerCP for 15 minutes in the dark, at room temperature. Stained cells were fixed 
overnight at 4°C in 5% formaldehyde, and analysed by FACS the following day.
S t a t is t ic a l  a n a l y s is
Statistical analysis used the SPSS for Windows Rel. 9.0.0 1998 package (SPSS Inc, 
Chicago). Comparison of means between study groups was performed by one-way analysis 
of variance (ANOVA). Mantel-Haenszel chi-square test with calculation of likelihood ratios 
and confidence intervals was used to compare dichotomous variables between study groups. 
If ELISpot assays had been performed on any individual at several time-points, only the 
earliest result was included in the general analysis of response associations. However, an 
epitope-specific response detected in an individual at any time-point was included in the 
analysis of epitope specificity. In comparing patterns of epitope recognition, the specificity 
of ELISpot responses was examined within class I HLA alleles where at least two different 
HTV-l epitopes had been studied (since >2 epitopes are needed to needed to examine 
differences in specificity) in a minimum of eight subjects (to avoid basing conclusions on 
overly small subject numbers). In order to control for multiple comparisons at each class I 
allele, the P-value calculated for epitope recognition at any given class I allele was corrected 
for the total number of epitopes tested for that allele.
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C h a p te r  t h r e e  S y s te m ic  HIV-1 e n v -sp e c if ic  CTL r e sp o n se s  in
HEPS SEX WORKERS
I n t r o d u c t io n
In HIV-infected subjects, CTL are crucial in controlling the burst of viremia 
associated with primary infection(253), and levels of CTL are inversely correlated with 
plasma viremia, at least during early HTV-l infection while the immune system is relatively 
intact(211, 212). However, HTV-1 replication is highly error prone(42), and mutational 
escape from a dominant CTL response has been associated with increased levels of viremia 
and with disease progression(255, 256, 261). Some regions of the virus, such as the major 
homology region within HTV-1 Gag, are highly conserved, so that mutation at these sites 
would seriously compromise viral survival(368). It would seem logical that CTL recognizing 
these highly-conserved regions, rather than more variable regions, would be most important 
in determining outcome. In actual fact, CTL directed against both conserved and variable 
regions appear to be important. While some CTL associated with improved outcome 
recognize highly conserved regions, such as Pol(395) and p24(280), others target more 
variable regions such as HTV-1 pl7(212) and Env(254). In this study, the presence, 
frequency and epidemiological correlates of HTV-1 Env-specific CTL were examined in 
seronegative sex workers from the Pumwani sex worker cohort.
This work described in this chapter continues the earlier research of Dr. Keith Fowke 
from the University of Manitoba, who both developed the bulk CTL assay protocol (see 
Section 2; Materials and Methods) and described HTV-specific CTL in a pilot study of HTV- 
resistant Kenyan sex workers(361). This initial work contributed towards his PhD thesis in 
1997.
I l l
D e f in it io n s  a n d  s e l e c t io n  o f  s t u d y  p o p u l a t io n s
Blood samples were obtained from HTV-1 seronegative sex workers during annual 
resurvey between the years 1994-1997. Proviral DNA PCR assays were negative in all cases. 
Since these sex workers had been enrolled in the cohort for highly variable periods of time 
(between 0-15 years), not all the women in the study met criteria for HTV-1 resistance, since 
this requires at least three years of seronegative follow-up within the Pumwani cohort. HTV- 
1 seronegative sex workers were therefore divided into three groups, based on the duration of 
prior HTV-1 exposure within the Pumwani cohort: those followed for three years or more 
(HTV-resistant sex workers); those followed for between 1-3 years; and newly enrolled 
seronegative women, enrolled in the cohort for <1 year (new negatives). In addition, HTV-1 
seronegative controls were selected from Kenyan women enrolled in a study of mother-to- 
child transmission of HTV-1(396). Although it is difficult to define any sexually active 
person as ‘low-risk’ when the population HTV-1 prevalence exceeds 15%(397), these women 
were deemed to be at relatively low risk of HTV-1 exposure, since they were currently in a 
monogamous relationship with an HTV-uninfected man.
M a t e r ia l s  a n d  M e t h o d s
HTV-specific CTL were assayed using bulk CTL culture, as described in Materials 
and Methods (Chapter 2). CTL were assayed against the HTV-1 clade B derived vaccinia 
construct vPE16. Although clade B Gag and Pol specific CTL were also examined in these 
early assays, the vaccinia constructs used were subsequently determined to be nonviable, and 
these results are not included in this thesis. Although HTV-1 clades A and D predominate in 
East Africa(394, 398-400), clade A based vaccinia immunogens were not available at the 
time that this thesis work started, and so only CTL responses capable of cross-reacting with 
clade B were examined. ^^Cr release assays were performed using autologous BCL as
112
targets, infected by either vaccinia-/ac or vaccinia-Env constructs. Effectors were used at 
three ratios, 50:1, 25:1 and 12.5:1, and all results are presented as percentage HIV-1 Env- 
specific lysis.
S y s t e m ic  HIV-1 E n v -s p e c if ic  CTL in  HEPS s e x  WORKERS
mV-1 clade B Env-specific CTL were examined in 71 HTV-l seronegative sex 
workers between 1995-99. All seronegative sex workers enrolled for under three years were 
sampled, and a convenience sample of the approximately 110 sex workers meeting criteria 
for HTV-1 resistance. The mean age of study subjects was 36 years, and the mean 
CD4/CD8+ lymphocyte counts were 863/mm^ and 709/mm^, respectively. All subjects were 
negative on PCR screening for HTV-1 proviral DNA. Thirty-three (46%) of the sex workers 
studied had been enrolled in the cohort for a sufficient time (<3 years) to meet criteria for 
HTV-1 resistance(29). Overall, HTV-1 Env-specific CTL were found in 25/71 (35%) 
seronegative sex workers, and in 0/9 lower-risk Kenyan controls (OR=7.2; P=0.007). CD8+ 
lymphocyte depletion resulted in a >50% reduction in HTV-specific activity in 3/4 CTL 
positive women, and a 40% reduction in 1/4 (data not shown).
The associations of Env-specific CTL with demographic, behavioural and 
immunological variables are shown in Table 3.1, overleaf. In general, there was no 
association between CTL and risk behaviours. There was no association with reported 
condom use, but CTL were more frequent in women on the oral contraceptive pill. CTL 
positive sex workers tended to be older, and to have been enrolled in the sex worker cohort 
for a longer period of time. Neither CD4 nor CDS counts were related to HTV-specific CTL. 
On univariate analysis, CTL appeared to be more common in women with certain class I 
HLA alleles (A*23, P=0.01; B*35, P=0.04). However, no HLA associations remained 
significant after correction for multiple comparisons.
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The most striking association found was that between the detection of HIV-1 Env- 
specific CTL and the duration of preceding seronegative cohort follow-up (see Figure 3.1). 
Over 50% of sex workers who had remained HTV-uninfected despite active sex work in the 
Pumwani cohort for >3 years, thereby meeting the definition of HTV-1 resistance, 
demonstrated HTV-1 Env-specific CTL (17/33). There was a stepwise decrease in the 
frequency of CTL among women enrolled in the clinic for shorter periods of time: 6/24 
(25%) of those enrolled 2-3 years, 2/14 (14%) of those enrolled <1 year, and 0/9 lower-risk 
Kenyan controls with no history of sex work (LR=15.1; P=0.002). No further increase in 
CTL frequency was noted beyond three years of follow-up.
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Table 3.1 Associations of systemic HIV-1 Env-specific CTL responses in HEPS sex 
workers
Variable Env CTL positive Env CTL negative P-value
(n=25) (n=46)
Condom use (%) 81.2 78.3 0.7
Daily clients 3.8 5.0 0.1
Seronegative follow-up 3.9 2.7 0.09
(years)
CD4 cells/mm^ 875 856 0.8
CDS cells/mm^ 712 708 0.9
Age (years) 35.9 33.0 0.05
Oral contraceptive 9/24 (38) 7/44 (16) 0.05
pill* (%)
The presence of HIV-1 Env-specific CTL, defined as HTV-specific lysis of >10%, was
examined in 71 seronegative sex workers. Women were divided into two groups based on 
the presence or absence of CTL, and epidemiological associations of Env-specific CTL are 
shown in the table above.
* data was not available for three sex workers
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Figure 3.1 Association between the duration of seronegative sex work in Pumwani 
and the frequency of HIV-1 Env-specific CTL.
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Seronegative sex workers within the Pumwani cohort were divided into groups based on the 
duration of their cohort enrolment, and a fourth group was composed of HIV-1 lower risk 
women with no history of sex work. A stepwise association was seen between the presence 
of HIV-1 Env-specific CTL and the prior duration of follow-up in the Pumwani cohort 
(LR=15.1; P=0.002). No further increase in CTL frequency was seen beyond three years.
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Although CTL assays were not examined in HIV-infected sex workers as part of this 
study, the mean level of HTV-specific lysis in positive CTL assays (those demonstrating HTV- 
1 Env-specific lysis >10%) was relatively low in the 25 seronegative sex workers with CTL 
responses, as shown in Table 3.2. The mean level of lysis was 15.5% at an effector to target 
ratio of 50:1, falling to 9.7% at an E:T ratio of 12.5:1. Levels of HTV-specific lysis did not 
vary with any demographic, behavioural or immunologic variable studied (data not shown).
Table 3.2 Low levels of HIV-specific lysis are seen in HEPS sex workers
E:T ratio Mean HTV-specific lysis Range
50:1 15.5% 6.8-32%
25:1 12.4% 0-27%
12.5:1 9.7% 1.3-29%
Percentage lysis of autologous BCL infected with vaccinia - HTV-1 clade B env constructs. 
Data are only shown for women with positive assays, defined as >10% lysis at >2 E:T ratios. 
Levels of Env-specific lysis were low in HEPS sex workers with virus-specific CTL, in 
general between 10-20%.
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R o l e  o f  HIV-1 E n v -s p e c if ic  CTL in  p r o t e c t io n  f r o m  HIV-1 in f e c t io n
Rates of HIV-1 infection after enrolment in the Pumwani cohort may be as high as 
50% per year. During the period 1980-1990, 75% of new enrolees become infected within 
five years of follow-up(29). With this intense infection pressure, there should be sufficient 
statistical power to correlate the presence/absence of HTV-l Env-specific cytotoxic T 
lymphocyte responses at enrolment with the rates of subsequent HTV-l seroconversion. Sex 
workers not yet enrolled long enough to meet criteria for HTV-1 resistance (>3 years) were 
therefore followed prospectively, with HTV-1 serology performed every six months.
Between April 1996 and October 1997, all eligible seronegative Pumwani sex 
workers (N=38) were recruited into a study of the protective effect of HTV-specific CTL. To 
differentiate them from HTV-resistant sex workers, these study subjects were known as new 
negatives (NN). Bulk assays were performed to examine the occurrence and frequency of 
CTL directed against HTV-1 clade B Env. Overall, CTL responses were detected in the blood 
of 8/38 (21%) NN sex workers. As of December 2000, HTV-1 infection has been 
documented in 6/38 sex workers (16%). This relatively low rate of seroconversion mirrors 
that seen in the Pumwani cohort as a whole over recent years, likely related to increased 
condom use and decreasing sexually-transmitted disease incidence in the cohort(39). Of the 
six seroconverters, none had previously demonstrated HTV-specific CTL, and no CTL- 
positive sex worker has yet seroconverted (0R=3.1, P=0.08; Table 3.3). Although these 
preliminary results suggest a role for CTL in ongoing protection against HTV infection, 
longer follow-up will be required before there is sufficient power to properly examine the 
relationship between Env-specific CTL and protection in a prospective fashion.
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Table 3.3 HIV-1 Env-specific CTL and subsequent seroconversion in newly- 
enrolled, HIV-1 seronegative Pumwani sex workers.
Env CTL negative Env CTL positive totals
seroconverted 6 0 6
seronegative 24 8 32
group totals 30 8 38
HIV-1 Env-specific CTL were examined at baseline in 38 newly-enrolled seronegative sex 
workers (NN), and were detected in 8/38 women. Six NN have gone on to seroconvert, none 
of whom had prior detectable CTL (P=0.08), giving a non-significant association between 
baseline CTL and protection from subsequent HTV-l infection.
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D is c u s s io n  a n d  c o n c l u s io n s
This work confirms that HTV-specific CTL are common in exposed, persistently 
seronegative subjects, and that these responses may be directed against the highly variable 
HTV-1 envelope region. Furthermore, these Env-specific CTL recognized clade B viral 
peptides, a clade which is particularly uncommon in Kenya, and to which they are unlikely to 
have been exposed(394). Cross-reactive CTL against clade B have previously been described 
in HTV-infected subjects from Uganda, where clades A and D also predominate(401), as well 
as in HTV-1 clade E infected Thai subjects (Hansasuta P, personal communication). These 
observations in both infected and HEPS subjects implies that some Env epitopes are 
conserved between the different HTV-1 clades, which is surprising given the extent of viral 
diversity within the HTV-1 envelope. However, these findings will be very important if HTV- 
specific CTL are to play a role in a protective vaccine. East Africa is a true ‘melting pot’ of 
HTV-1 clades, with almost all viral subtypes represented, and with inter-clade recombinants 
accounting for most recent infections within the Pumwani cohort (Weiser B, personal 
communication). It is therefore clear that uninfected sex workers will be exposed to multiple 
viral variants, and that if CTL are not able to recognize different clades, they are very 
unlikely to provide any significant degree of protection.
There is a very real concern that vaccine-induced CTL primed by a highly variable 
HTV-1 epitope might not recognize epitope sequence variants from another virus. The 
phenomenon of original antigenic sin means that if the cellular immune response is primed by 
one epitope, it may lack the flexibility to respond appropriately to challenge by an epitope 
sequence variant(249). Furthermore, in vitro these CTL may even antagonize clones that are 
specific for the new variant(402-404). Understandably, this has led researchers to suggest 
that epitopes included in a CTL based vaccine should be directed against epitopes that are as 
highly conserved as possible(405). The mapping of HTV-1 Env epitopes that are potentially
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conserved between clades A and B should therefore constitute an important focus of future 
HTV-l vaccine work.
Reasons for the association between HTV-1 Env CTL and oral contraception is not 
clear. There was no difference in condom use or numbers of clients between sex workers 
taking or not taking the OCR. Although women on the OCR tended to be a little older (34.6 
vs 33.2 years; R=0.4) and to have been in the Rumwani cohort for longer (8.1 vs 7.4 years; 
R=0.7), these associations were far from statistically significant. Certainly, it seems unlikely 
that taking OCR contributes to protection from HTV-1 infection, since oral contraceptives in 
this cohort have previously been associated with higher rates of both HTV-1 acquisition(24) 
and genital ulceration(22).
The fact that all HERS subjects tested both seronegative and proviral RCR negative 
makes it unlikely that CTL-positive women were sub-clinically infected, although this 
possibility cannot be definitively ruled out. In other HERS cohorts, CTL-positive individuals 
have been identified where viral DNA (but not virus) can be consistently isolated from their 
RBMC(247)(and McElrath J, personal communication). However, the lack of association 
between CD4 or CD8+ lymphocyte counts and the presence of CTL also suggests that 
women were not actually infected by HTV-1, or that if they were then the infection is so far 
without the expected immunologic consequences.
The clearest association with HTV-specific CTL was the duration of prior 
seronegative follow-up in the Rumwani cohort. This suggests one of two things:
1) HTV-1 Env-specific CTL are acquired over time in the subgroup of sex workers who 
remain HTV-uninfected after cohort enrolment; or
121
2) The subgroup of sex workers who already had HTV-1 Env-specific CTL at the time of 
cohort enrolment remained HTV-1 seronegative over time.
It is not possible to differentiate between these two hypotheses in the context of a cross- 
sectional study. Prospective follow-up of the newly enrolled sex workers will be more useful 
in this regard, and preliminary results suggest that CTL-positive women are less likely to go 
on to become HTV-infected. However, the lower-than-expected rate of seroconversion 
among new enrolees means that the definitive answer to this question will have to be deferred 
to a future date.
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C h a p te r  f o u r  S y ste m ic  CD8+ ly m p h o c y te  r e sp o n se s  t o
HIV-1 CTL e pito pes
I n t r o d u c t io n
There is substantial variation in susceptibility to HIV-1 infection, with some subjects 
remaining HIV-1 seronegative despite repeated exposure to virus(29). HIV-specific 
cytotoxic T lymphocytes (CTL) have been described in several HTV-exposed, persistently 
seronegative (HEPS) populations(7-9), and the generation of HTV-specific CTL has become a 
key goal in the development of a protective HTV-1 vaccine(406). HTV-specific CTL are also 
found in seropositive donors, where they are important in suppressing viremia and preventing 
disease progression(212, 254, 395), but are generally unable to prevent eventual 
immunosuppression and death. It remains unclear how HTV-specific CTL could play a role 
in protection against HTV-1 infection in HEPS subjects, whilst failing to eliminate the virus in 
the majority of those who are infected.
Protection in HEPS subjects is unlikely to be due to a stronger HTV-specific CD8+ T 
cell response, at least directed against epitopes defined in infected subjects, since the 
magnitude of this response to predefined epitopes is generally lower in blood than in those 
with persistent infection(363). Reduced HTV-1 susceptibility in the Pumwani cohort and in a 
Kenyan mother-child transmission cohort is associated with specific class I HLA molecules, 
in particular the A2 ‘supertype’, which consists of A*0201, A*0202, A*0205, A*0214 and 
A*6802(356, 407), and to a lesser degree with B*1801 and A*2402. These alleles might 
restrict particularly efficient HTV-specific CTL, or present specific “protective” 
epitopes(368). In HTV-infected subjects, quite different CTL epitopes may be recognized in 
primary and chronic infection(408). It is not clear whether this represents escape from or 
functional impairment of an early CTL response, or broadening of the CTL response as the
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host immune system is exposed to different HTV-1 epitopes. However, because the host 
immune system is better able to control viremia early in HTV-1 infection, the implication is 
that targeting certain epitopes may be associated with better immune control of HTV-1 
infection. Whether a similar phenomenon might occur in HEPS cohorts, perhaps explaining 
the HLA associations of reduced HTV-1 susceptibility, is unclear.
A separate possibility is that the CTL responses responsible for protection in HEPS 
sex workers are qualitatively different to those in persistently infected women. HTV-specific 
CTL in infected subjects demonstrate impaired maturation and reduced perforin expression 
when compared to CMV-specific CTL(264), and it may be that HEPS CTL are functionally 
intact, allowing improved viral control. Alternatively, it remains possible that these apparent 
functional defects in HTV-specific CTL simply reflect the fact that different host immune 
strategies are involved in the control of different persistent viral infections.
In order to begin to address these questions, the magnitude and specificity of CD8+ T 
cell responses to a panel of predefined CTL epitopes were examined in the Pumwani sex 
worker cohort, using the IFNy ELISpot assay. First, the ELISpot assay was validated, and 
firm criteria established for defining a positive response. The magnitude of responses in 
HEPS women was approximately tenfold lower than in infected subjects, so that protection 
from HTV-1 infection is not due to a stronger HTV-specific CD8+ response, at least against 
defined HTV-1 epitopes. The proportion of HEPS women demonstrating HTV-specific 
responses increased with increasing duration of HTV exposure, similar to HTV-1 Env-specific 
CTL responses (Chapter 3), and consistent with the development of acquired immunity to 
HTV. Interestingly, class I restricted CD8+ responses in chronically infected sex workers 
generally focused on certain dominant epitopes. However, these epitopes were rarely 
recognized by HEPS sex workers, who often targeted different epitopes, particularly 
restricted through those HLA alleles prospectively shown to be associated with HTV
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resistance in this cohort. This suggests that qualitative, rather than quantitative, differences 
discriminate HEPS CD8+ responses from those of chronically infected subjects.
Definitions and selection of study populations
Sex workers were enrolled during annual resurvey in the Pumwani sex worker clinic, 
between 1995-1999. As in the HTV-l Env-specific CTL study, seronegative sex workers 
were subdivided into three groups, based on the duration of prior seronegative cohort 
enrolment: those enrolled for over three years (thereby meeting criteria for HIV-1 resistance; 
group 1), those enrolled for 1-3 years (group 2), and sex workers followed for less than one 
year (group 3). All HEPS women were confirmed to be HIV-uninfected using a proviral 
PCR system which uses primers for env, nefm d vif HIV-1 provirus genes which have been 
specifically adapted to detect African clades, and which is sensitive to below five viral copies 
per 2x10^ PBMC(40). In order to minimize selection bias, all HEPS sex workers resurveyed 
in the clinic over the study period were included in the study, although the HLA haplotype in 
a few subjects meant that no predetermined HIV-1 epitopes were available from the panel.
Lower-risk HIV-uninfected control women with no history of commercial sex work 
were enrolled from a mother-child health care clinic in the Pumwani district of Nairobi, and 
from an infertility clinic in Nairobi’s Kenyatta National Hospital. Women with clinical or 
laboratory evidence of cervicitis were excluded.
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VALIDATION OF THE PEPTIDE-BASED ELISPOT ASSAY
Correlation between the IFN y ELISpot assay and other functional or phenotypic CTL 
markers
The endpoint of the peptide-based ELISpot assay is IFNy secretion in response to 
predetermined CTL peptide epitopes. Although this is also the functional response of most 
cytotoxic T lymphocytes, the ELISpot assay does not measure actual cytotoxicity in the way 
that a ^^Cr release assay does -  through cell lysis with release of intracellular chromium -  and 
so the ELISpot cannot be classified as a true cytotoxic T lymphocyte assay. In order to 
ensure that IFNy secretion was correlated with cytotoxicity, the ELISpot assay was used to 
screen for responses against a panel of HLA restricted epitopes in two HIV-infected sex 
workers (ML 1464, ML 1707) and one HEPS sex worker (ML 1250). A peptide-pulsed bulk 
line was then set up using the immunodominant epitope, and a chromium release assay 
performed at 21 days using peptide-pulsed autologous BCL as targets. In all three cases, a 
CTL line established using the immunodominant epitope demonstrated specific lysis of 
autologous BCL pulsed with these epitopes, although the levels of both IFNy secretion and 
target lysis were lower for the HEPS than for the infected subjects (see Figure 4.1, overleaf). 
A positive IFNy ELISpot assay does therefore appear to reflect the presence of an actual CTL 
population.
Although the chromium release assay is the most established method used to 
demonstrate CTL, two other techniques have recently been used to study epitope-specific 
CTL. The first method employs tetrameric complexes of HLA class I molecules, which are 
folded with predefined CTL epitope peptides, and conjugated to a fluorescent marker such as 
phycoerythrin (PE)(409). These tetramers will bind to CD8+ T cells bearing the TCR 
specific for that particular CTL epitope, and on FACS analysis will identify a discrete
126
population of epitope-specific CD8+ lymphocytes. Although class I tetramers can only 
demonstrate cell phenotype, the technique of intracellular cytokine staining, either used alone 
or in combination with tetramers, can be used to demonstrate functional responses to 
predefined CTL epitopes(264,408). Both these techniques are unable to detect CD8+ 
responses below a frequency of approximately 200 cells per million(230,408, 410), and have 
so far not been used to study CTL responses in HEPS subjects.
In order to confirm that results of the IFNy ELISpot assay correlate with those found 
using class I HLA tetramers and intracellular staining, an HIV-infected donor was screened 
for responses to a panel of HIV-1 peptide epitopes in an ELISpot assay (see Figure 4.2, 
overleaf). The dominant response was directed against B*5703 restricted p24 epitope 
KAFSPEVIPMF (2600 SFU /million PBMC). A strong CD8+ restricted response to this 
epitope was confirmed using a B*5703 KAF tetramer (1.9% of CD8+ lymphocytes; tetramer 
a kind gift of Dr G. Gillespie), and by epitope-specific IFNy release on intracellular cytokine 
staining (0.6% of CD8+ lymphocytes).
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Figure 4.1 IFNy secretion in an ex vivo ELISpot assay correlates with target 
cell lysis by CTL lines.
a) IFNy ELISpot assays
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HIV-l epitope-specific responses detected by ELISpot in two Pumwani sex workers, ML 
1464 (HIV-infected) and ML 1250 (HEPS). The assay dates and input cell numbers are 
shown above each photograph. Assays are run in duplicate, and PBMC are incubated 
overnight with either no peptide (media alone, negative control); PHA (positive control); or
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predefined HTV-l epitope peptides at 15pM. ML 1464 responds to peptide FPVTPQVPLR 
at a frequency of 700 SFU /million PBMC, and ML 1250 to peptide ILKDPVHGV at 235 
SFU/million PBMC.
b) epitope-specific killing by in vitro stimulated CTL lines
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The figure shows specific lysis of peptide-pulsed BCL by bulk CTL lines generated through 
in vitro stimulation and culture with the same peptide epitopes recognized in Figure 4.1(a). 
In both cases, specific lysis is when HLA-matched target cells are pulsed with the epitopes 
recognized in the ex vivo ELISpot assay. Assay methods are described in Chapter 2.
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Figure 4.2 IFNy secretion in an ex vivo ELISpot assay correlates with epitope
specific CD8+ responses measured using HLA class I tetramers and IFNy 
intracellular staining
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An immunodominant response to the same B*5703 restricted HIV-1 p24 epitope 
KAFSPEVIPMF in HIV-infected subject ML 1295 is consistently demonstrated using (a) the 
IFNy ELISpot (left hand bar, 2600 spot forming units /lO^ PBMC); (b) epitope-specific IFNy 
release using intracellular cytokine staining (0.6% of CD8+ lymphocytes); and (c) class I 
MHC tetramer binding (1.9% of CD8+ lymphocytes).
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Comparability of fresh and frozen PBMC specimens
Due to the nature of sample collection, ELISpot assays used either fresh or cryopreserved 
PBMC. In order to determine the comparability of fresh and frozen specimens, a number of 
validation tests were run before the project began, and statistical comparisons were also 
performed after the completion of the project.
a) Fresh/frozen comparison for non-HIV epitopes
Fresh PBMC from a healthy lab donor (HLA type A*0201, A*3201, B*0801, B*4402, 
Cw*0501, Cw*0701) were screened in an ELISpot assay against a panel of predefined HLA- 
restricted epitopes derived from the common virus pathogens influenza, EBV and CMV. 
PBMC drawn simultaneously were cryopreserved, thawed one week later, and screened for 
responses to the same peptide panel. There was a close correlation between epitope-specific 
response frequencies in fresh and cryopreserved specimens. In particular, no specific epitope 
responses were lost or gained as a result of cryopreservation. When these epitope-specific 
CD8+ responses were quantified, response frequencies measured using cryopreserved 
specimens were slightly lower, but were all >90% of those found using fresh PBMC. 
Furthermore, in this initial experiment there was no significant difference in the rate of 
background (spontaneous) IFNy release between fresh and frozen samples (see Figure 4.3, 
overleaf).
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Figure 4.3 Comparison of epitope-specific responses to common viral epitopes,
using either fresh or frozen PBMC.
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ELISpot IFNy responses to several predefined CTL epitopes from common virus pathogens 
were examined in a healthy lab donor, using either fresh PBMC (white bars) or cryopreserved 
PBMC drawn on the same date, thawed one week later (hatched bars). In all cases 1x10^ 
viable PBMC were used per well. Peptide epitopes used were the A2 restricted influenza 
epitope GILGFVFTL, the A2 restricted CMV epitope NLVPMVATV, and the B8 restricted 
influenza epitope BLRSRYWAI. Response frequencies using fresh and cryopreserved 
PBMC are very closly correlated.
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b) Initial fresh/frozen comparison in HIV-infected sex workers
Having found a close correlation between epitope-specific frequencies measured in fresh 
and frozen PBMC for non-HIV viruses, immunodominant response frequencies were then 
compared between fresh and frozen PBMC samples for fifteen HTV-infected sex workers 
from the Pumwani cohort. Results are shown in Figure 4.4, overleaf. Again, a fairly close 
correlation was seen between frequencies measured in fresh and frozen specimens. On 
average, epitope-specific frequencies were slightly higher when assayed in cryopreserved 
specimens, with mean response frequencies measured in fresh assays being 16.6% lower than 
those measured in frozen. However, there was no statistically significant difference between 
overall frequencies in fresh and frozen samples (1161.9 vs 970.3 SFU/10  ^PBMC; P=0.2). 
Background release of IFNy was significantly higher in assays using frozen specimens, 
however (111.3 vs 41.2 SFU/10  ^PBMC; P=0.001). Using paired t-test analysis, HTV- 
specific frequencies measured using cryopreserved PBMC samples for any given individual 
were higher than fresh by a mean factor of 1.2 (P=NS).
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Figure 4.4 HIV-specific responses to immunodominant epitopes in fresh and frozen
PBMC.
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A comparison of immunodominant CD8+ epitope response frequencies, measured using 
either fresh or cryopreserved PBMC samples. Frequencies obtained using fresh specimens 
are shown in the hatched bars, and using cryopreserved in the white bars. There was no 
significant difference in response frequencies, although there was a trend toward higher 
frequency responses in cryopreserved specimens.
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c) Fresh/frozen comparison in the larger cohort study
Post hoc analysis of HIV-specific responses was performed in the larger Pumwani cohort, 
comparing response frequencies between those with fresh PBMC assays (N=66) and those 
with frozen (N=112). Although the study was less controlled, since each subject does not 
serve as their own control, this analysis showed similar results. Overall, rates of background 
IFNy release were higher in assays using frozen samples (70.0 vs 25.1 SFU/10  ^PBMC; 
P<0.001), both in the HEPS group (67.4 vs 23.1 SFU/10* PBMC; P=0.04) and the HTV- 
infected group (73.7 vs 26.4 SFU/10* PBMC; P=0.001). However, assays performed using 
frozen PBMC were equally likely to give a positive result as those using fresh (76/112 vs 
46/66; P=0.8), and there was no difference between fresh/frozen groups in the frequency of 
immunodominant responses (P=0.5).
Establishing a cut-off for a positive HIV-specific response
In our early CD8+ studies the following criteria had been proposed for a positive ELISpot 
assay, based on a reported assay sensitivity as low as 1/50,000 PBMC(230):
(1) IFNy release seen in response to 1:100 PHA (positive control); and
(2) >20 mV-specific SFU/10  ^mononuclear cells; and
(3) SFU in HTV-l peptide wells exceeded background by a factor of at least two; and
(4) If serial dilutions had been established, a titratable response was required.
In order to validate these criteria, HTV-l ELISpot assays were performed for 18 lower- 
risk Kenyan women with no history of commercial sex work, using the same epitope panel as 
applied to studies in the sex worker cohort (see Appendix 1). No HTV-specific responses 
were detected against a total of 130 CTL epitope peptides, applying the predefined criteria for
137
a positive ELISpot assay (above). The mean HTV-specific response in controls was 5.4 
SFU/10  ^PBMC, with a standard deviation of 7.66, so that [p. + 2SD] was equal to 20.7 
SFU/10^. This correlates closely with the criteria originally used to define a positive assay.
Having validated the IFNy ELISpot, this assay was then used to study HTV-l epitope 
responses in HEPS and HTV-infected subjects from the Pumwani sex worker cohort.
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R e s u l t s
Frequency and magnitude of HIV-specific responses in the Pumwani cohort
CD8+ T cell responses were tested against a panel of 54 predefined CTL epitopes, 
listed in Appendix 1 at the end of this chapter, for 178 sex workers (91 HEPS and 87 
seropositive). Study subjects included all seronegative Pumwani sex workers sampled during 
the 1995-1999 period for whom HLA matched CTL epitopes were available in the panel.
HTV-l epitope-specific responses were more common in HTV-l seropositive than 
HEPS sex workers (79/87, 91% vs 43/91, 47%; LR=42.4; P<0.001), and immunodominant 
responses were approximately ten-fold stronger in seropositive women (mean 983.4 vs 85.8 
SFU/million PBMC; P<0.001). On average, responses in HEPS sex workers exceeded 
background by a factor of 3.3 (range 1-26.7), and in seropositive sex workers by a factor of 
36.1 (range 1-272). Responses were directed against a mean of 2.7 CTL epitopes overall, and 
were more broadly directed in infected sex workers, who recognized a mean of 3.1 epitopes, 
as opposed to 2.0 in HEPS (P=0.007).
There was no difference between seropositive and HEPS subjects in the number of 
HLA alleles restricting ELISpot responses (overall mean =1.5 class I HLA alleles; 1.6 vs 1.4 
respectively; P=0.2). Responders and nonresponders were similar in the number of epitopes 
screened and restricting HLA class I alleles tested. Therefore, interferon gamma responses to 
predefined HTV-l epitopes in HEPS women were neither stronger nor more broadly directed 
than in infected subjects.
HEPS women with an HTV-l epitope-specific response (N=43) were compared to 
those without (N=48; see Table 4.1 overleaf). Responses were not associated with self- 
reported levels of condom use, the number of daily clients, absolute CD4/CD8 lymphocyte 
counts, CD4/CD8 ratio, use of oral contraception, or any single class I allele. However, 
women with a positive response had been engaged in commercial sex work for a longer time
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(11.5 vs 7.6 years; P=0.02), and a stepwise increase in the frequency of ELISpot responses 
with increasing duration of seronegative clinic follow-up was seen again (LR=I4.3, P=0.001; 
see Figure 4.5, overleaf).
In addition, there was a positive correlation between the duration of uninfected clinic 
follow-up and the magnitude of HTV-specific responses (Pearson Correlation = 0.31; 
P<0.001). The association between the duration of uninfected HTV exposure and both the 
frequency and magnitude of HTV epitope-specific responses strongly suggests that immunity 
to HTV is acquired after cohort enrolment.
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Table 4.1 Epidemiological associations of HIV-specific CD8+ lymphocyte 
responses in HEPS sex workers.
Variable Positive assay (N=43) Negative assay (N=48) P-value
CD4 count/nun^ 929 881 0.5
CD8 count/mm^ 810 779 0.7
CD4/CD8 ratio 1.3 1.3 0.9
Clients /day 2.4 3.1 0.2
Condom use (%) 93.5 91.5 0.5
Duration of 11.5 7.6 0.02
prostitution (years)
Epitopes screened 6.6 5.5 0.2
HLA alleles screened 2.2 1.9 0.2
The presence of HTV-specific CD8+ responses (see text for definition) was examined in 91 
seronegative sex workers, and women were divided into two groups based on the presence or 
absence of detectable responses. The presence of CD8+ responses was most strongly 
associated with an increased prior duration of prostitution, so that the longer a woman had 
worked in prostitution without seroconverting, the more likely she was to have an HTV- 
specific CD8+ lymphocyte response.
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Figure 4.5 Duration of prior HIV-1 exposure and CD8+ responses in HEPS 
sex workers.
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Seronegative sex workers within the Pumwani cohort were divided into three groups based 
on the duration of their cohort enrolment, and a fourth group consisted of lower risk 
seronegative Kenyan women with no history of commercial sex work. A stepwise 
association was seen between the presence of HTV-specific CD84- lymphocyte responses and 
the prior duration of seronegative follow-up (LR=15.1; P=0.002; see Chapter 2 for definition 
of a positive response). No further increase in response frequency was seen beyond three 
years.
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These data were generated using the predefined cut-off for a positive assay of 20 
SFU/10  ^PBMC above background (see Materials and Methods). In the absence of 
universally established criteria for a positive ELISpot assay, the robustness of this association 
was tested by using positive cut-offs of both 50 SFU and 100 SFU/10  ^PBMC. In each case, 
a similar association was found between duration of follow-up and a positive ELISpot assay 
(LR=7.0, P=0.03; and LR=5.4, P=0.07 respectively), although the proportion of HEPS 
women with a positive assay decreased as the cut-off was increased, reducing the statistical 
power of any comparisons.
IFNy ELISpot responses are CD8+ lymphocyte mediated
CD8+ depletion assays were performed using PBMC from ten HTV-resistant and five 
mV-infected sex workers; and using cervical specimens from three resistant and three 
infected sex workers. PBMC depletion assays were run using cryopreserved samples 
obtained from the same time point as a known positive sample, run with CD8+ undepleted 
and depleted thawed PBMC. Systemic responses were significantly diminished or abrogated 
after CD8+ lymphocyte depletion in 8/10 (80%) resistant and 5/5 (100%) HIV-infected sex 
workers (see Figure 4.6, overleaf). In addition, stimulation of PBMC by the peptide epitope 
recognized in ELISpot, followed by intracellular cytokine staining for IFNy, demonstrated a 
discrete population of CD8+ lymphocytes producing IFNy (data not shown).
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Figure 4.6 HIV-specific ELISpot responses are reduced or abrogated after 
CD8+ depletion.
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(b) HTV-infected sex workers (N=5)
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Figure 4.6 shows TFTSFy ELISpot response frequencies to predefined HTV-l epitopes using 
whole PBMC (hatched bars) or CD8+ depleted PBMC (white bars); responses were 
considered to be CD8+ lymphocyte mediated if depletion resulted in >50% diminution in 
responses. Using these criteria, responses were CD8+ mediated in 5/5 HTV-infected sex 
workers and 8/10 HEPS sex workers.
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Epitope specificity of responses in HEPS and HIV-infected women
Results were available for 168 sex workers (N=83 HEPS, N=85 HTV-infected). 
Women were selected for the epitope specificity studies if: (1) the specificity of ELISpot 
responses was examined within class I HLA alleles where at least two different HTV-l 
epitopes had been studied, since >2 epitopes are needed to needed to examine differences in 
specificity; and (2) assays had been run in a minimum of eight subjects, to avoid basing 
conclusions on overly small subject numbers.
Among subjects with CD8+ responses restricted through a given class I allele, 
responses in HTV-infected sex workers often focused on epitopes rarely or never recognized 
by HEPS subjects (see table overleaf). For instance, p l7  epitope SLF/YNTVATL was 
recognized by 21/25 (84%) of infected subjects with an A2-restricted response, compared to 
only 1/10 (10%) of HEPS (OR 17.7; P<0.004). Likewise, HTV-infected sex workers with 
allele-specific responses were more likely to respond to the A24 p24 epitope 
RDYVDRFFKTL, the A*6802 pol epitope ETAYFTLKL, the B14 p24 epitope 
DRFF/WKTLRA, and the B 18 ne/epitope YPLTFGWCY/F.
In some cases, HEPS sex workers were also seen to preferentially recognize a certain 
epitope, in particular A*6802 pol epitope DTVLEDTNL and the B 18 p24 epitope 
FRDYVDRFY/FK. Almost all A2-restricted responses in HEPS were directed towards the 
pol epitope TLKD/EPVHGV (7/10 responders), but responses to this epitope were also 
relatively common in HTV-infected subjects (14/25 responders). Strikingly, these differences 
in epitope specificity were only seen for responses restricted by class I HLA alleles A2,
A24, A*6802, B14, and B 18, previously shown to be associated with resistance to HTV-l in 
this cohort(356).
146
Table 4.2 Proportion of sex workers with a positive MHC class I restricted CD8+ 
response who recognize certain HIV-1 epitopes
Restricting HLA 
allele
HIV-1 epitope Gene
product
HEPS HIV-
infected
Likelihood ratio 
(corrected P-value)^
A2 SLF/YNTVATL pl7 1/10 22/26 18.3 (P<0.004)
ILKD/EPVHGV pol 7/10 14/26 NS
A*6802 ETAYFILKL pol 3/12 9/11 7.9 (0.01)
DTVLEDINL pol 11/12 6/11 4.4 (0.08)
A24 RDYVDRFFKTL p24 0/4 6/10 7.2 (0.03)
(R)YLR/KDQQLL gp41 3/4 10/10 NS
B14 DRFF/WKTLRA p24 0/4 6/7 14.4 (0.004)
DLNMM/TLNI/VV p24 4/4 3/7 4.8 (0.1)
B18 YPLTFGWCY/F nef 1/4 8/9 5.3 (0.04)
FRDYVDRFY/FK p24 3/4 1/9 5.3 (0.04)
Table 4.2 shows the proportion of HEPS and HTV-infected sex workers responding to certain 
predefined epitopes. Only sex workers with positive ELISpot responses restricted by the 
given class I HLA allele are included in this analysis. As shown, HEPS and HTV-infected sex 
workers who had a HTV-specific CD8+ response restricted by a given class I allele often 
recognized quite different epitopes.
 ^P-value corrected for the number of epitopes compared at a given class I allele, by 
multiplying the uncorrected P-value by the number of epitopes compared.
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There were no differences between HEPS and seropositive sex workers in A2 allele 
subtypes, and no differences were apparent in A2-restricted epitope recognition based on A2 
allele subtype (data not shown). No significant differences were found between HEPS and 
seropositive women in the specificity of responses restricted by seven other class I alleles, 
where similar patterns of epitope recognition were seen in HEPS and infected subjects (data 
not shown). Insufficient subjects and/or epitopes were studied to examine differences in 
specificity at nine class I alleles. Overall, sex workers with at least one of the class I HLA 
alleles associated with protection from HIV-1 infection were more likely to have an HTV- 
specific response than those without any of these alleles (33/60 vs 10/31; LR=4.3, P=0.04). 
Taken together these data suggest that the beneficial effect of these HLA alleles in resistance 
to HTV infection could be related to a greater likelihood of generating a CTL response to a 
repertoire of "protective" HTV-l epitopes.
Epitope immunodominance in HEPS and HIV-infected women
As noted above, infected sex workers tended to focus CD8+ responses on epitopes 
infrequently recognized by HEPS sex workers, while epitopes recognized by HEPS women 
were not recognized, or were recognized at a low frequency, by seropositive women. To look 
at this in a different way, we compared the patterns of allele-specific epitope 
immunodominance between HEPS and infected sex workers. This analysis was restricted to 
those class I alleles where differential epitope recognition had been observed (A2, A24, 
A*6802, B14 and B18), and P-values were corrected for the number of epitope pairs 
compared at each allele. Significant differences or trends in epitope immunodominance were 
seen for responses restricted by all those class I alleles associated with protection in the 
Nairobi sex worker cohort (see table overleaf).
148
Table 4.3 Dominant epitopes restricted by various MHC class I alleles in HEPS and 
HIV-infected sex workers
Restricting class 
I allele
HIV-1 epitope (gene 
product)
Immunodominant
(HEPS)
Immunodominant
(HIV-infected)
Likelihood ratio 
(P-value)^
A2 ILKD/EPVHGV (pol) 7/10 5/26 11.8 (0.05)
SLF/YNTVATL (pl7) 1/10 18/26
A24 (R)YLR/KDQQLL (env) 3/4 4/10 7.2 (0.15)
RDYVDRFFKTL (p24) 0/4 6/10
A*6802 DTVLEDINL (pol) 10/12 2/11 10.6 (0.001)
ETAYFILKL (pol) 2/12 9/11
B14 DLNMM/TLNI/VV 4/4 1/7 9.4 (0.01)
(p24) 0/4 6/7
DRFF/WKTLRA (p24)
B18 FRDYVDRFY/FK (p24) 3/4 1/9 5.3 (0.02)
YPLTFGWCY/F (nef) 1/4 8/9
Table 4.3 demonstrates that HEPS sex workers rarely recognize those predefined HIV 
epitopes that are immunodominant in HIV-infected subjects, and that in some cases they 
focus on different predefined epitopes. Only subjects with an HTV-specific response 
restricted by the relevant class I allele are included in this analysis, and the immunodominant 
epitope is defined as the predefined HTV-l CTL epitope from the panel (see addendum) that 
results in the highest frequency IFNy response.
 ^P-value corrected for the number of epitope pairs compared at each class I allele, by 
multiplying the uncorrected P-value by the number of epitope pairs.
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HIV-1 Env responses in HEPS women not recognizing predefined epitopes
Since the peptide epitopes used in the ELISpot assay had generally been mapped 
within HIV-infected donors, it is possible that responses to unique HEPS CTL epitopes 
would be missed. This possibility was investigated in 30 HEPS sex workers meeting criteria 
for HTV-l resistance, but who had had no response detected against the panel of 54 
predefined HTV-l CTL peptides (see Appendix) in assays performed at 1-5 different time 
points (mean 2.4 time points). These women were then screened for CD8+ responses against 
vaccinia constructs containing the HTV-l clade A env, HTV-l clade A gag, lac (control) 
genes, using a vaccinia ELISpot assay (see Materials and Methods). HTV-l Env-specific 
responses were detected in 10/30 HEPS women (33%; response range 25-645 SFU/10^ 
PBMC), in the absence of responses to predefined epitopes, and HTV-l clade A Gag 
responses in 2/30 subjeets (7%; range 55-165 SFU/10^ PBMC). CD8+ lymphocyte depletion 
resulted in >50% reduction in HTV-specific activity in all cases.
The panel of predefined CTL epitopes used in screening assays was not exhaustive, 
since it did not include several class 1 restricted epitopes that are newly described or 
infrequently recognized(389). However, in 4/10 of the HTV-l Env responders, all previously 
described HLA-matched Env epitopes had been screened without any positive response, and 
all described Gag epitopes had been screened in both HTV-l Gag responders. This strongly 
suggests that CD8+ responses in these HEPS women were directed against previously 
unmapped CTL epitopes.
Although numbers were small, the proportion of sex workers in this subgroup with 
vaccinia Env-specific CD8+ responses was also correlated with the duration of preceding 
seronegative follow-up (LR=5.0; P=0.08), as was seen in the larger Pumwani cohort for both 
HTV-l Env-specific bulk CTL and peptide ELISpot responses.
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Figure 4.7 HIV-1 Env CD8+ responses in HEPS women not recognizing predefined 
epitopes also correlate with the duration of seronegative follow-up
<1 year (n=5) 1 -3 years (n=4) >3 years (n=21 )
duration of seronegative clinic foiiowup
Seronegative sex workers within the Pumwani cohort who had no detectable response to the 
panel of predefined HTV-l CTL epitopes (see addendum) were divided into three groups 
based on the prior duration of their cohort enrolment, and HTV-l Env-specific responses were 
examined using a vaccinia ELISpot assay (see Chapter 2). Although subject numbers were 
small, a stepwise association was found between the occurrence of HTV-specific CD8+ 
lymphocyte responses and the prior duration of seronegative follow-up (P=0.08).
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D is c u s s io n  a n d  c o n c l u s io n s
The extraordinarily high risk of incident HIV-1 infection in the Nairobi sex worker 
cohort plateaus after three years of HIV-uninfected follow-up, an observation best explained 
by the presence of HTV-l resistance in a minority of women(29). Both classical CTL 
responses(361, 368) and IFNy responses directed against HTV-l CTL epitopes(368) have 
been previously demonstrated in these HTV-resistant women, despite a lack of detectable 
HTV-l infection or conventional antibody responses. The current study constitutes the most 
complete examination of CD8+ lymphocyte responses performed in this or any other HEPS 
cohort, examining 91 seronegative sex workers who had been followed previously for a mean 
of 5.4 years (range, 0-14 years).
The finding that HTV-specific CD8+ lymphocyte responses become more frequent 
and stronger in the seronegative women with the longest duration of HTV-l exposure mirrors 
earlier findings examining HTV-l Env-specific CTL in this cohort. Taken together, these 
observations provide a clear association between CD8+ responses and resistance to HTV-l 
infection, and strongly suggest that HTV-specific immunity is acquired over time. However, 
because an observational study cannot prove causality, it remains possible that HTV-specific 
CD8+ lymphocyte responses are not protective, but constitute an epi-phenomenon related to 
exposure of sex workers protected from HTV-l infection by an alternate mechanism. This 
mechanism is not likely to be intrinsic resistance of CD4 cells, increased production of CC 
chemokines, or HTV-l coreceptor abnormalities(353), but could relate to genetic factors, 
since family studies in the Pumwani cohort have found an inherited predisposition to reduced 
HTV-l susceptibility (Kimani J, unpublished data). HTV proviral DNA can been detected in 
the PBMC of some HEPS subjects in other cohorts(247), and so it is also possible that HTV- 
resistant sex workers have actually been infected by HIV, but are able to control viral 
replication to a level that is undetectable by conventional means.
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It has been suggested in the past that HTV-resistant sex workers could be protected 
due to an especially vigorous CTL response(411). However, both ex vivo ELISpot and semi- 
quantitative bulk CTL culture (Chapter 3) have shown that HTV-specific CTL are 
considerably weaker in HEPS than in infected sex workers. This may reflect the fact that the 
antigenic load is small in HEPS women in the absence of persistent infection, or may relate to 
the site of antigen exposure. HEPS women are exposed to relatively low doses of HTV-l in 
the genital tract, and to date no evidence of plasma viremia has been found in this group, 
even using ultrasensitive PCR analysis of HEPS women with transient CD4+ lymphopenia 
(Kaul R, unpublished data). Low-frequency responses in the blood may also reflect the fact 
that HTV-specific CD8+ lymphocytes induced through mucosal exposure do not persist in 
blood, but traffic to mucosal sites of exposure, as has been shown in models of mucosal 
infection by attenuated STV(332). Alternatively, because the genital tract does not contain 
mucosal inductive sites, HTV-l exposure limited to this site may be a relatively inefficient 
means of inducing a cellular immune response(302). These hypotheses will be discussed 
further in Chapter 5.
Although HTV-l CTL epitope-specific responses were common in both HEPS and 
seropositive women, we demonstrated significant differences between these groups in the 
epitope specificity of responses restricted by certain class 1HLA alleles. This differential 
epitope recognition was only seen for responses restricted by class 1 alleles previously 
associated with a reduced risk of HTV-l seroconversion in this cohort(356), namely HLA A2, 
A*6802, A24, B14 and B18 (allele B14 was associated with reduced seroconversion in this 
HLA study, although this did not reach statistical significance due to low subject numbers: 
OR=0.36; 95% Cl 0.1-1.4; P=0.1).
The phenomenon of differential epitope recognition has been described recently in the 
context of primary versus chronic HTV-l infection(408). In this study, A2-restricted
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responses to the epitope SLYNTVATL were shown to be immunodominant during chronic 
infection (as they were within our cohort of HIV-infected sex workers), but were not seen in 
any of eleven subjects with primary infection. A SLYNTVATL-specific response developed 
later in two subjects, 5-20 months after primary infection, but was not important in the initial 
control of viremia. Similarly, these observations in the Pumwani cohort suggest that 
responses to the A2-restricted epitope SLYNTVATL, as well as to several other epitopes 
commonly recognized in the context of chronic HTV-l infection, are not important in 
protection against HTV-l infection. This is despite the fact that SLYNTVATL-specific CTL 
have been shown to be important in controlling viremia and disease progression in chronic 
HTV infection(212, 395). However, the timing of our sampling does not allow a detailed 
analysis of changes in epitope specificity during primary infection.
Several hypotheses could explain the association between protection from HTV-l 
infection and differential epitope recognition. HEPS responses might be directed against 
more highly-conserved regions of the virus, minimizing the possibility of viral escape, or 
against gene products critical for viral replication(368). However, although three of the 
differential epitopes overlap within the highly conserved Major Homology Region (MHR) of 
HTV-l gag, this region does not appear to be recognized preferentially by HEPS women: two 
of those epitopes (A24 RDYVDRFFKTL and B14 DRFFAVKTLRA) are more commonly 
recognized by seropositive women, and one (B18 FRDYVDRFF/YK) by HEPS.
Furthermore, the heterogeneity of CTL epitopes preferentially recognized by HEPS subjects 
argues against a focus of these responses on particular viral gene products. Of the four 
epitopes, two are found within HTV-l pol (A2 TLKD/EPVHGV in reverse transcriptase and 
A*6802 DTVLEDTNL in protease),and two within HlV-1 p24 (B14 DLNM/TLNl/VV and 
B18 FRDYVDRFY/FK). Beyond the investigative scope of this thesis is the possibility that 
peptide epitopes in HEPS and HTV infected women are processed by different pathways.
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perhaps by cross presentation and the endogenous pathway, respectively, which might result 
in the presentation of different epitopes.
Low cell surface density of naturally processed CTL epitope peptides may limit the 
effectiveness of HTV-specific CTL. However, Tsomides and colleagues have demonstrated 
that the A2-restricted epitope SLYNTVATL (preferentially recognized by seropositive 
women in our study) is displayed on the cell surface at approximately thirty times the level of 
TLKEPVHGV (preferentially recognized by HEPS women)(169). Variations in cell surface 
expression of CTL epitopes are therefore unlikely to explain the phenomenon of differential 
epitope recognition. This observation has parallels with studies in a murine model of LCMV 
infection, which showed that the relative abundance of different CTL epitopes on infected 
cells closely correlated with the magnitude of the epitope-specific CTL response. However, 
the quantitative hierarchy of CTL activity was not reflected in the ability of these CTL to 
protect against LCMV infection following adoptive transfer: the best protection in this study 
was mediated by CTL specific for a subdominant epitope(207).
Finally, it is possible that there are functional differences between CTL specific for 
different epitopes, particularly since HTV-specific CTL in chronically infected donors 
demonstrate relatively low levels of perforin expression and cytolytic function(264). It is 
feasible that this impaired CTL function could be related in some way to the epitope 
specificity of CTL in seropositive donors, perhaps because immune-driven viral escape leads 
to reduced function or loss of epitope-specific responses important in early viral control. 
Subsequent reduced effector function might then either relate to host immune reliance 
initially subdominant CTL, or on dominant CTL whose function has been compromised by 
epitope variation. Given the low frequency of PBMC responses in HEPS subjects, detailed 
comparison of CTL function between HEPS and infected donors may require the cloning and
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subsequent expansion of these low-frequency CTL, since HEPS responses are generally 
below the detection limit of the ex vivo tetramer assay(409).
In our study, HTV-specific responses were not detected in 42% of women meeting 
criteria for HTV-l resistance. This could be due to the protection of some HEPS subjects in 
this cohort by other immune responses, including HTV-specific IgA(365), CD4-mediated T 
helper responses(T), and noncytolytic CD8+ mediated inhibition of HTV-1(371). However, it 
is also possible that CTL epitope responses were present, but fell below the threshold of 
detection of our assays. HTV-specific CTL are detected intermittently in HEPS individuals, 
possibly due to varying levels of antigen exposure or assay limitations(363). More 
importantly, the panel of 54 HTV-l CTL epitopes used in the ELISpot assays did not include 
every CTL epitope described to date, so that certain epitope responses might have been 
missed, and the estimated breadth of response might have been falsely narrowed.
Alternatively, the finding of differential epitope recognition raises the possibility that 
HEPS sex workers target epitopes completely distinct from those mapped in seropositive 
women. Since almost all HTV-l CTL epitopes to date have been mapped in infected donors, 
responses to unique HEPS epitopes could be missed. If this were the case, then one might 
expect that some HEPS sex workers would have CTL directed against ‘unmapped’ epitopes. 
This hypothesis is supported by the finding of HTV-l Env-and Gag-specific responses in 
HEPS sex workers not recognizing any epitopes included in our panel. Although the panel 
did not include all epitopes mapped to date, 4/10 Env responders and 2/2 Gag responders had 
been screened against all known Env or Gag epitopes without response. This strongly 
suggests the recognition of previously undefined epitopes.
CTL-based preventative HTV-l vaccine studies may therefore benefit from a focus on 
previously-defined CTL epitopes which are preferentially recognized in HEPS individuals, as 
well as from a search for novel protective epitopes within HEPS cohorts.
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Appendix 1. Panel of 54 predefined HIV-1 cytotoxic T lymphocyte peptide 
epitopes used in IFNy ELISpot assays
Peptide sequence Gene
product
Position Clade specificity HLA restriction
GSEELRSLY pl7 71-79 B A1
ISERILSTY Rev 55-63 B A1
ILKD/EPVHGV Pol 476-484 A/B A2
SLF/YNTVATL pl7 77-85 A/B A2
TLNAWVKVFV p24 150-159 A/B A2
ALKHRAYEL/ Nef 190-198 A/B A2
AFHHVAREL
KIRLRPGGK pl7 18-26 A,B,D A3
RLRDLLLIVTR gp41 775-785 B A3
S/AIFQSSMTK Pol 325-333 A/B A3, A ll ,  A33
DLSHFLKEK Nef 86-94 B A3
QVPLRPMTYK Nef 73-82 B A ll
AVDLSHFLK Nef 84-92 B A ll
lYQEPFKNLK Pol 508-516 B A ll
TLYCVHQRI pl7 84-92 B A ll
(R)YLR/KDQQLL gp41 591-598 A/B A24
LFCASDAKAY gpl20 53-62 B A24
DSRLAFHHM Nef 186-194 B A24
RDYVDRFFKTL p24 296-306 A A24
VSFEPIPfflY gpl20 263-272 B A29
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DTVLEDINL Pol 85-93 A A*6802
ETAYFYILKL Pol 744-752 A,B,D A*6802
ULWQRPLV Pol 58-67 a ,b ,d A74
IPRRIRQGL gp41 848-856 A,B,D B7
TPGPGV/IRYPL Nef 128-137 B B7
FPVTPQVPLR Nef 68-77 B B7
SPRTLNAWV p24 148-156 B B7
GPKVKQWPL Pol 171-180 A,B,C,D B8
YLKDQQLL gp41 586-593 B B8
GGKKKYRL pl7 24-31 A B8
DRFFAVKTLRA p24 298-306 A/B B14
DLNMMLNIV/ p24 183-191 A/B B14
DLNTMLNVV
ERYLRDQQL gp41 589-597 A B14
RAEQASQEV p24 305-313 B B14
YPLTFGWCY/F Nef 135-143 B/D B18, B49
FRDYVDRFY/FK p24 293-302 B,D/A,C B18
KRWnL/MGLNK p24 263-272 B B27
TAVPWNASW gp41 606-614 B B35
VPLRPMTY Nef 75-82 B B35
H/NPDIVIYQY Pol 342-350 A/B B35
PPIPVGDIY p24 260-268 B B35
IPLTEEAEL Pol 447-455 B B51
DPNPQEVVL gpl20 77-85 B B51
LPCRIKQn gpl20 378-385 B B51
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AT/SQEVKNWM p24 177-185 A/B B53
DTINEEAAEW p24 203-212 A B53
QATQEVKNW p24 308-316 A B53
EVKNWMTETL p24 313-322 A B53
TSTLQEQIGW p24 235-243 A,B B57/58
L/ISPRTLNAW p24 147-155 A/B B57/58
KAFSPEVIPMF p24 153-164 B B57/58
QAISPRTL p24 145-152 B Cw3
SFNCGGEFF gpl20 376-383 B Cw4
KYRLKHLVW pl7 728-736 A Cw4
QASGEVKNW p24 176-184 B Cw4
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C h a p te r  f iv e  H IV -sp ec ific  CD8+ ly m p h o c y te  r e sp o n se s  in
THE GENITAL TRACT OF HEPS SEX WORKERS
I n t r o d u c t io n
Heterosexual sex accounts for 70-80% of new HIV-1 infections in the developing 
world(412), and so immune responses conferring protection against HTV are likely to be 
active at the level of the genital mucosa. HTV-specific IgA has been described in the genital 
tract of sexually exposed HEPS subjects(365), but it has been suggested that HTV-specific 
humoral responses alone may be insufficient to protect against infection(406). HTV-specific 
T helper and cytotoxic T lymphocyte (CTL) immune responses have been detected in the 
blood of HEPS individuals(7-9), including the Pumwani sex worker cohort (Chapters Three 
and Four). Furthermore, the acquisition of these responses over time, and the differential 
recognition of HTV-l epitopes between HEPS and infected sex workers, both suggest that 
HTV-specific CTL may be causally associated with protection against HTV-l infection.
However, although CD8+ lymphocytes from HEPS donors can protect against 
systemic HTV-l challenge in a SCTD/beige mouse model(413), other murine experiments 
have shown that mucosal rather than systemic (splenic) HTV-specific CTL are necessary to 
confer resistance to mucosal viral transmission(341 ). In addition, in a macaque model of STV 
infection, long-term protection against mucosal transmission of STV was only conferred to 
those animals that developed mucosal CTL after jejunal exposure to STV(339). These studies 
suggest that although HTV-specific CTL are likely to be important in mediating protective 
immunity, these responses may need to be present in the genital tract to prevent heterosexual 
HTV-l acquisition. CTL have been demonstrated in the genital tract of HTV-infected 
women(327, 330), but there has been little data regarding mucosal CTL responses in the 
genital tract of exposed, uninfected populations. This may be partly due to the difficulties
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inherent in demonstrating low frequency CTL using samples obtained from a site with a rich 
microbial flora, and which contain relatively few T lymphocytes.
The IFNy ELISpot assay, previously used to document HIV-specific CD8+ responses 
in the blood of both HTV-infected and HEPS donors(368) (and Chapter Four), provides an 
estimate of antigen-specific CD8+ lymphocyte frequencies, and there is a close correlation 
between these frequencies and those measured by either tetrameric MHC-peptide complexes 
or limiting dilution CTL assays(230, 410, 414). ELISpot also has the advantage of being an 
overnight assay, thereby minimizing the effect of contamination with genital tract flora, and 
requires fewer input cells than standard bulk CTL assays(415). For these reasons, the 
interferon-y ELISpot assay was used to estimate simultaneous CTL frequencies in the cervix 
and blood of HEPS and HTV-infected Pumwani sex workers.
Definitions and selection of study populations
Systemic and cervical responses to previously defined HTV-l CTL epitopes were 
studied in a selected subgroup of the HEPS and HTV-infected sex workers, attending the 
annual clinic resurvey between October 1998 -  February 1999. Because the influence of 
coexistent STI on immune responses in the genital tract mucosa is unknown, any women with 
clinical or laboratory evidence of STI were excluded. Lower-risk HTV-uninfected control 
women were enrolled from a mother-child health care clinic in the Pumwani district of 
Nairobi, and from an infertility clinic in Nairobi’s Kenyatta National Hospital. A physical 
examination was performed, and blood was drawn for HTV-l and syphilis (rapid plasma 
reagin; RPR) serology. In both groups women with clinical or laboratory evidence of 
cervicitis were excluded, as were those with any history of commercial sex work. Informed 
consent was obtained from all study participants, and the study conformed to ethical 
guidelines from the University of Manitoba and the University of Nairobi.
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HTV-l peptides were selected from a panel of previously-defined A-, B- and D-clade 
CTL epitopes. Epitope selection was based on (1) the class I HLA haplotype of the donor; 
and (2) where possible, on the results of previous systemic HTV-specific CTL assays in this 
population. As detailed in the Materials and Methods section (Chapter Two), mononuclear 
cells for analysis were obtained from density centrifugation of cervical cytobrush and blood 
specimens, counted, and used in a standard overnight ELISpot assay.
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R e s u l t s
Adequacy of sampling using the cervical cytobrush
In total, 27 HTV-resistant sex workers and 16 HTV-infected sex workers were 
enrolled. The cervical samples from ten HTV-resistant and five HTV-infected sex workers 
were inadequate for analysis (no response seen to PHA). Simultaneous cervical and systemic 
responses could therefore be studied for 17 resistant and 11 HTV-infected sex workers. The 
mean cytobrush yield for adequate cervical samples was 4.4 x 10  ^CMC (range 8 x 10"^  -  1.2 
X  10  ^CMC), and for inadequate samples was 6 x 10"^  CMC. The cell yields of adequate 
cervical samples did not differ between positive and negative assays (4.3 x 10  ^and 5 x 10  ^
cells respectively; p=0.6). HTV-l infection status did not influence cell yield from cervical 
cytobrushes (4.6 x 10  ^CMC for HTV-infected, and 4.3 x 10  ^for HTV-resistant; p=0.8).
Phenotypic analysis of cervical cytobrush specimens
Phenotypic analysis was performed on CMC specimens from three HTV-resistant and 
two infected sex workers (a representative example is shown overleaf, in Figure 5.2). A well- 
defined CD8/CD3 double positive lymphocyte population was present in all samples tested, 
with CD8+ lymphocytes comprising 11.8-24.1% of the gated lymphocyte subpopulation 
(0.1-0.4% of total events). No differences were noted in CD8+ lymphocyte frequencies 
according to HTV-l infection status.
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Figure 5.1 Cytobrush specimens contain a well-defined CD3+/CD8+ 
population
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A cervical cytobrush specimen obtained from HEPS sex worker ML 1072 demonstrates a 
well-defined CD3+/CD8+ double-positive population. CD3 FITC (FLl-H) is represented on 
the Y axis, and CD8 PE (FL2-H) on the X axis.
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HIV-infected subjects had a mean CD4+ lymphocyte count of 416/mm^ (160- 
780/mm^) and CD8+ count of 1164/mm^ (770-2730/mm^). HIV-resistant sex workers had a 
mean CD4+ count of 967/mm^ (660-1602/mm^) and CD8+ count of 893/mm^ (320- 
1360/mm^).
HIV-specific CD8+ lymphocytes in the genital tract of HEPS and infected women
HIV-specific CD8+ responses were found in the cervix and/or blood of 11/17 (65%) 
of HIV-resistant sex workers, and 8/11 (73%) of HTV-infected sex workers. However, no 
conclusions can be drawn from the relative proportions of HEPS and infected women 
demonstrating CD8+ responses, since several HEPS women were enrolled on the basis of 
prior systemic CD8+ responses, resulting in a selection bias. Epitope responses in the cervix 
were associated with a systemic response to the same epitope in 9/11 (82%) resistant and 7/8 
(88%) infected sex workers. HTV-specific CD8+ responses were apparently localized to the 
blood in three subjects (2/11 HTV-resistant and 1/8 HTV-infected subjects), and to the cervix 
in three subjects (2/11 resistant and 1/8 infected subjects). Figure 5.2 (below) demonstrates 
the occurrence and magnitude of HTV-l epitope-specific CD84- responses in the blood and 
genital tract of the HEPS sex worker subgroup.
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Figure 5.2 HIV epitope-specific responses in the blood and genital tract of HEPS 
Kenyan sex workers
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The figure shows the occurrence and frequency of HIV epitope-specific responses in the 
blood (peripheral blood mononuclear cells; PBMC) and genital tract (cervical mononuclear 
cells; CMC) of 18 HEPS sex workers. Methods and criteria for a positive ELISpot assay are 
discussed in the text. HIV-specific responses were found in the blood and/or genital tract of 
14/18 HEPS sex workers, and an epitope-specific response in one anatomical site was highly 
correlated with a response to the same epitope in the other. Responses were also common in 
the genital tract of HIV-infected sex workers, and their specificity again mirrored that of 
systemic responses (data not shown).
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In keeping with previous observations (Chapter Four), CD8+ lymphocyte responses in 
HIV-infected sex workers tended to be greater in magnitude than those in resistant women, 
both in blood (606.4 vs 61.3 SFU/10® PBMC; p=0.01) and cervix (189.4 vs 76.2 SFU/10* 
CMC; p=0.1). No HTV-specific responses were found in the blood or cervix of seven low- 
risk Kenyan controls. Again, because there had been considerable bias in the selection of 
epitopes for analysis in this study, the specificity of responses could not be compared 
between genital tract and blood, or between HEPS and HTV-infected sex workers.
CD8+ depletion assays using cervical specimens from three resistant and three 
infected sex workers were diminished or abrogated in all subjects (see Figure 5.3, overleaf), 
confirming that CD8+ mononuclear cells mediate these cervical responses.
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Figure 5.3 CD8+ depletion results in the reduction or abrogation of HIV 
epitope-specific responses in both the blood and the genital tract
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CD8+ depletion using magnetic beads coated with monoclonal antibodies specific for human 
CD8 (see text for details) resulted in the reduction or abrogation of the HIV epitope-specific 
responses seen in both PBMC and CMC of HTV-infected (N=3) and HEPS (N=3) subjects. 
Figure 5.3 shows ELISpot response frequencies in whole PBMC/CMC (hatched bars), and in 
CD8+ depleted cell suspensions (white bars).
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Relative magnitude of CD8+ responses in the blood and genital tract
Although both systemic and cervical responses were weaker in HEPS than infected 
women, CD8+ responses were somewhat enhanced in the cervix of HEPS sex workers.
While responses were considerably stronger in the blood of infected women, when compared 
to the cervix they were slightly stronger in the genital tract of HEPS women (see Figure 5.4, 
overleaf). In order to look at the relative intensity of systemic and cervical responses, a 
cervical-systemic differential was calculated for each peptide epitope by subtracting the 
peptide-specific systemic (PBMC) response from the cervical (CMC) response. This showed 
that the cervical responses were relatively enriched in the HEPS group, (mean differential 
+12.4 SFU/10^; p=NS), while in the HTV-infected group systemic responses were 
considerably more intense than cervical responses (mean differential -320.6 SFU/10^; 
p=0.006 between groups).
Persistence of CD8+ responses in the genital tract of HEPS women
Where it was possible for HEPS sex workers, follow-up cervical specimens were 
obtained after a positive ELISpot assay. Persistent HTV-specific responses were found in the 
cervix of 3/4 HTV-resistant sex workers, at an interval of 5-21 weeks (see Figure 5.5). The 
intensity of cervical responses had increased from baseline in two resistant sex workers 
(ML889, 20 to 150 SFU/10^ CMC; ML1792, 25 to 67 SFU/10^ CMC), and had decreased in 
one (ML1622, 200 to 50 SFU/10^ CMC). Cervical CTL could no longer be detected in one 
resistant sex worker (ML1589, 25 to 0 SFU/10^ CMC). Data were not available concerning 
changes in sexual behaviour over the intervening period.
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Figure 5.4 HIV-specific responses are enhanced in the genital tract of HEPS
sex workers, when compared to infected women
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The vertical columns represent the mean HIV-specific response seen in cervical 
mononuclear cells (clear bars) or PBMC (cross-hatched bars) of HEPS and HTV-infected 
populations. While genital tract responses are slightly stronger than blood in HEPS women 
(differential +12.4 SFU), blood responses are three-fold stronger than genital tract in infected 
women (differential -320.6 SFU).
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Figure 5.5 Persistence of HIV-specific CD8+ responses in the genital tract of
HEPS sex workers
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The vertical bars represent the frequency of HTV-specific IFNy responses in the genital tract 
at the initial sampling timepoint (hatched bars), or at follow-up 5-21 weeks later (white bars). 
Persistent responses to predefined HTV-l CTL epitopes were found in cervical mononuclear 
cells from 3/4 HTV-resistant sex workers.
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D is c u s s io n  a n d  c o n c l u sio n s
This work was the first demonstration of HTV-specific CD8+ lymphocyte responses in 
the genital tract of HEPS subjects, and the first use of the ELISpot assay to examine genital 
tract responses in HTV-infected women. The possibility that genital tract CTL might play a 
key role in protection against sexually-acquired HTV-l infection was suggested by Belyakov 
et al, who showed that mucosal HTV-specific CD8+ CTL conferred long-lasting immune 
resistance to mucosal viral transmission in mice, while systemic (splenic) CTL alone were 
unable to protect against mucosal transmission(338, 341). More recently, Murphey-Corb et 
al have shown that MHC class I-restricted CTL directed against viral Env in the jejunal 
lamina propria are absolutely correlated with protection from colonic STV challenge(339). 
Although systemic (blood) CD8+ and CTL responses had been previously described in the 
cohort of HEPS sex workers, because the vast majority of HTV-l transmission in this group 
occurs during heterosexual intercourse(24) these animal findings could have great relevance 
to the Pumwani women. In fact, it is quite plausible that HTV-specific CTL in the cervix 
might play a more direct role than systemic responses in immune-mediated protection against 
HTV-l.
If mucosal HTV-specific CTL in the genital tract play a critical role in protection 
against HTV-l infection in this sex worker population, then enrichment of the responses in the 
cervix might be predicted, since this is the site of actual viral exposure. In keeping with this 
hypothesis, we found that cervical responses were slightly enhanced relative to systemic CTL 
in HTV-resistant sex workers. The converse was true in HTV-infected women, who showed 
considerable enrichment of HTV-specific responses in the blood. Although overall responses 
were weaker in HTV-resistant than HTV-infected sex workers, their relative enhancement at 
the site of repeated viral exposure is consistent with the suggestion of a major role in 
protection against heterosexual transmission of HTV-l. Much work remains to be done on
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the phenotype of mononuclear cells from the cervix. However, since it seems likely that 
fewer of these mononuclear cells are actually lymphocytes than is the case for PBMC, it is 
possible that this study underestimated the strength of CD8+ responses in the genital tract.
The female genital tract is quite capable of supporting antigen-specific CTL(299). 
Both cervix and vagina have been shown to contain CD3+, CD4+ and CD8+ lymphocyte 
populations, and CD3+ cytolytic activity is present throughout the menstrual cycle(57, 347, 
416). Although HIV-specific CD8+ lymphocyte responses had not been previously 
demonstrated in mucosal specimens from HEPS donors, Musey and colleagues demonstrated 
that mV-specific CTL (involving both CD4+ and CD8+ cells) could be generated from 
genital specimens of HTV-infected women(327). In these HTV-l-infected women, 
comparisons of intra-individual cervical and blood CTL specificities also indicated that 
epitopes recognized by CTL in the cervix were commonly recognized in the blood, although 
relative frequencies of CTL in cervix and blood were not examined. The importance of these 
responses in the genital tract of HTV-infected individuals is not clear, although they could 
potentially play a part in reducing HTV transmission to sexual partners.
HTV-specific cervical CTL responses persisted for up to five months in the majority 
of HTV-resistant sex workers studied, although no response was detected at follow-up in one 
woman. The latter finding is not unexpected, since the detection of HTV-specific CTL was 
intermittent in previous studies of blood from HEPS individuals(363), and cervical specimens 
from HTV-infected women(327). In the latter study, cervical CTL were detected at least once 
in 63% of HTV-infected subjects, and in approximately 50% of cervical specimens at follow- 
up, findings that are quite similar to our own in both HTV-resistant and infected women.
This study used an IFNy ELISpot assay to demonstrate CD8+ lymphocyte-mediated 
HTV-specific responses from cervical and blood specimens. ELISpot has been previously 
used to document HTV-specific responses in both HTV-infected(279) and HEPS(368) donors.
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Estimates of antigen-specific CD8+ lymphocyte frequencies using ELISpot correlate well 
with those measured by either tetrameric MHC-peptide complexes or limiting dilution CTL 
assays (LDA)(410, 414). However, the ELISpot technique has the advantage over tetramer 
staining of increased sensitivity at low precursor frequencies (1/50,000 as opposed to 
l/5,000)(230), and ELISpot also allows rapid screening of responses against a wide variety of 
HTV-l CTL epitopes, many of which are not currently available as MHC-peptide tetramers.
In comparison to LDA, the ELISpot is a relatively short assay, and so is less subject to 
overgrowth by genital tract flora. In addition, ELISpot requires fewer input cells than LDA, 
making it better suited to analysis of samples with relatively few T lymphocytes.
In summary, we have been able to demonstrate CD8+ lymphocyte responses to HTV-l 
CTL peptide epitopes in the cervix of HEPS Kenyan sex workers. The specificity of these 
responses was generally mirrored by that of systemic (PBMC) responses, providing no 
evidence of differential specificities at these sites, although this study was not well designed 
to pick up such differences. These HTV-specific responses were enhanced in the genital tract, 
at the likely site of repeated viral exposure, and persisted for up to five months. Overall, 
these data suggest that HTV-specifie CD8+ responses in the genital tract may play a role in 
protection against heterosexual HTV-l infection in exposed, uninfected individuals.
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Chapter  six  H IV-specific  m ucosal IgA and  system ic  T  helper
RESPONSES IN HEPS PROSTITUTES
In t r o d u c t io n
Over the past decade it has become clear that not all people are equally susceptible to 
infection by HIV-1, and that some HEPS individuals may remain HIV-1 seronegative despite 
repeated viral exposure(9). Establishing immune correlates of resistance to HIV-1 infection 
is key to the development of a protective vaccine(406). The work presented so far in this 
thesis has focused on HTV-specific cytotoxic T lymphocyte responses in the Pumwani HEPS 
cohort, demonstrating CTL against a range of viral epitopes and/or gene products. However, 
there are two other types of HTV-specific immunity that have been described in HEPS 
individuals, and these may also be important in protection against infection.
Most global mV-1 transmission occurs across a mucosal surface, which may be the 
female genital mucosa (during vaginal sex), the rectal mucosa (during anal sex), or the 
oropharyngeal mucosa (during oral sex, or through breast-feeding)(338). For this reason, the 
study of HTV-specific mucosal immune responses in HEPS subjects has become a focus of 
research interest, and Chapter Five outlined the demonstration of HTV-specific CD8+ 
lymphocyte responses in the cervix of the Pumwani HEPS sex workers. IgA is the key 
antibody isotype in mucosal secretions(302), and as reviewed in the introduction, secretory 
IgA is thought to function in four main ways:
(a) by binding to pathogens in the mucosal lumen, blocking pathogen-receptor 
interaction;
(b) through classical antibody-mediated neutralization;
(c) by inhibiting the transcytosis of HTV-1 virions across the epithelial monolayer;
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(d) through the formation of immune complexes in the mucosal lumen(299, 301, 
302).
Recently, HTV-1 Env-specific IgA has been demonstrated in the blood and genital tract of 
exposed, seronegative individuals from HTV serodiscordant couples(365, 372).
There is evidence that TL-5, the cytokine that is key in IgA isotype switching(308, 
310,417), may also have a role in promoting cellular immune responses(311). CD4+ 
mediated T helper responses may be necessary for CTL to be effective in controlling HTV- 
1(267), and these have also been described in several HEPS cohorts(358, 359, 361). 
However, it is not clear how the cellular and humoral arms interact in the setting of HTV-1 
exposure, and whether they might be co-dependent or independent mechanisms of immune 
protection against HTV-1.
In order to address these questions, genital tract secretions and saliva were obtained 
from HEPS sex workers, and tested for HIV-1 Env-specific IgA and IgG. Simultaneously, 
PBMC were tested for evidence of T helper responses against HTV-1 Env, to delineate any 
possible relationship between humoral and cellular defences at these distinct sites.
Definitions and selection of study populations
All sex workers were enrolled through the prostitute clinic in the Pumwani area of 
Nairobi, Kenya. From May to June of 1997, we studied mucosal and systemic HTV-specific 
immune responses in an unselected subgroup of consecutive HIV-resistant and HTV-infected 
sex workers returning for resurvey. Because N. gonorrhoeae produces IgA proteases, which 
might theoretically interact with HTV-specific IgA defences in the genital tract during an 
episode of gonorrhoea, only women with no clinical evidence of cervicitis and a negative 
cervical culture for N. gonorrhoeae were eligible for study enrolment.
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Lower-risk HIV-uninfected control women were enrolled from a family-planning 
clinic in Nairobi, which is participating in ongoing HTV-1 surveillance(381). Informed 
consent was obtained, and a standardized questionnaire administered. This questionnaire 
included data concerning lifetime number of sexual partners, history of commercial sex work, 
perceived risk of sexually-transmitted disease (STD) or HTV-1 exposure from current sexual 
partner(s), history of past or present STDs, and other perceived HTV-1 risk factors. A 
physical examination was performed, blood drawn for HTV-1 serology and RPR, and 
bacterial cultures taken. An HTV-1 risk score was calculated for lower-risk HTV-uninfected 
women, in order to estimate the lifetime risk of HTV-1 exposure. This took the form of an 
additive score, and was based on the following parameters: history of ever having sold sex 
(five points); lifetime reported sexual partners (one point each); past or present STD (either 
clinical or laboratory diagnosis, one point); regular sexual partner has other sexual partners 
(one point). For these women, data on frequency of condom use were available only for the 
current, stable sex partner, and so was not incorporated into the lifetime risk score. No data 
was available regarding the HTV-1 serostatus of the current partner, or the frequency of 
certain risk behaviours (eg: anal intercourse, TV drug use), although the latter behaviours are 
very rare among Kenyan sex workers.
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Table 6.1 Baseline behavioural and demographic characteristics of the 68 sex
workers studied
Characteristic HTV- resistant HTV-infected Lower-risk P-valuet
(N=21) (N=19) (N=28)
CD4 count/mm^ 659 380 716 <0.001;
NS*
CDS count/mm^ 591 989 704 <0.001;
NS*
Prostitution 10.6 6.5 N/A 0.01
duration (years)
Clients/day 2.7 4.5 N/A 0.005
(mean)
Condom use (% of 59.9 88.0 N/A 0.01
clients)
t  Pearson’s chi-squared test of significance used for categorical variables; analysis of 
variance for comparison of means.
* P-values for comparison of HEPS with HIV-infected women and lower-risk controls, 
respectively.
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RESULTS
Presence and correlates of genital tract HIV-1 Env-specific IgA
Twenty-one HIV-resistant sex workers, 19 HTV-infected sex workers and 28 lower-risk, 
uninfected women were enrolled in the study. There were demographic and immunologic 
differences between the three study groups, as would be expected (see Table 6.1 on the 
previous page). Compared to HTV-infected prostitutes, HEPS women had fewer clients but 
used condoms more often. CD4 lymphocyte counts were lower in HTV-infected women than 
in uninfected women (mean 380 vs 691/mm^; p<0.0001), but did not differ between HTV- 
resistant sex workers and lower-risk HTV-uninfected women (659 vs 716/mm^; p=0.4).
Mean levels of cervical and vaginal IgA were significantly higher in HTV-resistant 
women than in those infected by HTV-1 (all p<0.01) or for lower-risk uninfected controls (all 
p<0.01; see Figure 6.1, overleaf). Levels of mucosal HTV-specific IgA exceeding the cut-off 
value for significance (defined as /^seronegative controls + 2 SD; see Chapter Two) were present in 
the genital tract of 16/21 (76%) resistant women, 5/19 (26%) infected women, and 3/28 
(11%) lower-risk uninfected controls (p <0.0001). Levels of HTV-specific mucosal IgA at the 
two genital sites were highly correlated. This was the case whether all three study groups 
were analyzed (correlation coefficient 0.71; p<0.001), or only HEPS sex workers (correlation 
coefficient 0.56, p=0.008).
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Figure 6.1 HIV-1 Env-specific IgA in the genital tract
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Figure 6.1 shows levels of HTV-specific cervical and vaginal IgA for 21 HTV-resistant sex 
workers, 19 HTV-infected sex workers, and 28 lower-risk uninfected control women (see text 
for methods). IgA levels are reported as absorbance at 450nm. Although overall IgA levels 
were low when compared to IgG (see page 183), HTV-specific IgA was common in HEPS sex 
workers and rare in both infected sex workers and lower risk controls.
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No correlation was found between the presence of HTV-specific IgA in the genital 
tract of resistant sex workers and immunologic parameters (CD4 or CDS lymphocyte counts), 
behavioural factors (duration of prostitution, frequency of condom use, number of clients per 
day, or type of contraceptive use), or demographic factors (age). For lower-risk uninfected 
control women, no correlation was found between genital tract IgA and immunologic or 
demographic factors. However, in this lower-risk group the presence of HTV-specific IgA in 
the genital tract was associated with HTV-1 risk-taking behaviours. Three lower-risk control 
women had significant levels of genital IgA, and these women were more likely to have had 
previous exposure to HTV-I, as reflected by a higher mean HTV-I risk score (mean risk score 
6.6 ± 3.8 vs 3.5 ±1.8; p=0.004). In particular, their regular sexual partner was more likely to 
have other sexual partners (p=0.02), and they were more likely to have a past history of 
commercial sex (p=0.03).
HTV-specific IgA was infrequent among HTV-infected sex workers, present in the 
genital tract of five women (26%). No correlation was found between stage of HTV-I 
infection, as reflected by CD4 lymphocyte counts, and titres of cervical or vaginal IgA (p=0.6 
and p=0.62 respectively).
HTV-specific IgG was found in the genital tract of no (0/21) resistant sex workers, all 
(19/19) seropositive sex workers, and 1/28 (3.5%) lower-risk women (p<0.0001; see Figure 
6.2, overleaf). The presence of IgG in the genital tract of lower-risk uninfected women was 
not associated with increased risk-taking behaviours, as reflected by the HTV-I risk score 
(data not shown). By definition, all HTV-infected subjects and no HTV-uninfected subjects 
had an HTV-specific systemic IgG response.
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Figure 6.2 HIV-1 Env-specific IgG in the genital tract
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Levels of HTV-specific cervical and vaginal IgG are shown for 21 HIV-resistant prostitutes, 
19 HTV-infected prostitutes, and 28 lower-risk uninfected controls. IgG levels are reported as 
absorbance at 450nm. With the exception of one lower risk woman, IgG levels were high in 
HIV-infected subjects and absent in HEPS / lower risk subjects.
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HIV-specific salivary IgA
The same trends seen in the genital tract were also apparent in salivary samples, with 
higher levels of HTV-specific IgA found in HEPS women (mean absorbance 1.18) than in 
either infected sex workers (mean 0.66) or lower-risk controls (0.58; P=0.006; see Figure 6.3, 
below). However, there was considerably more variability in the levels of salivary IgA found 
in lower-risk controls than had been seen in genital tract samples, perhaps related to the crude 
technique used in sample collection (direct collection of saliva into a 50cc conical tube). 
When a cut-off for a positive assay was calculated as [pcontrois + 2SD], there was no 
significant difference between the number of HEPS women with salivary IgA (4/19, 21%) 
and low-risk controls (2/28, 7%; P=0.2). However, HEPS women were more likely than 
HTV-infected (0/19, 0%) to have salivary IgA (LR 6.0; P=0.01).
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Figure 6.3 Levels of HIV-specific IgA in the saliva
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Levels of HIV-specific salivary IgA are shown for 19 HTV-resistant prostitutes, 19 HTV- 
infected prostitutes, and 28 lower-risk uninfected controls. IgA levels are reported as 
absorbance at 450nm. Although HTV-specific IgA tended to be more common in the saliva of 
HEPS women than in infected (P=0.01) or lower risk women (P=0.2), levels of salivary 
virus-specific IgA were much more variable in the genital tract, possibly related to sampling 
technique (see text).
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Presence and correlates of systemic HIV-1 Env-specific Th responses
Positive T helper responses to the five antigenic HTV-I envelope peptides (an TL2 
stimulation index >4 for at least two antigenic peptides) were detected in 11/20 (55%) 
resistant sex workers, 4/18 (22%) HTV-infected sex workers (P=0.04, for comparison with 
resistant sex workers), and 1/25 (4%) lower-risk uninfected women (P<0.0001, for 
comparison with resistant sex workers; see Table 6.2, overleaf). Stimulation indices for all 
five antigenic HTV-1 envelope peptides were highly correlated (all correlation coefficients 
>0.44; P<0.001). T helper responses were more common and stronger in the HEPS subjects 
studied, in contrast to CTL or CD8+ IFNy responses, where HEPS responses had been 
significantly less common and weaker than those seen in HTV-infected sex workers (see 
Chapters 3 and 4). Comparison of mean stimulation indices between HEPS and HTV-infected 
subjects showed trends to or significantly higher responses for all five antigenic peptides in 
HEPS sex workers (P=0.03-0.15), but not for the non-antigenic peptide P23 (P=0.2).
Although there was a clear association between the presence of Th responses and 
HTV-1 resistance, Th responses were not associated with either the presence of genital HTV- 
specific IgA (P=0.8), or with duration of sex work (P=0.5). However, in the great majority of 
subjects meeting criteria for HTV-1 resistance, either HTV-1 specific mucosal IgA or HTV-1 
specific Th responses (or both) were detected (18/20 women; 90%). Resistant women with a 
positive IL-2 response tended to have been enrolled in the sex worker cohort for a longer 
period of time (6.1 ± 1.6 vs 4.9 ±1.5 years; P=0.1), and CD4 lymphocyte counts tended to 
be higher in this group (656 ± 181 vs 514 ± 197/nun^; P=0.1).
The one lower-risk, uninfected woman with a positive HTV-specific T helper response 
did not appear to have engaged in any high-risk behaviours (based on her HTV-1 risk score), 
and no mucosal IgA was detected in this woman.
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Table 6.2 Systemic HIV-specific T helper responses in HIV-1 resistant sex workers, 
HIV-1 infected sex workers, and lower risk control women
(a) The frequency of systemic HIV-specific T helper responses* in the three study 
groups
HTV-1 resistant HTV-1 infected Lower risk P-value^
sex workers sex workers controls
HTV-specific T 
helper response
11/20 (55%) 4/18 (22%) 1/25 (4%) <0.01
* Defined as an IL2 stimulation index (SI) of >4 in response to stimulation by two or more 
antigenic HIV-1 envelope peptides (16).
f  Comparison of HTV-1 resistant sex workers with either HTV-infected or lower risk women.
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(b) The relationship between systemic HIV-1 specific T helper responses and 
mucosal IgA in the subset of HIV-1 resistant^ sex workers
Study
subject
Positive T
helper
response*
Medial MN T1 Th-IV nib T2 HIV env
specific
IgA
1025 1 212.00 157.0 255.3 84.36 79.60 40.46 1
1072 1 1241.00 30.54 20.83 11.64 1.29 .13 1
1192 0 3012.00 1.95 .41 2.92 1.96 18.46 1
1260 1 1588.00 46.68 .41 11.50 3.96 .15 0
1266 1 4652.00 6.94 9.31 6.23 3.78 6.77 0
1275 1 1657.00 2.15 6.81 11.29 3.01 .52 1
1358 0 460.00 .81 .87 .97 9.75 1.87 0
1362 1 2551.00 4.52 10.03 .40 34.83 .62 0
1498 1 2152.00 .27 5.99 7.71 .60 34.58 1
1529 0 1761.00 2.87 4.19 2.73 1.83 1.10 0
1536 0 3504.00 .87 1.52 3.07 4.29 1.68 1
1552 0 18763.00 1.22 1.04 1.12 .78 .98 1
1573 1 1225.00 8.19 8.06 9.35 8.16 9.80 1
1589 1 2541.00 19.47 23.38 15.32 1.41 15.96 1
1593 0 5524.00 1.58 .23 .09 .23 .34 1
1635 0 8071.00 1.25 .12 .08 1.75 .05 1
1643 1 303.00 1.79 2.99 13.85 77.41 .94 1
1732 1 2541.00 5.52 5.73 8.44 2.02 .76 1
1747 0 2030.00 .61 1.27 .74 9.31 .78 1
HIV-1 resistance as defined by Fowke et al(29).
* Defined as an IL2 stimulation index (SI) of >4 in response to stimulation by two or more 
antigenic HIV-1 envelope peptides(418).
^  Media results expressed as mean counts per minute (cpm) after CTLL cultures were pulsed 
with [^H] thymidine at 24 hours (see methods); results for each antigenic peptide are then 
shown as a stimulation index (cpm of peptide stimulated PBMCs divided by mean cpm of 
unstimulated cells from the same subject).
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D is c u s s io n  a n d  c o n c l u s io n s
This study shows that in a group of sex workers who have epidemiological evidence 
of resistance to HTV-I infection, resistance is highly associated with the presence of HTV- 
specific IgA in the genital tract. These data suggest that one mechanism of protection against 
HTV-1 infection in these women is mucosal IgA antibody. In addition, these data suggest that 
the genital tract is an effective site for the induction of mucosal IgA responses in humans, 
since these sex workers are only likely to be exposed to HTV-1 at the level of the genital 
mucosa. Oral sex, anal sex and intravenous drug use are reported extremely rarely in this 
population(24). HTV-specific IgA was also found in the genital tract of a minority (11%) of 
lower-risk, HTV-uninfected women. In this lower-risk group, HTV-specific genital IgA was 
associated with a history of high-risk sexual behaviour. These observations provide further 
support for the hypothesis that mucosal IgA responses may play a key role in resistance 
against HTV infection, originally raised by Clerici et al(365), and suggests that the presence 
of HTV-specific mucosal IgA may be a marker for high-risk sexual behaviour.
The mechanism by which mucosal IgA might protect against HTV-1 infection is not 
clear, although more recent work in the Pumwani cohort suggests that at least two 
mechanisms may be involved(419): (1) direct neutralization of HTV-1(420), and (2) blocking 
of HTV-1 transcytosis across the intact mucosal epithelium(421). However, levels of HTV- 
specific IgA in the infected mother do not appear to correlate with rates of virus transmission 
through breast feeding(422). This implies that there may be functional differences between 
the HTV-specific IgA found in HEPS and HTV-infected subjects. In keeping with this 
hypothesis, novel specificities of IgA from HEPS subjects are already beginning to be 
described(373).
It is striking that in this sex worker population, HTV-specific IgA was relatively rare 
in the genital tract of infected women (26%). IgG antibody responses can mask IgA antibody
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responses, presumably by competing with IgA for binding sites on HIV-1 antigens, so that 
the frequency of genital tract IgA may be underestimated. However, virus-specific IgA was 
found in the vaginal washes of most HIV-infected women from other Italian and African 
cohorts(365,423). The discrepancy is not explained by more advanced disease in our study 
population, since our study found no association between mucosal IgA and CD4 lymphocyte 
counts in HTV-infected women. In addition, the mean CD4 lymphocyte count was higher in 
our HTV-infected subjects than in those reported by Clerici's group (mean CD4 lymphocyte 
count 380/mm^ vs 160/mm^)(365). The lower frequency of virus specific IgA in the genital 
tract of these HTV-infected sex workers may therefore be due to differences in the genital 
tract environment, or to genetic differences between the infected populations.
The genital tract environment in this cohort is likely to differ from that of other 
cohorts, due to the frequent occurrence of sexually-transmitted infections in sex workers.
The monthly incidence of Neisseria gonorrhoeae infection among sex workers in Pumwani 
may be as high as 20%(424). IgAl proteases are produced by Neisseria gonorrhoeae(425, 
426), and the activity of these enzymes may result in a local functional IgA deficiency, 
facilitating mucosal colonization and penetration by microorganisms or allergens(427). It is 
therefore possible that genital infection by Neisseria gonorrhoeae results in a transient 
deficiency of HTV-specific IgA at the mucosal surface. This might result in the increased 
shedding of HTV-1 in genital secretions of infected persons, since it has been suggested that 
HTV-specific IgA responses in vaginal secretions may play an important role in reducing 
levels of infectious virus(423). Furthermore, a transient deficiency in genital tract IgA could 
enhance host susceptibility to sexually acquired HTV-1 infection in HTV-exposed, uninfected 
persons. This study has an insufficient power to address these hypotheses, since only one 
subject had culture-proven gonorrhoea at the time of screening (and hence was excluded from
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the main analysis). This HTV-resistant woman did not have HTV-specific IgA in the genital 
tract.
Current thinking holds that a humoral response alone, as defined by a systemic IgG 
response, is unlikely to confer protective immunity(294). It has been hypothesized that a 
systemic cellular response may be necessary for protective immunity, either alone or in 
combination with a systemic humoral response(406). For this reason, the induction of an 
HTV-specific cytotoxic T lymphocyte response has been identified as a fundamental goal in 
the development of a preventative ATDS vaccine(428). We found that an HTV-specific T 
helper response was highly associated with HTV-1 resistance, present in over 50% of resistant 
sex workers, but was only seen in a minority of HTV-infected sex workers or lower-risk, 
uninfected controls. This confirms previous observations within this cohort(361) and other 
HTV-uninfected, highly exposed groups(7, 359, 365), and reconfirms the importance of HTV- 
specific cellular responses as a goal in vaccine trials. However, the fact that these cellular 
responses were not correlated with HTV-specific mucosal IgA responses suggests that 
systemic cellular and mucosal humoral responses may represent separate, independent 
immune mechanisms of protection against HTV-1 infection. Using systemic cellular 
responses alone as an end-point in vaccine trials may therefore prove to be inadequate.
The three groups of women in this study were selected on the basis of differences in 
HTV-1 infection status, and in rates of ongoing exposure to HTV-1. The groups also differed 
in several other respects, as was shown in Table 6.1. HTV-resistant women had been 
involved in sex work for a longer time than infected women. However, the definition of 
HTV-1 resistance requires continued work in the sex trade for at least three years without 
HTV-1 infection, and so it is not surprising that resistant women had a longer duration of sex 
work than their HTV-infected counterparts. Although HTV-resistant women had fewer clients 
per day than infected sex workers, they used condoms less frequently and had been involved
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in sex work longer, so that overall levels of HTV-I exposure are unlikely to differ 
significantly. There were also several differences between the lower-risk, HTV-uninfected 
group and the two sex worker groups. Hormonal contraceptive use was more common in the 
lower-risk women, almost certainly because they were enrolled through a family-planning 
clinic. This difference is unlikely to have influenced results, since no association was found 
between hormonal contraceptive use and HTV-specific genital IgA in any of the study groups 
(data not shown).
In conclusion, HTV-specific IgA was present in the genital tract of most Kenyan sex 
workers who have evidence of HTV-1 resistance. HTV-specific IgA was also found in the 
genital tract of a minority of lower-risk uninfected women, where it was associated with 
high-risk sexual behaviour. T helper responses to HTV-1 envelope peptide epitopes were 
highly associated with HTV-1 resistance, but did not otherwise correlate with the presence of 
HTV-specific mucosal IgA. These data suggest a role for mucosal HTV-specific IgA 
responses in resistance to HTV-1, independent of host cellular responses, and suggest that the 
induction of both these immune responses might be an appropriate goal for protective 
vaccines currently under development.
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C h a p te r  se v e n  L a te  s e r o c o n v e r s io n  in  HEPS w om en  d e sp ite
PRIOR H IV -spec ific  im m u n it y
I n t r o d u c t io n
Individuals exhibit differential susceptibility to infection by HTV-l, with a minority 
remaining uninfected despite repeated viral exposure(29). HTV-specific immune responses, 
in particular cytotoxic T lymphocytes (CTL), may play an important role in protection from 
infection in HTV-exposed, persistently seronegative (HEPS) subjects(9). The generation of 
HTV-1 CTL responses has therefore been identified as a key goal in the effort to develop a 
preventative HTV-1 vaccine(406). However, the durability and protective efficacy of CTL 
responses in HEPS subjects is unclear, making it difficult to develop vaccination strategies.
There is a complex relationship between plasma viremia and levels of HTV-1 CTL, 
with substantial evidence that CTL play an important role in controlling viremia(253). High 
levels of HTV-specific CTL are found in acute infection, and may fall below the limits of 
detection as the early peak in viral load decreases, particularly in the context of complete 
viral suppression with antiretroviral therapy(429-431). In chronic infection there is an 
inverse correlation between the numbers of circulating HTV-specific CD8+ T cells and the 
plasma viral load(212), but this population also declines to undetectable levels following 
successful antiretroviral therapy(430,432, 433), with a half-life of approximately 45 
days(430). Furthermore, there seems to be an antigenic threshold below which HTV-specific 
CTL in infected persons cannot be detected(434). These observations suggest that the 
maintenance of a circulating HTV-specific effector CTL population, which directly kill 
infected cells and produce antiviral cytokines such as IFNy, is dependent on an ongoing 
antigenic stimulus. However, a memory CTL population, which can undergo multiple
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divisions and replenish the effector population(435), is maintained in HIV-infected subjects 
after antiretroviral therapy has reduced viremia below the limits of detection(431).
Transient HTV-l exposure in seronegative individuals may result in the generation of 
HTV-specific CTL(7, 9), but whether this exposure results in long-lived HTV-specific CTL 
memory is unknown. CTL responses can be detected after a single percutaneous exposure to 
infected blood, and fall below the limits of detection within 2-8 months(362). These studies 
of HTV-specific CTL after transient exposure have studied CTL activity using in vitro culture 
of peripheral blood mononuclear cells (PBMC) after restimulation with HTV antigens(361- 
364, 366, 368-370), which is presumed to expand both memory and effector CTL 
populations(415). The loss of these responses within months of viral exposure therefore 
suggests a loss of both effector and memory CTL in the periphery. This would be in keeping 
with other virus infections, where maintenance of protective memory CTL in the periphery is 
short-lived in the absence of antigen(245).
The waning of protective CTL immunity in the absence of antigen therefore 
constitutes a potential problem confronting a CTL-based HTV vaccine. A second theoretical 
problem is the evasion of protective epitope-specific CTL by viral variants bearing amino 
acid substitutions within the target epitope, as has been seen in a vaccine model of STV 
infection(258). The phenomenon of CTL mutational escape is well described in HTV- 
infected subjects, where it may be associated with increased viral load and disease 
progression(255, 261, 392).
In the four-year period between 1996-2000, eleven sex workers who had previously 
met criteria for HTV-1 resistance seroconverted. Since HTV-specific cellular and IgA 
responses had been studied prior to seroconversion in several of these women, as part of the 
work already covered in this thesis, the phenomenon of late seroconversion was explored 
further. In particular, three hypotheses were addressed: (1) that late infection might represent
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HIV-1 infection in those sex workers who lack HTV-1 immune responses; (2) that, if prior 
CTL had been demonstrated, women were infected by primary viral escape variants; or (3) 
that late infection represented the waning of epitope-specific immunity.
Definitions and selection of study populations
All study subjects were enrolled through the dedicated sex worker clinic in Pumwani, 
Nairobi. Women were classified as HTV-resistant if they remained HTV-1 seronegative and 
polymerase chain reaction (PCR) negative for at least three years while continuing in sex 
work(29). Late seroconverters (cases) comprised women who had met criteria for HTV-1 
resistance, but subsequently seroconverted between January 1996 -  December 1999. Each 
case was compared with two persistently seronegative sex workers (controls) who: (1) had 
been reviewed in the clinic in the same year as the index case; (2) had at least one PBMC 
sample available; and (3) had been enrolled in the cohort at as close a time as possible to the 
index case, to control for changes in sexual behaviour over time. Lower-risk HTV-uninfected 
control women were enrolled from a family-planning clinic in Nairobi, which is participating 
in ongoing HTV-1 surveillance(381).
Behavioural data up to the time of seroconversion was obtained from standardized 
questionnaires administered at clinic recruitment and annually thereafter(24). Data collected 
include the number of daily clients, consistency of condom use, methods of contraception, 
prior duration of prostitution, sexual practices with clients, and other HTV-1 risk factors such 
as blood transfusion, rape and intravenous drug use. Additional information obtained at the 
time of seroconversion included any break from sex work over the past year, any recent 
medical events such as vaccination or any new medication(s), and whether the subject had 
sex with a partner known to be HTV-infected.
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R e s u l t s
HIV-specific CD8+ responses prior to late seroconversion
Pre-seroconversion PBMC specimens were available for 7/11 cases, with appropriate 
HLA class I epitope peptides for 6/7 cases. HTV-specific responses were found in the most 
recent preseroconversion test for 4/6 (67%) cases, 5-18 months prior to HTV-1 
seroconversion (see Table 7.1, overleaf), with response frequencies from 20-168 SFU/10^ 
PBMC. In cases ML 857 and ML 1203 epitope-specific responses were detected at >2 time- 
points prior to seroconversion, and were confirmed using a bulk CTL chromium release assay 
(including the low-frequency ELISpot response in ML 1203 on 01/03/97 to epitope 
DTVLEDINL, at 20 SFU/IO'' PBMC).
Cases where pre-seroconversion PBMC were available did not differ from cases 
without PBMC in HTV exposure parameters over the year preceding seroconversion, either in 
the duration of prior seronegative follow-up (7.7 vs 6.2 years; P=0.2), the number of clients 
per day (3.8 vs 3.2; P=0.7), or condom use (78% vs 55%; P=0.4). No samples drawn from 
seroconverters within two months prior to their presumed date of infection were tested.
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Table 7.1 Pre-seroconversion CD8+ responses in late seroconverters
Subject (conversion 
date)
Assay date Peptide epitope 
response
HLA restriction, 
HIV gene product 
(clade)
Spot-forming units 
/lO^ PBMC
ML 857 (28.08.98) 01.03.97 DTVLEDINL A*6802 pol (A) 100^
H/NPDIVIYQY B35 pol (A/B) 100^
21.10.97 DTVLEDINL A*6802 pol (A) 65
09.06.98 DTVLEDINL A*6802 pol (A) 113
H/NPDIVIYQY B35 pol (A/B) 75
ML 1203 01.03.97 DTVLEDINL A*6802 pol 20^
(04.06.98) FPVTPQVPLR B7 nef(B) nd^
17.12.97 DTVLEDINL A*6802 pol (A) 168
FPVTPQVPLR B7nef(B) 43
ML 1575 10.06.97 None
(08.05.98) 21.10.97 None
ML 1592 18.04.96 None
(07.07.96)
ML 1707 23.10.97 DTVLEDINL A*6802 pol (A) 36
(05.01.98)
ML 1760 30.05.97 ILKD/EPVHGV A2 pol (A/B) 90
(16.05.98)
These ELISpot results confirmed in bulk cytotoxic T lymphocyte assays.
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The pattern of epitope recognition prior to HTV-1 infection was similar to the rest of 
the HEPS sex workers (see Chapter 4). The most common HTV-1 CTL epitope recognized 
was DTVLEDINL, an A-clade, A*6802-restricted HTV-1 pol epitope (N=3; ML 857, ML 
1203, ML 1707). Other epitopes recognized included TLKDPVHGV, an A-clade, A2- 
restrictedpol epitope (N=l; ML 1760); FPVTPQVPLR, a B7-restricted « e /epitope (N=l;
ML 1203); and HPDTVIYQY, a B35-restricted, A-clade pol epitope (N=l; ML 857).
Other HIV-specific immune responses prior to late seroconversion
HTV-specific T helper assays have been performed for a relatively small proportion of 
HEPS women in the Pumwani cohort, and to date no women with a positive Th response 
have seroconverted (0/20 women). HTV-specific IgA studies, looking for the presence of 
antibody by ELISA (see Chapter 6), and the effect of IgA on virus neutralization or 
transcytosis, have been performed on a larger number of women. In total, 2/37 (5%) of 
women with HTV-specific IgA activity have gone on to seroconvert.
Late seroconversion is not generally due to CTL escape
A total of six HTV-1 CTL epitopes were recognized in pre-seroconversion ELISpot 
assays from four women (one epitope in two women, and two epitopes in the other two 
women). Pro viral DNA corresponding to these epitopes was amplified and sequenced from 
the infecting viral strains, as shown in Table 7.2. Twenty epitope sequences were obtained in 
each case, to rule out sequence variation in rare quasispecies. In 5/6 viral epitopes the 
infecting sequence was identical (20/20 sequences) to that recognized in pre-seroconversion 
ELISpot ± bulk CTL assays. However, the sequence of the B35-restricted HTV-1 pol epitope 
in seroconverter ML 857 differed from that recognized pre-seroconversion (NPEIIIYQY vs
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HPDrVIYQY), although these amino acid substitutions have all been previously described in 
clade A HIV-1 strains(389).
Bulk CTL assays were performed for ML 857 using pre-seroconversion PBMC 
stimulated by either the HPDIVIYQY or NPEIUYQY epitope variants. The HPDIVIYQY- 
stimulated CTL line demonstrated low-level specific lysis of targets pulsed with epitope 
HPDIVIYQY (as recognized in the ELISpot assay) but not with epitope NPEIIIYQY. The 
NPEmYQY-stimulated CTL line did not recognize targets pulsed with either epitope (see 
Figure 7.1). This confirms that pre-seroconversion PBMC from this HEPS subject 
recognized epitope HPDIVIYQY, but not the infecting variant NPEIUYQY. Although this 
raises the possibility that ML 857 was infected by an escape variant, it should be emphasized 
that (1) no escape was seen within the second CTL epitope (DTVLEDINL) recognized by 
this HEPS subject, and (2) this sequence is well described in clade A HIV-1(389).
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Table 7.2 Amino acid sequences of HIV-1 CTL epitopes recognized in pre­
seroconversion ELISpot assays, and sequence of infecting virus.
Subject Epitope sequence: 
pre-seroconversion ELISpot
Epitope sequence: 
infecting virus
ML 857 DTVLEDINL DTVLEDINL (20/20)
HPDIVIYQY NPEIIIYQY (20/20)
ML 1203 DTVLEDINL DTVLEDINL (20/20)
FPVTPQVPLR FPVTPQVPLR (20/20)
ML 1707 DTVLEDINL DTVLEDINL (20/20)
ML 1760 ILKDPVHGV ILKDPVHGV (20/20)
The table shows the sequence of the HTV peptide epitope recognized prior to seroconversion 
and the actual sequence of this epitope in the infecting HTV strain. Epitopes were sequenced 
from twenty viral clones, and the proportion with a given sequence are shown in parentheses.
201
Figure 7.1 Pre-seroconversion PBMC from ML 857 recognize the clade A consensus 
epitope, but not the corresponding epitope from the infecting virus
a) ML 857 CTL line generated using consensus A-clade epitope (HPDIVIYOY)
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b) ML 857 CTL line generated using epitope variant from infecting isolate (NFEHIYOY)
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A bulk CTL line generated from pre-seroconversion PBMC using the HIV-1 clade A Pol 
consensus epitope HPDIVIYQY recognizes autologous BCL targets pulsed with peptide 
HPDIVIYQY, but not with the infecting epitope variant NPEIUYQY (Figure 7.1a). A bulk 
CTL line generated from pre-seroconversion PBMC using the infecting epitope variant 
NPEIUYQY does not recognize targets pulsed with either the consensus epitope 
HPDIVIYQY, or the infecting variant NPEIUYQY (Figure 7.1b).
Recognition is defined as >10% specific lysis of peptide-pulsed target cells by a bulk CTL 
line (see text for assay details).
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Strength and specificity of CD8+ responses, before and after seroconversion
HIV-specific ELISpot responses had been present prior to seroconversion in 4/6 of 
women who had met criteria for HIV-1 resistance, and in one resistant subject who has 
seroconverted subsequently (ML 1250). In these five women, CD8+ responses before 
seroconversion were compared with responses seen within one year after. More epitopes and 
more gene products were recognized after infection (mean of 3.0 vs 1.4 epitopes, and 2.4 vs 
1.2 gene products; P=0.08 and P=0.004, respectively), and dominant CD8-H responses were 
stronger (1244.8 vs 180.4 SFU /million PBMC; P=0.05). HIV-1 infection was therefore 
associated with broadening and strengthening of CD8+ responses.
In addition, CD8+ responses before and after HIV-1 infection showed the same 
pattern of differential epitope recognition as was seen in our larger cross-sectional analysis of 
the cohort (see Table 7.3; overleaf). An A*6802-restricted response to DTVLEDINL was 
seen in three subjects before seroconversion (ML 857, ML 1203, ML 1707), but after 
seroconversion was either lost (ML 857, ML 1707) or was superceded by responses to 
A*6802 ETAYFILKL (ML 1203). Likewise, A2-restricted responses to ILKD/EPVHGV in 
two HEPS sex workers were either lost completely (ML 1250), or became subdominant (ML 
1760). In both these cases, the dominant A2-restricted epitope after HTV infection was 
SLF/YNTVATL. In the remaining two sex workers, no HDTV-specific responses had been 
seen prior to infection, but dominant responses following infection recognized epitope 
SLF/YNTVATL in both cases (ML 1575, ML 1592). It therefore seems that CD8+ epitope 
specificity is related to the HTV-1 infection status of an individual donor, and is unlikely to 
reflect selection through polymorphic antigen processing or other immune response genes.
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Table 7.3 Specificity and frequency of CD8+ responses before and after 
late seroconversion
Subject HIV-1 CTL epitope HLA class I 
restriction
Before (SFU/10^ 
PBMC)
After (SFU/10" 
PBMC)
ML 857 DTVLEDINL A*6802 373 4
H/NPDIVIYQY B35 100 65
PPIPVGDIY B35 0 2350
VPLRPMTY B35 13 185
ML 1203 DTVLEDINL A*6802 168 133
ETAYFILKL A*6802 18 1310
FPVTPQVPLR B7 43 845
TPGPGV/IRYPL B7 33 965
IPRRIRQGL B7 0 325
SPRTLNAWV B7 0 160
ML 1250 ILKD/EPVHGV A2 235 0
SLF/YNTVATL A2 10 60
ML 1575 SLF/YNTVATL A2 0 33
ML 1592 SLF/YNTVATL A2 25 100
ML 1707 DTVLEDINL A*6802 36 0
ETAYFILKL A*6802 0 50
RDYVDRFFKTL A24 0 640
ML 1760 ILKD/EPVHGV A2 90 168
SLF/YNTVATL A2 0 400
KRWIIL/MGLNK B27 10 1864
ETAYFILKL A*6802 5 400
Positive responses are shown in bold font. In general, criteria for a positive response were an 
mV-specific response >20 SFU /million PBMC, and at least 2x background (see text).
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Epidemiological correlates of late seroconversion
Demographics and HTV-1 risk-taking behaviour did not differ significantly between 
the 11 seroconverters and 22 matched, persistently seronegative controls (see Table 7.4; 
below). Risk factors such as anal sex, sex during menses and intravenous drug use were rare, 
and no subject reported nonconsensual sex during the past year, recent vaccination, or recent 
blood transfusion. There was no association between seroconversion and method of 
contraception or the occurrence of an STI over the past year. Having stopped sex work 
entirely for at least two months during the preceding year was associated with seroconversion 
(82% of seroconverters vs 41% of controls; OR=6.5, CI95% 1.1-37.5; P=0.04), as was a 
reduction in the number of daily clients by >2 /day (55% vs 18%; OR=5.4, CI95% 1.1-26.9; 
P=0.04). Overall reduction in sex work, defined as either having taken a break or reduced the 
number of daily clients, was therefore also significantly associated with late seroconversion 
(91% vs 45%; OR=12.0, CI95% 1.3-110.5; P=0.03). Seroconverters who had temporarily 
stopped sex work had done so for an average of 12.4 months (range 2-60 months), and there 
was no significant difference in ‘break’ duration between sex workers who seroconverted and 
persistently seronegative controls (12.4 vs 5.7 months; P=0.4).
Reasons for temporarily stopping sex work were most commonly social (travelling 
home, other employment, social commitments). Of the 9/11 cases that had taken a break 
from sex work, four reported no sexual activity over this time, and one reported sex with a 
single partner who tested HTV-1 seronegative. The remaining four women reported 
monogamy or serial monogamy with partner(s) of unknown serostatus, and who were 
unwilling to present for HTV-1 testing. No late seroconverter had stopped sex work due to 
illness, although 4/11 women described “flu-like” symptoms upon resumption of sex work, 
which could have been compatible with acute HTV-1 infection.
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Table 7.4 Case-control comparison of late seroconverters witb enrolment- 
matched controls remaining HIV-1 seronegative
Seroconverters
(N =ll)
Seronegative
controls
(N=22)
P-value* (OR; 
95% Cl)
Mean age (years) 35.3 37.8 0.3
Duration of follow-up 6.9 6.8 0.9
(years)
Prostitution duration 10.8 12.0 0.6
(years)
Condom use at 73.5 70.0 0.8
enrolment (%)
Condom use at 80 82.4 0.7
seroconversion (%)
Clients /day at 5.5 6.1 0.6
enrolment
Clients /day at 2.4 3.7 0.3
seroconversion
>2 month break from 9/11 9/22 0.04
sex work in past year (6.5; 1.1-37.5)
Fewer^ clients in past 6/11 4/22 0.04
year (5.4; 1.1-26.9)
Either break or fewer 10/11 10/22 0.03
clients (12.0; 1.3-110.5)
New high-risk sexual 4/11 3/22 0.2
behaviour* (3.6; 0.6-20.4)
Injection drug use, 1/11 0/22 0.15
past year (oo; N/A)
ANOVA for comparison of means; Mantel-Haenzel Common Odds Ratio Estimate for 
comparison of discrete variables.
 ^Reduction in number of daily clients by >2 over the past year.
* Either started to practice anal intercourse or sex during menses over the past year.
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Late seroconversion was seen in two women who had not taken a break from sex 
work, ML 1575 and ML 1760. An HIV-specific response had been detected one year prior to 
seroconversion in ML 1760, but no responses had been found in ML 1575 (Table 7.1). While 
ML 1760 had not reduced the number of daily clients (N=5 clients /day), condom use had 
increased from 86% to 100% over the year preceding seroconversion, and then fallen again to 
80% at the time of seroconversion.
Prospective analysis of CD8+ responses in HEPS controls
Unfortunately, samples from the late seroconverters themselves were not available 
from the correct time points to demonstrate that stopping sex work had been followed by a 
decline in epitope-specific responses, which was in turn followed by HlV-1 seroconversion. 
We therefore elected to study HTV-l epitope-specific responses prospectively in the 22 
persistently HlV-1 seronegative sex worker controls who did or did not report a period of 
reduced sex work. HLA class 1 epitopes were not available for ML 1705. No HIV-specific 
ELISpot responses were found at any time for 7/21 controls (33%), while responses were 
demonstrated at >1 visit (range, 1-5) for 14/21 controls (68%). Table 7.5 summarizes all the 
ELISpot data available from these 22 controls.
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Table 7.5 Summary of HIV-1 CD8+ epitope-specific responses among 22 highly- 
exposed, persistently seronegative sex worker controls
Subject Epitopes recognized 
in IFNy ELISpot*
Proportion of assays 
positive
Peak response 
(SFU/10^ PBMC)
ML 851 DTVLEDINL 2/5 45
TPGPGIRYPL 3/5 40
FPVTPQVPLR 1/5 112
ML 887 ILKDPVHGV 2/5 188
YLRDQQLL 4/5 30
PPIPVGDIY 2/5 83
NPDIVIYQY 2/5 151
ML 1192 ILKD/EPVHGV 2/4 40
ML 1250 TSTLQEQIGW 1/4 50
ISPRTLNAW 1/4 20
KAFSPEVIPMF 1/4 20
ILKDPVHGV 2/4 260
ML 1437 DTVLEDINL 1/2 85
ML 1441 None 0/1
ML 1573 KYRLKHLVW 1/1 50
ML 1589 LSPRTLNAW 2/4 50
ML 1593 None 0/1
ML 1601 DTVLEDINL 2/2 128
ML 1643 None 0/2
ML 1668 AIFQSSMTK 1/2 40
YPLTFGWCY/F 1/2 40
ML 1671 ETAYFILKL 2/2 333
ML 1693 LSPRTLNAW 1/3 20
ML 1700 None 0/3
ML 1705 N/A
ML 1726 None 0/3
ML 1732 FRDYVDRFFK 2/3 37
ML 1747 None 0/2
ML 1749 ILKD/EPVHGV 2/3 75
ALKHRAYEL 1/3 25
ML 1766 None 0/2
ML 1792 DLNMMLNIV 2/4 23
RAEQASQEV 2/4 308
See text for definition of an HIV-1 epitope-specific response.
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Seven ELISpot-positive controls (ML 851, ML 1192, ML 1250, ML 1437, ML 1693, 
ML 1732 and ML 1749) reported a break from sex work of two months or more during the 
study. In 6/7 cases, HTV-specific responses were no longer seen in PBMC drawn 2-8 months 
following this break. Four of these women had retired from sex work altogether, and this was 
associated with the loss of HTV-specific responses in 3/4 women, although one woman 
maintained a response to the B 18 p24 epitope FRDYVDRFFK for >1 year (the HTV 
serostatus of her regular sex partner was unknown). Three women resumed sex work after a 
break (ML 1250, ML 1749, and ML 851, who later retired completely), and in each case 
HTV-specific responses were redetected after a lag of 1-12 months. It should be pointed out 
that in ML 1250 a broad response was detected after restarting sex work, but waned eight 
months later without any change in risk behaviour, and she went on to seroconvert.
HTV-specific responses were detected in seven persistently seronegative controls that 
had not taken a break from sex work. PBMC were only available for ML 1573 at a single 
time-point, and so results from serial assays are available for six women. In 4/6 controls 
HTV-specific responses could be detected throughout the study. The specificity of these 
responses was constant in two women (ML 1601, A*6802 pol epitope DTVLEDINL; and 
ML 1671, A*6802 RT epitope ETAYFTLKL), and varied in two women (ML 1792, from B 14 
restricted p24 epitope DLNMMLNTV to RAEQASQEV; ML 887 recognized a variety of 
epitopes). In ML 1589 an initial response was lost over the course of the study without a 
reported break from sex work or change in risk behaviour. ML 1668 had no initial response, 
but developed responses to A33 pol epitope AIFQSSMTK and B49 n e /epitope 
YPLTFGWCY/F after nine months, while reducing condom use from 100% to 33%.
In summary, there was a significant overall association between stopping sex work 
and a loss of HTV-1 epitope-specific responses: 6/7 women who lost responses over the
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course of the study had stopped sex work, while only 1/6 women who maintained epitope- 
specific responses had stopped sex work (OR=30.0; CI95% 1.5-612; P=0.03).
Summary of HIV-specific immunity in late seroconverters and controls
Although ELISpot assays were performed for the majority of late seroconverters and 
controls, using predefined CDS epitopes, other HIV-specific immune responses had been 
examined in a subgroup of women. These responses included IL2 production in response to 
predefined T helper epitopes(361, 418); HTV-l env specific responses in an ex vivo ELISpot 
or after in vitro stimulation(361,418); and IgA in the genital tract or plasma which was 
specific for HTV-1 env, or was able to neutralize HTV-1 or block mucosal HTV-1 
transcytosis(418-421). Table 7.6 summarizes all assays of HTV-specific immunity performed 
in all late seroconverters (prior to infection) and non-seroconverting controls. Since some 
late seroconverters have been infected for a number of years, fewer assays of HTV-specific 
immunity have been performed in this group overall. Although small numbers of subjects 
have been examined, it is interesting to note that late seroconversion has occurred in some 
cases despite prior HTV-1 specific IgA and CD8+ responses directed against HTV-1 env or 
predefined CTL epitopes, but has not yet occurred in any women with demonstrated prior T 
helper responses.
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Figure 7.2 Temporal relationship between sex work activity and HIV-specific 
CD8+ responses in HEPS prostitutes
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HTV-specific ELISpot responses are shown on the Y-axis as SFU/10  ^PBMC. Solid lines 
represent IFNy release in response to HTV-1 CTL peptide epitopes, and the dashed line 
represents the IFNy response to RIO medium alone. Assay date is shown on the X axis, 
together with the reported number of daily clients and percentage condom use. Taking a 
break from sex work completely was generally associated with a transient loss of HTV- 
specific ELISpot responses, demonstrated by ML 1192 (Figure 7.2a), ML 1589 (Figure 7.2b), 
and ML 1749 (Figure 7.2c). HTV-specific responses tended to be maintained in the absence 
of a break from sex work (data not shown).
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Table 7.6 Summary of all assays of HIV-specific immunity* performed in late
seroconverters (prior to seroconversion) and non-seroconverting controls
Study number Late
seroconverter
(1/0)
HIV-1 env 
specific CD8+ 
response **
Predefined 
CD8+ epitope 
ELISpot 1
HIV-1 env T 
helper 
response t
HIV-1 specific 
IgA response |
ML 851 0 1 1 1
ML 857 1 1 1 0
ML 887 0 1 1 0 1
ML 1192 0 1 0 1
ML 1203 1 1
ML 1250 1 1 1 0 1
ML 1434 1 1
ML 1437 0 0 1
ML 1441 0 0 0
ML 1573 0 1 1 1 1
ML 1575 1 1 0
ML 1589 0 1 1 1
ML 1592 1 0
ML 1593 0 0 0 0 1
ML 1601 0 1 1
ML 1626 1
ML 1643 0 0 1 1
ML 1668 0 1 1
ML 1671 0 1 1
ML 1685 1
ML 1693 0 1
ML 1700 0 1 1
ML 1705 0 1
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ML 1707 1 1 1
ML 1726 0 0 0
ML 1730 1 0 0
ML 1732 0 0 1 1 1
ML 1747 0 1 0 1
ML 1749 0 1 0 1
ML 1760 1 0 1
ML 1763 1 0 1
ML 1766 0 0
ML 1792 0 1 1
* Assay results are expressed as 1 (positive), 0 (negative) or an empty box (not done)
** HTV-l env specific CD8+ responses detected using either the ex vivo IFNy ELISpot assay 
or after in vitro generation of CTL lines (see Chapter 2 for method details).
I  Responses to predefined HTV-1 CD8+ epitopes detected using either the ex vivo IFNy 
ELISpot assay or after in vitro generation of CTL lines (see Chapter 2 for details), 
t  T helper response defined as an IL2 stimulation index greater than 4 for two or more 
antigenic HTV-1 envelope peptides (see Chapter 2 for details).
$ HTV-1 specific IgA response defined as either the demonstration of HTV-1 specific IgA by 
ELISA (see Chapter 2 for details), or the specific inhibition of HTV-1 replication(420) or 
mucosal transcytosis(421) by IgA purified from these subjects (the latter two studies were 
performed primarily by investigators at the Karolinska Institute, Stockholm, and not by the 
examinee).
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D is c u s s io n  a n d  c o n c l u s io n s
Despite intense HTV-1 infection pressure, the subgroup of HDTV-resistant prostitutes in 
Pumwani have (by definition) remained uninfected for periods of up to fifteen years(29).
This HTV-l resistance has been associated with various HTV-specific immune responses 
including T helper responses, plasma and mucosal IgA, and CTL epitope responses, 
suggesting that resistance may be immune mediated(170). However, the phenomenon of 
HTV-1 resistance is not absolute: although the incidence of new HTV-1 infections declines 
sharply after two years of follow-up, occasional séroconversions are seen as late as ten years 
after enrolment, as demonstrated by Figure 7.3, an update of a previously-described survival 
analysis(29).
Figure 7.3 Time to HIV-1 seroconversion after enrolment in the Pumwani 
sex worker cohort, 1983-1999
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In this study we have described all eleven sex workers who had met HTV-1 
resistance criteria but subsequently seroconverted during the period 1/1/96 -  31/12/99 (and 
have mentioned one sex worker who seroconverted after this date, in 2000). These women 
had been followed for an average of 6.9 years prior to seroconversion, had had an estimated 
527 unprotected exposures to HTV-1 (based on mean client numbers and condom use, 
assuming a 17.7% HTV-1 prevalence among clients(436)), and are quite representative of the 
overall HTV-resistant cohort. By definition, seroconversion in this resistant cohort is a rare 
event, and as a result the number of study subjects is necessarily small.
If HTV-specific CTL are responsible for resistance to HTV-1 infection, then the most 
obvious explanation for late seroconversion would have been that these women did not have 
pre-existing CTL. However, pre-seroconversion HTV-1 epitope-specific responses were 
found in 5/7 (71%) of seroconverters as long as three years before conversion, in keeping 
with the proportion of the cohort demonstrating CD8+ responses in other studies (55-65%; 
Chapters 3 and 4). These responses were demonstrated by IFNy ELISpot in 5/5 cases, and 
were confirmed in a classical chromium release assay in three cases. It is therefore clear that 
late seroconversion can occur despite pre-existing HTV-specific CTL. Although pre­
seroconversion responses could only be tested in 7/12 seroconverters, predicted levels of 
HTV-1 exposure in these cases did not differ from those without available PBMC.
Ultimately, whether pre-existing CTL were present in 5/7 or 5/12 late seroconverters, the fact 
remains that seroconversion occurred despite HTV-specific CTL in a substantial proportion of 
these women.
Although amino acid substitutions within immunodominant CTL epitopes can lead to 
viral escape and disease progression in HTV-infected subjects(255, 392), viral epitope 
sequences from seroconverters matched those recognized by pre-seroconversion 
ELISpot/CTL assays for 5/6 epitopes. Infection by a potential escape variant occurred for 1/6
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epitopes (ML 857 HPDIVIYQY NPEIIIYQY), and a bulk CTL assay confirmed that pre­
seroconversion PBMC did not recognize the epitope variant. However, no sequence variation 
was seen within a second CTL epitope recognized by this subject prior to seroconversion, 
which therefore cannot be entirely explained by CTL escape. Furthermore, it is possible that 
this sequence variation was due to chance, since the amino acid substitutions seen within this 
epitope have all been previously described in clade A HIV-1 (389). Overall, it seems unlikely 
that viral CTL escape was a major factor in late HIV-1 seroconversion in these women.
Since HTV-l epitope-specific responses had been demonstrated prior to 
seroconversion, we initially hypothesized that seroconversion might have occurred due to 
some behavioural factor associated with increased viral exposure, such as an increase in the 
number of clients or a new type of high-risk sex, which had overwhelmed pre-existing 
protective CTL responses. A case control study was therefore performed, comparing 
seroconverters with enrolment-matched, persistently seronegative controls. No increase in 
classical HTV-1 risk-taking behaviours was seen. In fact, although the sample size was 
necessarily small, cases were more likely than controls to have reduced sex work (and 
presumably their HTV-1 exposure) over the past year, either by stopping sex work 
temporarily or by reducing their number of clients. The association of HTV-1 seroconversion 
with reduced sex work seems initially counter-intuitive, but it might be compatible with a 
loss or diminution of HTV-specific CTL in the absence of ongoing antigenic stimulation, as is 
seen in chronic HTV-1 infection in the context of complete viral suppression with 
antiretroviral therapy(429,430, 433). Antigenic stimulus is required to maintain effector 
CTL(429). Even memory CTL, which are able to undergo multiple divisions and replenish 
the effector population(435), and which may be maintained in chronic HTV-1 infection in the 
absence of detectable virus(431), require persistence of antigen for maintenance in the 
periphery(245, 432).
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Ideally, to test the hypothesis that late seroconversion in these sex workers was related 
to the loss or waning of HTV-l epitope-specific responses after a break from sex work, 
seroconverters should have been assayed immediately post-break. The demonstration that 
pre-existing HTV-specific responses had been lost, with subsequent seroconversion upon 
resuming sex work, would have provided the strongest possible evidence for the hypothesis. 
Unfortunately, cases generally did not present to the clinic until several months after 
resuming sex work and subsequently seroconverting, so this was not possible. However, 
persistently seronegative women who had not reduced sex work were able to maintain 
epitope-specific responses, while responses were consistently lost in the context of stopping 
sex work. These observations suggest that HTV-1 epitope-specific responses would also have 
been lost following a break from sex work in those women who subsequently seroconverted. 
However, more frequent testing of sex workers before and after any break from sex work will 
be necessary to clearly demonstrate an association between reduced antigen exposure, the 
loss of HTV-specific CTL, and subsequent seroconversion.
The timing of HTV-1 testing does not enable us to completely rule out that some 
women seroconverted prior to the break from sex work. However, no seroconverter had 
stopped sex work due to illness, and 4/11 women described “flu-like” symptoms upon 
resumption of sex work, which could have been compatible with acute HTV-1 infection.
The ELISpot assay used in this study measures IFNy release by CD8+ T cells in 
response to specific HTV-1 CTL epitope peptides as a surrogate for conventional chromium 
release CTL assays(415). The use of MHC-peptide tetrameric complexes to study this HEPS 
cohort is limited by the fact that precursor frequencies are generally below the threshold of 
tetramer detection (>200 /lO^ PBMC), and are frequently directed against epitopes which are 
not available in MHC-peptide tetrameric complexes. In the ELISpot assay PBMC are 
exposed to antigen for a relatively short time (6-16 hours), and so the assay should detect
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circulating antigen-specific effector (rather than memory) CTL. We did not study memory 
CTL in the context of stopping sex work. However, it is not clear that a memory CTL 
population would be able to protect against an infectious mucosal exposure, since for other 
mucosal infections an effector CTL response may be essential for protection against 
subsequent challenge(231). It is therefore plausible that CTL-mediated protection against 
HTV-1 may be lost as effector CTL frequencies fell below an as yet unknown protective 
threshold.
It is not clear why, after stopping sex work for several months, restarting sex work 
should result in seroconversion in some women, and in the return of HTV-1 epitope-specific 
responses in others, presumably due to the boosting of memory CTL after antigen exposure. 
There are several possible explanations. CD8+ lymphocyte responses may persist in some 
women after a break from sex work, but below the level of ELISpot detection. Alternatively, 
epitope-specific responses in blood may not accurately reflect those at the level of the genital 
mucosa, which may be more relevant in protection from sexual transmission (Chapter 5). 
Finally, the influence of antigen exposure on other HTV-specific immune responses 
previously described in this cohort, such as T helper responses(361) and HTV-specific IgA 
(Chapter 6), could not be properly examined in this study (although mucosal IgA had been 
tested before seroconversion in three cases, ML 1203, ML 1250 and ML 1575, and had been 
detected in 2/3; Table 7.6). The exact nature of the viral contact after a period of reduced 
HTV-1 exposure, including such factors as viral phenotype and the dose or route of exposure, 
may be crucial in determining whether exposure results in boosting of protective immunity or 
the establishment of productive infection.
In summary, it is clear that HTV-1 resistance is not absolute, and that seroconversion 
can infrequently occur despite pre-existing HTV-specific CD8+ responses. The association 
between late seroconversion and reduced sex work, and the finding that HTV-specific effector
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responses fluctuate depending on levels of antigen exposure, suggests that ongoing antigenic 
exposure may be necessary to maintain a protective CTL response. The positive implication 
for preventative HTV-l vaccine development is that HTV-1 resistance may not be an all-or- 
none phenomenon, but rather an immunologic state which is inducible given the correct 
antigenic stimulus. However, it also suggests that maintenance of HTV-1 immune resistance 
will require ongoing antigenic priming, either through intermittent vaccine boosters, or 
through the use of vaccine strategies employing persistent antigen.
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Chapter  eight  Sum m ary  and future directions
The work presented in this thesis has aimed to expand our understanding of the 
immune correlates of resistance to HIV infection. Resistance to HTV cannot be 
experimentally defined in a human model, as HTV-l challenge in uninfected subjects would 
be ethically unacceptable, and it is difficult to reproduce the complexities of the human 
system in an animal model. This work has therefore focused on a unique group of sex 
workers in Nairobi, who remain HTV-l seronegative despite multiple exposures. Resistance 
to HTV-1 infection is defined epidemiologically, and is a relative phenomenon, but earlier 
statistical modelling clearly shows that these women do not simply represent the “tail end of 
the curve”(29). The principle findings of my research in this cohort were:
HIV-specific immune responses are common in HEPS sex workers(361, 419, 437-439)
Several HTV-specific immune responses previously described in other HEPS cohorts, 
namely CTL, T helper responses and mucosal IgA, were common in the Pumwani cohort. 
The proportion of HEPS sex workers demonstrating these responses ranged from 55% for T 
helper responses to 76% for mucosal IgA. Although HTV-specific CTL were more common 
in infected than HEPS sex workers, T helper responses and IgA were actually more 
commonly detected in HEPS sex workers. A possible mechanism of immune protection that 
remains to be explored is CD8+ noncytotoxic anti-HTV activity, which has been 
demonstrated in several other HEPS cohorts(371).
Independence of humoral and cellular immune responses(418, 419)
Humoral and cellular responses appeared to be independent phenomena. While both 
T helper and IgA responses were common in the HEPS cohort, the presence or absence of
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one did not affect the probability of finding the other. In addition to re-emphasizing the 
likely heterogeneous nature of resistance to HIV-1, this finding raises the possibility that 
different strategies will be necessary to induce the various effector arms involved in 
protection.
Acquisition of CTL responses over time(437,439)
Cross sectional analysis demonstrated that the longer a sex worker had remained 
uninfected within the Pumwani cohort, the more likely she was to have an HTV-specific CTL 
and/or CD8+ lymphocyte response. In addition, the strength of responses correlated with the 
duration of prior seronegative cohort enrolment. There are two possible explanations for this:
1) Sex workers with HTV-specific CTL/CD8+ responses already present at cohort enrolment 
are subsequently less likely to become infected, and so CTL/CD8+ responses become 
progressively more concentrated in the subgroup of sex workers who remain uninfected.
2) HTV-specific CTL/CD8+ responses can be acquired over time, and sexual contact with 
HTV-1 will either result in productive infection of the sex worker, or in the induction of a 
specific CTL/CD8+ response.
It should be pointed out that neither of these possibilities necessarily entails protection 
from HTV-1 infection by a CTL/CD8+ response. It is still possible that these responses result 
from nonproductive sexual exposure to HTV-1, but that actual protection from infection is 
mediated by an alternative mechanism that remains undefined. The only way to definitively 
test the causal association between CTL/CD8+ responses and protection from infection is to 
experimentally induce CTL/CD8+ responses in a high-risk cohort, and to see whether these
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responses are protective. This work is now beginning in Nairobi, in the context of phase I 
trials of a CTL-based HIV-1 vaccine.
Functional differences in HEPS CTL(437)
HIV-specific CD8+ lymphocyte responses were logio weaker in HEPS than in 
infected subjects, and levels of HIV-specific lysis were also low in semi-quantitative 
chromium release assays. Although there was relative enhancement of HEPS responses in 
the genital tract, it was clear that protection from HIV-1, as opposed to the establishment of 
chronic infection, was not likely to be due to stronger CTL responses. However, CD8+ 
responses in HIV-infected and HEPS women tended to be directed against different viral 
epitopes, a phenomenon only seen for responses restricted by the class I alleles that have been 
associated with HIV resistance in this cohort. These data suggest that the role of certain HLA 
alleles in resistance to HIV infection could relate to a greater likelihood of generating a CTL 
response to a repertoire of "protective" HIV-1 epitopes. It will be important to study possible 
functional differences between CTL in HEPS and HIV-infected sex workers. Although 
limitations in current technology make this work difficult, it may be possible through the 
isolation of HEPS CTL clones, or through the development of novel tetramers with the 
sensitivity to detect low level HEPS responses.
Unmapped CTL epitopes(439)
In addition to the recognition of different predefined CTL epitopes in HEPS and HTV- 
infected sex workers, Env-specific CTL were found in some HEPS subjects who had no 
responses to any previously defined Env CTL epitopes. This suggests that there may be 
unmapped ‘resistant’ epitopes within HIV-1 Env, and by extension within other gene 
products, which has obvious implications for developing CTL based vaccines. It will be
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important to start to map these HEPS epitopes. If possible, this should done using 
overlapping peptides from clades A and/or D, the HIV-1 subtypes to which Pumwani sex 
workers are most likely to have been exposed.
HIV-specific immunity in the genital tract(418, 419, 438)
HIV-specific IgA and CD8+ responses were found in the genital tract of HEPS sex 
workers, with the latter enhanced compared to blood. This suggests that protective immune 
responses may need to be present at the actual site of mucosal HIV-1 exposure, as has been 
demonstrated previously in several animal models(338, 341). Work in collaboration with 
other investigators has demonstrated that IgA antibodies might play an important functional 
role in HIV-1 resistance, since they were able to neutralize HIV-1(420) and to block viral 
transcytosis(421). Work is ongoing to map the epitope specificity of these IgA antibodies, as 
well as to examine the role of HTV-l exposure in maintaining these responses. In addition, a 
cohort-wide survey of genital tract CD8+ responses has been initiated. This work will 
examine possible differences in epitope specificity between the blood and genital tract, and 
will examine the role of antigen in maintenance of genital tract cellular responses.
HIV-1 resistance is not absolute(440)
Several HTV-l ‘resistant’ sex workers were infected by HTV-l during the course of 
this study, despite prior HTV-specific immune responses, including IgA and CTL/CD8+ 
responses. In addition, the prior existence of epitope-specific CTL/CD8+ responses did not 
generally exert a strong enough immune pressure to select for viral escape variants. Clearly, 
these observations were disappointing. Late seroconversion was associated with a prior 
reduction in the intensity of sex work, either through decreasing client numbers or through a 
temporary break from sex work, and may have been due to the waning of HTV-specific
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immunity in the absence of antigen. This is particularly likely to be a problem if the 
persistence of mucosal CD8+ responses is necessary for ongoing protection from HTV-l 
infection, since the maintenance of peripheral memory is dependent on antigen(245,432).
A key question that remains unanswered is whether late seroconversion represents the 
emergence of previously suppressed virus, or whether the phenomenon represents new 
infection. Detailed viral analysis, including sequence comparisons between infecting virus 
and those strains circulating in Nairobi now and over the past decade, may help to provide an 
answer(2, 441). Preliminary work has found that circulating recombinant forms (CRFs) are 
present in the peripheral blood of most late seroconverters, but only in a minority of HTV- 
infected long-term survivors. Three hypotheses could explain these findings, and are 
currently under investigation (Weiser B et al, unpublished data).
(a) There is an increased prevalence of recombinant virus among those strains which are 
currently circulating in Nairobi.
(b) Recombinant strains are more virulent, and so are better able to infect HEPS women, 
either by escape from clade-specific immunity or through a different mechanism.
(c) Circulating CRFs represent HTV-l reinfection and recombination with pre-existing virus, 
which may have been previously suppressed below the level of detection.
HIV-1 exposure and maintenance of CTL(440)
In HEPS sex workers who remained HTV-uninfected, virus-specific CD8+ responses 
generally waned when sexual HTV-l exposure was reduced, and continued sex work was 
associated with persistence of CD8+ lymphocyte responses. This may reflect the 
maintenance of a critical level of antigen exposure. However, the ELISpot assay primarily 
measures effector CTL. Alterations in CD8+ response frequencies in the blood do not
227
necessarily reflect CD8+ memory responses, nor the behaviour of effector CD8+ responses in 
the genital tract. Although the role of ongoing sex work in maintaining IgA responses was 
not examined in this study, mucosal IgA responses in another HEPS cohort have been shown 
to wane in the absence of high-risk sexual behaviour(365). It will be important to confirm 
and expand this work, since the implication is that intermittent boosting may be necessary for 
vaccine strategies that employ nonpersistent antigen. To this end, work is continuing in two 
directions:
1) A more detailed analysis of the impact of breaks from sex work on HTV-specific 
CD8+ responses, expanding the focus to include T helper responses, genital tract 
CD8+ responses, and mucosal/plasma IgA.
2) Examining the persistence of a central memory population after a break from sex 
work, using limiting dilution analysis.
Implications for a protective HIV-1 vaccine
Overall, this work suggests that HTV-l resistance may be immune mediated, and that 
it should be possible to replicate these immune responses in the context of an HTV-l vaccine. 
If possible, care should be taken to induce a range of HTV-specific immune responses, 
including IgA, CTL and T helper responses. It will be important to induce these responses in 
the genital tract, as well as the blood, and this may require novel vaccine delivery systems. 
Finally, in the absence of vaccine strategies that employ persistent antigen, it seems likely 
that vaccine boosting will be required.
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